Mutant ngal proteins and uses thereof

ABSTRACT

In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.

This application is a continuation-in-part of International Application No. PCT/US2011/037774, filed on May 24, 2011, which claims the benefit of U.S. Provisional Patent Application No. 61/347,587, filed May 24, 2010, and U.S. Provisional Patent Application No. 61/354,973, filed Jun. 15, 2010, the contents of each of which are hereby incorporated by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety.

All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety.

A portion of the disclosure of this patent document contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

BACKGROUND

NGAL (Lipocalin 2) is a small protein with a molecular weight of about 22 kD. NGAL binds to iron-binding siderophores, such as enterochelin, with high affinity and thus chelates and traffics iron. Once produced in cells, NGAL is secreted into the extracellular space and transported to the kidney where it passes the filtration barrier of the glomerulus and enters the primary urine. However NGAL is then efficiently reabsorbed by megalin receptors localized on the apical side of the epithelia of the proximal tubules. Once NGAL is reabsorbed and endocytosed, it is trafficked to lysosomes and degraded. Once degraded, any iron which NGAL transported to the kidney is reabsorbed.

SUMMARY OF THE INVENTION

The present invention is based, in part, on the development of mutant versions of the NGAL protein that are not reabsorbed in the kidney and thus, unlike wild-type NGAL, are excreted in significant amounts in the urine. Like wild-type NGAL, these mutant forms of NGAL have the ability to bind to iron-binding siderophores, such as enterochelin. Thus, these NGAL mutants can be used to traffic iron out of the body by facilitating its excretion in the urine. As such, the mutant NGAL proteins of the invention can be used in the treatment of iron overload and diseases and disorders associated with iron overload. In addition, the mutant NGAL proteins of the invention have bacteriostatic activity and can be used to treat bacterial infections of the urinary tract. These and other aspects of the present invention are described in more detail below, and in other sections of this application.

In one embodiment the present invention provides a mutant NGAL protein comprising an amino acid sequence that is at least 70% identical to the sequence of wild-type human NGAL (SEQ ID NO. 1), or a fragment thereof, wherein one or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 is mutated by deletion or by substitution with a non-positively charged amino acid residue, and wherein one or more of, or preferably all of, residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the mutant NGAL protein is able to bind to a siderophore and/or to a siderophore-iron complex, and/or is excreted in the urine, and/or has bacteriostatic activity.

In preferred embodiments five, six, seven, eight, nine, ten, or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.

In some embodiments the % of the mutant NGAL protein that accumulates in the urine following systemic administration of the mutant NGAL protein to a subject is greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject. In some embodiments the % of the mutant NGAL protein that accumulates in the urine following systemic administration of the mutant NGAL protein to a subject is greater than 10-fold or greater than 100-fold more than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject. In one embodiment the % of the mutant NGAL protein that accumulates in the urine three hours after systemic administration of the mutant NGAL protein to a subject is 1% or more, or 2% or more, or 5% or more, or 10% or more, or 20% or more. This is significantly higher than the % of WT NGAL protein that accumulates in the urine—typically only about 0.1% of WT NGAL that is administered to a subject systemically accumulates in the urine over the same time period.

In some embodiments the present invention provides a nucleic acid sequence that encodes a mutant NGAL protein. In some embodiments the present invention provides an expression vector comprising such a nucleic acid sequence operatively linked to a promoter. The present invention also provides bacterial cells and mammalian cells that stably express such nucleic acids and that may be useful for the production of recombinant mutant NGAL proteins.

The present invention also provides pharmaceutical compositions comprising the mutant NGAL proteins of the invention and pharmaceutical compositions comprising complexes of such mutant NGAL proteins together with a siderophore, such as enterochelin, pyrogallol, carboxymycobactin, catechol, or variants thereof.

In one embodiment, the siderophore is pH insensitive. In another embodiment, the siderophore binds to the mutant NGAL protein and iron at urinary pH. In another embodiment, the siderophore binds to the mutant NGAL protein and iron in the urine.

In one embodiment, the siderophore binds to the mutant NGAL protein and iron at blood pH. In another embodiment, the siderophore binds to the mutant NGAL protein and iron in the blood. In one embodiment, the mutant NGAL protein and the siderophore are present in a 1:1 molar ratio. In one embodiment, the mutant NGAL protein and the siderophore are present in a 1:3 molar ratio.

The present invention also provides methods for treating iron overload in a subject in need thereof, comprising administering to the subject an effect amount of a pharmaceutical composition comprising a mutant NGAL protein.

The present invention also provides methods for treating iron overload in a subject in need thereof, comprising administering to the subject an effect amount of a pharmaceutical composition comprising a mutant NGAL protein and a siderophore.

The present invention also provides methods for treating bacterial urinary tract infections in a subject in need thereof, comprising administering to the subject an effect amount of a pharmaceutical composition comprising a mutant NGAL protein.

The present invention also provides methods for treating bacterial urinary tract infections in a subject in need thereof, comprising administering to the subject an effect amount of a pharmaceutical composition comprising a mutant NGAL protein and a siderophore.

The present invention provides for a polypeptide that encodes a K3 NGAL protein and comprises an amino acid sequence that is identical to SEQ ID NO. 2.

The present invention also provides for a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 2, at least 95% identical to SEQ ID No. 2, at least 90% identical to SEQ ID No. 2, at least 80% identical to SEQ ID No. 2, or at least 70% identical to SEQ ID No. 2.

The present invention provides for a nucleic acid encoding a polypeptide that encodes a K3 NGAL protein and comprises an amino acid sequence that is identical to SEQ ID NO. 2. The present invention also provides for a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 2, at least 95% identical to SEQ ID No. 2, at least 90% identical to SEQ ID No. 2, at least 80% identical to SEQ ID No. 2, or at least 70% identical to SEQ ID No. 2.

The present invention provides for a pharmaceutical composition comprising a polypeptide that encodes a K3 NGAL protein and comprises an amino acid sequence that is identical to SEQ ID NO. 2. The present invention also provides for a pharmaceutical composition comprising a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 2, at least 95% identical to SEQ ID No. 2, at least 90% identical to SEQ ID No. 2, at least 80% identical to SEQ ID No. 2, or at least 70% identical to SEQ ID No. 2.

The present invention provides for a K3 NGAL protein comprising an amino acid sequence that is identical to SEQ ID NO:2, or a fragment thereof, wherein the K3 NGAL protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

The present invention also provides for a polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO. 252.

The present invention also provides for a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No. 252.

The present invention provides for a nucleic acid encoding a polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO. 252. The present invention also provides for a nucleic acid encoding a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No. 252.

The present invention provides for a pharmaceutical composition comprising a polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO. 252. The present invention also provides for a pharmaceutical composition comprising a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No. 252.

In another aspect, the present invention provides for a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

In one embodiment, the K3Cys protein has bacteriostatic activity.

In one embodiment, the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of the WT NGAL protein to a subject over the same time period.

In another embodiment, the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is about 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.

In another embodiment, the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is 10-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.

In another embodiment, the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is 100-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.

In one embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 1%, 2%, 5% or more. In another embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 15%, 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95% or more.

In one embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 50% or more. In another embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 70% or more. In another embodiment, the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3Cys protein to a subject is about 85% or more.

In one embodiment, the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of the WT NGAL protein to a subject over the same time period.

In another embodiment, the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is about 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold or more lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of the WT NGAL protein to a subject over the same time period.

In one embodiment, the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is 10-fold or more lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of WT NGAL protein to a subject over the same time period.

In another embodiment, the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is 100-fold or more lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of WT NGAL protein to a subject over the same time period.

In one embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 1% or less. In another embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 2% or less. In another embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 3% or less. In another embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 4% or less. In another embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 5% or less.

In another embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or less. In one embodiment, the % of K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is about 15%, 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95% or less.

In another aspect, the present invention provides for a pharmaceutical composition comprising a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

In another aspect, the present invention provides for a pharmaceutical composition comprising a complex of a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

In one embodiment, the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants thereof. In another embodiment, the siderophore is pH insensitive. In one embodiment, the siderophore binds to the K3Cys protein and iron at urinary pH. In another embodiment, the siderophore binds to the K3Cys protein and iron in the urine. In one embodiment, the siderophore binds to the K3Cys protein and iron at blood pH. In another embodiment, the siderophore binds to the K3Cys protein and iron in the blood.

In one embodiment, the K3Cys protein and the siderophore are present in a 1:1 molar ratio. In another embodiment, the K3Cys protein and the siderophore are present in a 1:3 molar ratio.

The present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO. 252.

The present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No. 252.

The present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

The present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

The present invention also provides for a method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO. 252.

The present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No. 252.

The present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

The present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.

In another aspect, the present invention provides for a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In one embodiment, six or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid. In another embodiment, seven or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.

In one embodiment, eight or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid. In another embodiment, nine or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.

In one embodiment, ten or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.

In one embodiment, the K3Cys mutant protein has bacteriostatic activity.

In one embodiment, the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is greater than the % of K3Cys protein that accumulates in the urine following systemic administration of the K3Cys protein to a subject over the same time period.

In another embodiment, the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is about 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold or more greater than the % of K3Cys protein that accumulates in the urine following systemic administration of K3Cys protein to a subject over the same time period.

In another embodiment, the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is 10-fold or more greater than the % of K3Cys protein that accumulates in the urine following systemic administration of K3Cys protein to a subject over the same time period.

In another embodiment, the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is 100-fold or more greater than the % of K3Cys protein that accumulates in the urine following systemic administration of K3Cys protein to a subject over the same time period.

In one embodiment, the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 1%, 2%, 5% or more. In another embodiment, the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In one embodiment, the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 15%, 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95% or more.

In one embodiment, the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of the K3Cys protein to a subject over the same time period.

In another embodiment, the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is about 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold or more lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of the K3Cys protein to a subject over the same time period.

In one embodiment, the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is 10-fold or more lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of K3Cys protein to a subject over the same time period.

In one embodiment, the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is 100-fold or more lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of K3Cys protein to a subject over the same time period.

In one embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 1% or less. In another embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 2% or less. In another embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 3% or less. In another embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 4% or less. In another embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 5% or less.

In another embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or less. In one embodiment, the % of K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is about 15%, 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95% or less.

In another aspect, the present invention provides for a nucleic acid sequence that encodes a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for an expression vector comprising a nucleic acid sequence that encodes a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, operatively linked to a promoter, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a bacterial cell that stably expresses a nucleic acid sequence that encodes a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a mammalian cell that stably expresses a nucleic acid sequence that encodes a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a pharmaceutical composition comprising a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Tip 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a pharmaceutical composition comprising a complex of a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Tip 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In one embodiment, the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants thereof. In another embodiment, the siderophore is pH insensitive. In one embodiment, the siderophore binds to the K3Cys mutant protein and iron at urinary pH. In another embodiment, the siderophore binds to the K3Cys mutant protein and iron in the urine. In one embodiment, the siderophore binds to the K3Cys mutant protein and iron at blood pH. In another embodiment, the siderophore binds to the K3Cys mutant protein and iron in the blood.

In one embodiment, the K3Cys mutant protein and the siderophore are present in a 1:1 molar ratio. In another embodiment, the K3Cys mutant protein and the siderophore are present in a 1:3 molar ratio.

In another aspect, the present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys mutant protein.

In another aspect, the present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys mutant protein and a siderophore.

In another aspect, the present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys mutant protein.

In another aspect, the present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys mutant protein and a siderophore.

In another aspect, the present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

In another aspect, the present invention provides for a method for treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a complex of a K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, and a siderophore, wherein (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.

These and other embodiments of the invention are further described in the following sections of the application, including the Detailed Description, Examples, Claims, and Drawings.

BRIEF DESCRIPTION OF THE FIGURES

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the United States Patent and Trademark Office upon request and payment of the necessary fee.

FIG. 1. Alignment of Ngal protein from human (HsNgal; NP_(—)005555 —WT Human NGAL—SEQ ID NO: 1), mouse (MmNgal; NP_(—)032517, SEQ ID NO:17), rat (RnNgal; NP_(—)570097, SEQ ID NO:18), Chimpanzee (PtNgal, XP_(—)001153985, SEQ ID NO:14), bovine (BtNgal; XP 605012; SEQ ID NO:16), dog (CfNgal; SEQ ID NO:12), wild boar (SsNgal; SEQ ID NO:13), Rhesus Monkey (MamNgal, SEQ ID NO:15), and horse (Equus caballus (Ec) NGAL, SEQ ID NO:11). Human NGAL protein sequence is Bold, and the amino acid residues on the surface of NGAL proteins are underlined. Δ and ⋄ indicate the conserved and the non-conserved positively charged residues (Arginine [R], Lysine [K] and Histidine [H]) on the surface of functional Ngal protein, respectively. Magenta: positive charged residues; Blue: negative charged residues; red: nonpolar and hydrophobic residues; Green: polar and hydrophilic residues.

FIG. 2. Comparison of human (SEQ ID NO: 19) and mouse (SEQ ID NO: 20) megalin proteins. The sequences of the human and mouse megalin proteins were aligned by using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/), and were shown to share 76% identity and 87% similarity, respectively.

FIGS. 3A-3D. Screening for NGAL mutants exhibiting specific accumulation in urine. FIG. 3A. NGAL mutants bind to enterochelin (Ent) and ⁵⁵Fe³ to form a complex. Apo NGAL mutant protein (4 nmol) was mixed with equal molar Ent and ⁵⁵Fe³, and incubated at room temperature (RT) for 30 minutes. The mixture was then washed for 4×5 minutes in a filter column with a 10K cutoff, and the NGAL-bound Ent-⁵⁵Fe³⁺ was calculated as percentage of the starting total ⁵⁵Fe³⁺. FIGS. 3A-3D. The prepared NGAL-Ent-⁵⁵Fe³⁺ complex was intraperitoneally injected into mice (female, 4 weeks), and the urine, FIG. 3B, was collected for 3 hours in a metabolic cage. Liver, FIG. 3C, and kidneys, FIG. 3D, were dissected and solubilized in 1MNaOH and 2% SDS for examination of ⁵⁵Fe³ accumulation, expressed as a percentage of total NGAL-Ent-⁵⁵Fe³⁺ complex.

FIGS. 4A-4B. Comparison of structures of wild-type NGAL and the K3 mutant NGAL protein. FIG. 4A. Crystal structure of wild-type NGAL protein (Accession number: 1nglA.pdb) was used to predict the 3D structure of the K3 mutant protein by using Swissmodel (http://swissmodel.expasy.org). The organization of the Ent-iron binding pocket in the K3 protein is predicted to be very similar to that in wild-type NGAL. FIG. 4B. The K3 mutant protein has less positively charged residues (arginine, lysine or histidine) on its surface in comparison to wild-type NGAL according to the modeled 3D structure. Positive charged residues are shown as ball-and-stick molecules, and the yellow color indicates the solvent accessible surface of the NGAL protein.

FIG. 5. Percentage recovery of ⁵⁵Fe³⁺ following injection of NGAL mutant proteins complexed with enterochelin and ⁵⁵Fe³⁺. The amount of NGAL-bound Ent-⁵⁵Fe³⁺ was calculated as percentage of the starting total ⁵⁵Fe³⁺. Recovery in the urine, kidney, lung, spleen, liver, and heart is shown. D1 is SEQ ID NO: 32; B1 is SEQ ID NO: 24; K1 is SEQ ID NO: 7; K2 is SEQ ID NO: 3; K3 is SEQ ID NO: 2; K5 is SEQ ID NO: 6; I5 is SEQ ID NO: 45.

FIGS. 6A-6B. FIG. 6A. Left Enterochelin:Fe. The essential siderophore of gram negative organisms. It is composed of three catechol groups bound together by a backbone. Iron (red) is bound with affinity 10-49M. FIG. 6B. Right Enterochelin:Fe bound within the calyx of the Ngal protein with an affinity of 0.4 nM.

FIG. 7. Clearance of Ngal by the proximal tubule. Fl-Ngal was introduced into the peritoneum, and after 1 hour the kidney harvested. Ngal was localized to proximal tubule lysosomes.

FIG. 8. While ligand-metal charge-transfers between Ent and Fe3+ (lmax=498 nm) were not modified by the addition of Ngal protein (note red coloration in 2 left tubes), catechol:Fe3+ converted from a FeL complex (blue, lmax=575 nm) to a FeL3 complex (red, lmax=498 nm) when bound to Ngal (right tubes) and produced an identical spectrum as Ent:Fe.

FIG. 9. Trafficking of 55Fe bound to Ngal through the serum to the kidney was visualized by radioautography. Note the black silver grains in proximal tubules but not in distal nephrons after introduction of Ngal:Ent:55Fe or Ngal:catechol:55Fe.

FIG. 10. Urine was collected from both wild type and megalin deleted mice. Ngal was detected by immunoblot using polyclonal anti-mouse Ngal antibodies.

FIG. 11. Human kidney biopsy for AKI stained with anti-Ngal antibodies. Note the association of NGAL with Bowman's Capsule and with the proximal tubule (red-brown staining) apical endosomes.

FIG. 12. Release of ligands from Ngal as a result of acidification. Low pH released 55Fe from Ngal:catechol:FeIII complexes but not from Ngal:Ent:FeIII. FeIII loading at pH 7.0 was defined as 100% of the assay. Catechol differed significantly from Ent (P=0.00012).

FIG. 13. Top Urine Immunodetection by Western Blot of WT and mutant Ngal species in the urine 3 hrs after i.p. injection (80 micrograms). Middle Starting Material shows immunoblot of purified WT and Mutant Ngal proteins (100 ng) and Bottom SDS-Page and Coomassie stain of each mutant. The designations “WT” and “K numbers 1-8” represent Wild Type and actual Mutants K1, K2, D1-4-2-1-1, K5, D1-4-2-1-1-4, K3, WT-3 and WT4.

FIG. 14. 55Fe3+ retaining activity of wild-type and mutant Ngal:Ent. The designations “WT” and “K numbers 1-8” represent Wild Type and actual Mutants K1, K2, D1-4-2-1-1, K5, D1-4-2-1-1-4, K3, WT-3 and WT4.

FIGS. 15A-15B. Determination of the affinity of siderophore:iron in complex with wild type Ngal.FIG. 15A. Fluorescence quenching analysis of Ngal with siderophores (“L”) FIG. 15B. or Ngal with FeIII-siderophores (“FeL3”). Note that FeIII dramatically enhanced the affinity of Ngal for different catechols. 2,3DHBA=Ent.

FIG. 16. Analysis of 55Fe3+ which was delivered by wild-type or mutant Ngal:Ent into mouse urine. The designations “WT” and “K numbers 1-8” represent Wild Type and actual Mutants K1, K2, D1-4-2-1-1, K5, D1-4-2-1-1-4, K3, WT-3 and WT4.

FIG. 17. Ngal effectively chelates FeIII. Conversion of HPF to fluorescein (Ex 490 nm, Em 515 nm) was detected in the presence of catechol, ironIII and H2O2 (black line), but the addition of Ngal blocked this reaction (grey line); P<10-5.

FIG. 18. K3 Ngal mutant inhibits the Redox Activity of Iron. Oxidative radicals produced by Fe(III), catechol and H2O2 was detected by a fluorescent probe, 3′-(p-hydroxyphenyl) fluorescein (HPF), and the production of the Oxidative radicals was completely inhibited by wild-type (WT) and K3 Ngal proteins.

FIG. 19. Shows sequences and amino acid alignment of WT NGAL (SEQ ID NO: 1) and K3 NGAL (SEQ ID NO: 2).

FIG. 20. Left tube shows that NGAL binds Catechol:Fe found in the urine, generating a bright red color. The tube contains the K3 mutant form of NGAL which can bypass the proximal tubule and deliver Iron or Apo-NGAL to the urine. Right tube: Apo-Ngal. These data show that the K3 NGAL is capable of binding to siderophores such as Ent:Fe and therefore are predicted to transport iron from the blood into the urine.

FIG. 21. Amino acid sequence of K3Cys protein (Seq ID NO: 252).

FIGS. 22A-22B. FIG. 22A. Left: Western blot of different species of NGAL. Wild type NGAL forms protein dimers (46-50 KDa) from monomers (at 23-25 KDa). Similarly the Mutant1 (K3 NGAL) forms dimers from monomers. However, Mutant2 (K3Cys) only forms monomers. Right. NGAL proteins (Wt, Mut1 and Mut2) were injected into mice, and the NGAL proteins in the urine (uWt=urinary wild-type protein; uMut1=urinary Mut1 K3 and uMut2=urinary Mut2 K3Cys) were collected at two different time points, and analyzed by Western Blot. For each protein (uWt, uMut1 and uMut2), the 1st lane on the Western blot represents proteins that were collected in the urine 20 min. after the injection and the 2nd lane on the Western blot represents proteins that were collected from the mouse at 180 min. after the injection. Very low levels of uWt appear in urine, whereas higher levels of both uMut1 and uMut2 appear in urine. uMut1 forms both monomers and dimers, whereas uMut2 only forms monomers. FIG. 22B. Mice were injected with NGAL proteins (Wt, Mut1 and Mut2) that were labeled with the dye Alexa Fluor 568 (Molecular Probes—Invitrogen), which covalently attaches to the proteins. The urinary NGAL proteins (uWt, uMut1 and uMut2) were subsequently collected from the urine, and tested for by color at either 20 min or 180 min after collection (see tubes from left to right: 1st tube: uWt; at 20 min; 2nd tube: uWt at 180 min. 3rd tube: uMut1 at 20 min; 4th tube: uMut1 at 180 min; 5th tube: uMut2 at 20 min; 6th tube: uMut2 at 180 min tube). The darker the color, the higher the amount of protein present in the urine. These data demonstrate that both K3 and K3Cys can traffic to the urine but K3Cys appears more efficient.

FIG. 23 and FIG. 24. Distribution of NGAL:Ent:Fe in kidney and urine 180 minutes after their introduction in mice. Either wild-type NGAL protein (Wt) or K3Cys protein (Mutant (K3cys)) was introduced in mice and the percentage of iron recovered in either the urine or the kidney of the injected mouse was determined. The Y-axis represents the percentage of recovered iron. FIG. 23 and FIG. 24 are different mice. Note that iron associated with wild type NGAL remains in the kidney, while iron associated with the K3Cys is found in the urine, rather than in the kidney.

FIG. 25. Distribution of NGAL (Wt, K3 or K3Cys) labeled with the dye Alexa Fluor 568 (Molecular Probes—Invitrogen) in the mouse. Note that Wt NGAL is taken up by the kidney's proximal tubule, but limited uptake by K3 and K3Cys. Even more striking is the fact that K3Cys is essentially not found in the body (it is all excreted into the urine) whereas K3 is found in the liver's Kupffer cells (bright red staining).

FIG. 26. Top row Alexa568-mutant NGAL is captured in scattered cells in the collecting ducts outlined by collagen, including ATPase+ intercalated cells and Aquaporin2+ collecting ducts. Bottom row: Comparison wt, mut1, mut2 uptake in AE1+ cells.

FIG. 27. Three cell lines. LLCPK distinguishes wt and mutant Ngal and takes up only wt Ngal (red uptake), Intercalated cells take up both wild type and mutant Ngal, whereas UB cells take up neither wt nor mutant Ngal Green=fluorescent dextran which demonstrates that all of the cell lines have active endocytosis and highlights the fact that each have distinct NGAL uptake profiles.

FIG. 28. Superimposed structures of wild type and mutant 1 of Ngal demonstrating nearly identical structures with the potential to bind siderophores and iron (red sphere). Mutant amino acids are indicated in yellow.

FIGS. 29A-29C. Redox measurements of mutant Ngal. In the first two panels, the conversion of HPF to fluorescein is detected in the presence of catechol or Ent and iron. However, when Ngal species are added, the activity is suppressed. Similarly when conversion of ferric to ferrous iron is detected (due to the intrinsic reductase activity of catechol groups), Ngal species suppressed the activity. Mutant Ngal was as effective as wt NGAL.

FIG. 30. Purification of NGAL protein. NaCL gradient showing that the small peak contains the majority of the NGAL protein.

DETAILED DESCRIPTION

The present invention is based, in part, on the development of mutant versions of the NGAL protein that are not reabsorbed in the kidney and thus, unlike wild-type NGAL, are excreted in the urine. These mutant forms of NGAL have the ability to bind to iron-binding siderophores, such as enterochelin, and can be used to traffic iron out of the body by excretion in the urine. As such, the mutant NGAL proteins of the invention can be used in the treatment of iron overload and diseases and disorders associated with iron overload. In addition, the mutant NGAL proteins of the invention have bacteriostatic activity and can be used to treat infections of the urinary tract. Thus, the present invention provides mutant NGAL proteins, pharmaceutical compositions comprising such mutant NGAL proteins, either alone or complexed with siderophores, and the use of such mutant NGAL proteins and compositions in the treatment of various disorders and diseases, such as in the treatment of disorders associated with iron overload and in the treatment of bacterial infections of the urinary tract. These and other aspects of the present invention are described more fully below, and also in other sections of this application.

As discussed herein, a series of defined mutations in the positive surface residues of Ngal were made and clones that traffic into the urine (i.e. bypassing megalin) were identified. A mutation in the unpaired cysteine was introduced to block the homodimerization of the NGAL mutant referred to as a “K3” NGAL. In the resultant new NGAL protein, called K3Cys, the cysteine residue at position 87 in K3 NGAL is substituted with a serine residue. This substitution resulted in the loss of dimerization of the K3Cys protein, which forms monomers. This K3Cys protein appeared earlier in the urine than K3 NGAL protein which was still capable of dimerization. This nearly complete loss of NGAL from the mouse by filtration and urinary excretion is most likely a result of the lower molecular weight of the monomeric-non dimerizable species.

ABBREVIATIONS AND DEFINITIONS

The abbreviation “NGAL” refers to Neutrophil Gelatinase Associated Lipocalin. NGAL is also referred to in the art as human neutrophil lipocalin, siderocalin, a-micropglobulin related protein, Scn-NGAL, lipocalin 2, 24p3, superinducible protein 24 (SIP24), uterocalin, and neu-related lipocalin. These alternative names for NGAL may be used interchangeably herein. Unless stated otherwise, the term “NGAL”, as used herein, includes any NGAL protein, fragment, or mutant. In some embodiments the NGAL protein is wild-type human NGAL. In other embodiments the NGAL protein is a mutant NGAL protein.

The abbreviation hNGAL refers to human NGAL.

The abbreviation “WT” refers to wild-type, such as a wild-type nucleotide or amino acid sequence.

The abbreviation “K3Cys” refers to a mutant K3 NGAL protein (SEQ ID NO:2) that contains a cysteine residue at position 87. The amino acid sequence of K3Cys is represented by SEQ ID NO: 252. The designation “K3Cys” is used interchangeably with the designations “K3 Cys”, “K3Cys protein”, “K3 Cys NGAL” and “K3Cys NGAL”.

The phrase “K3Cys mutant” refers to a K3Cys protein that contains one or more amino acid mutations, including, but not limited to, substitutions, deletions and insertions. The designation “K3Cys mutant” is used interchangeably with the designation “K3Cys mutant protein”.

As used herein the term “about” is used herein to mean approximately, roughly, around, or in the region of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20 percent up or down (higher or lower).

NGAL

NGAL is a small protein with a molecular weight of about 22 kD and is a siderophore binding protein. A siderophore is an organic molecule that binds to and chelates iron. Bacteria produce the siderophore enterochelin, and mammals endogenously express a similar type, but simpler molecule called catechol. Enterochelin has an extremely high affinity for iron, and wild type NGAL has a high affinity for the enterochelin-iron complex. The enterochelin-iron-NGAL complex is pH insensitive and the bound iron is redox inactive. Thus the iron bound by such NGAL complexes is not available to catalyze oxygen radical formation, making NGAL an ideal iron chelator for in vivo use.

NGAL, and once produced in cells, is secreted into extracellular space and quickly cleared by kidney with a half-life of 10 minutes. Serum and urine levels of the protein can become very high in a number of disease models. The NGAL protein is transported into the kidney of healthy humans and can pass the filtration barrier of the glomerulus (the cut-off size of filtration is about 70 kD) to enter the primary urine, but then NGAL is efficiently reabsorbed by megalin or megalin-cubilin-cubilin receptors localized on the apical side of the epithelia of the proximal tubules. Megalin is a universal receptor with broad substrate specificity and is expressed at the apical surface of the proximal tubules of the kidney where it is involved in protein reabsorption. The binding of megalin to its substrates is mediated by ionic interactions, and its negative charged substrate binding domains can efficiently bind to the positively charged surfaces of proteins in the urinary filtrate. Once absorbed and endocytosed, NGAL is trafficked to lysosomes, where it is degraded. Once degraded, the iron which NGAL transported to the kidney is reabsorbed.

K3 NGAL

The present invention provides mutant NGAL proteins, including, but not limited to those which have been mutated to remove positively charged residues that may be involved in the megalin interaction.

The terms “mutant NGAL protein” and “NGAL mutant” as used herein, refer to a protein or an amino acid sequence that differs by one or more amino acids from the amino acid sequence of WT human NGAL (SEQ ID NO. 1, see sequence of HsNGAL in FIG. 1).

The invention provides for a mutant NGAL protein, K3 (or K3 NGAL, or K3 NGA1 protein), that has an amino acid sequence identical to SEQ ID NO: 2 (Table 2).

Like WT NGAL, K3 NGAL has high affinity for enterochelin-iron complexes but appear to have significantly reduced affinity for megalin. Thus, rather than being reabsorbed by a megalin receptor mediated mechanism in the kidney, K3 NGAL of the invention, and complexes of K3 NGAL with enterochelin and iron, are not efficiently reabsorbed in the kidney and are instead excreted in the urine. The K3 NGAL protein of the invention can thus be used to efficiently remove excessive iron from the body and traffic it into the urine in a safe redox inactive form. Furthermore, previous reports have shown that NGAL-enterochelin-iron has little or no chemical or cellular toxicity, suggesting that it could be safely used therapeutically, for example in the therapeutic treatment of diseases and disorders associated with iron overload, such as hemochromatosis.

K3Cys

The present invention provides a mutant K3 NGAL protein, “K3Cys”, which comprises a K3 NGAL protein (SEQ ID NO:2) in which the cysteine residue at position 87 (Cysteine 87) was substituted with a serine residue. The amino acid sequence of K3Cys is identical to SEQ ID NO:252. Thus, rather than being reabsorbed by a megalin receptor mediated mechanism in the kidney, K3Cys, and complexes of this mutant with enterochelin and iron, are not efficiently reabsorbed in the kidney and are instead excreted in the urine. K3Cys can thus be used to efficiently remove excessive iron from the body and traffic it into the urine in a safe redox inactive form. Furthermore, previous reports have shown that NGAL-enterochelin-iron has little or no chemical or cellular toxicity, indicating that it could be safely used therapeutically, for example in the therapeutic treatment of diseases and disorders associated with iron overload, such as hemochromatosis.

In one aspect, the present invention provides a K3Cys protein that comprises, consists essentially of, or consists of an amino acid sequence that is identical to SEQ ID NO. 252, and wherein the K3Cys protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than the WT NGAL protein, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the WT NGAL protein, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to the WT NGAL protein, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the WT NGAL protein, and wherein the K3Cys protein also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity.

In another aspect, the present invention provides a K3Cys protein that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98%, or at least 99% identical to SEQ ID NO. 252, and wherein the K3Cys protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than the WT NGAL protein, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the WT NGAL protein, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to the WT NGAL protein, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the WT NGAL protein, and wherein the K3Cys protein also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity.

K3Cys Mutants

The present invention also provides for K3Cys mutants, which comprise K3Cys proteins that contain one or more amino acid mutations, including, but not limited to, substitutions, deletions and insertions.

K3Cys mutants may have one or more “non conservative” changes, as compared to K3Cys, wherein a given amino acid is substituted with another amino acid that has different structural or chemical properties. In several embodiments of the invention basic/positively charged lysine, arginine, and/or histidine residues on the surface of K3Cys mutants, such as those that interact with megalin, are mutated by substituting these residues with non-basic/non-positively charged residues. These are non-conservative changes. For example, in several embodiments of the invention basic/positively charged lysine (Lys-K), arginine (Arg-R), and/or histidine (His-H), residues, such as those on the surface of K3Cys mutants that may be involved in the megalin interaction, are substituted with non-basic/non-positively charged residues such as alanine (Ala-A), asparagine (Asn-N), aspartic acid (Asp-D), cysteine (Cys-C), glutamine (Gln-Q), glutamic acid (glu-E), glycine (Gly-G), isoleucine (Ile-I), leucine (Leu-L), methionine (Met-M), phenylalanine (Phe-F), proline (Pro-P), serine (Ser-S), threonine (thr-T), tryptophan (Trp-W), tyrosine (Tyr-Y), and valine (Val-V). In some embodiments, basic/positively charged lysine, arginine, and/or histidine residues are substituted with negatively charged residues such as aspartic acid (Asp-D) and glutamic acid (Glu-E).

In some embodiments, the K3Cys mutant may have one or more “conservative” changes, as compared to K3Cys, wherein a given amino acid is substituted for another amino acid that has similar structural or chemical properties. For example, in some embodiments it is desirable to either leave the residues of the K3Cys mutant that are involved in the siderophore interaction intact or to only make conservative changes at those residues. Various other conservative amino acid substitutions may be made throughout the K3Cys mutant, such as conservative amino acid substitutions that do not destroy the ability of the K3Cys mutant to transport iron out of the body. One type of conservative amino acid substitution refers to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic hydroxyl side chains is serine and threonine; a group of amino acids having amide containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur containing side chains is cysteine and methionine. Useful conservative amino acids substitution groups are: valine leucine isoleucine, phenylalanine tyrosine, lysine arginine, alanine valine, and asparagine glutamine.

The K3Cys mutant may contain various mutations (including additions, deletions, and substitutions), including, for example, additions to or deletions from the N- and/or C-termini of the K3Cys mutant. Any such mutations can be made to the extent that they do not adversely affect the ability of the K3Cys mutant to bind to a siderophore, to transport iron, and/or to be excreted in the urine.

In further embodiments, the K3Cys mutant may comprise one or more non-naturally occurring amino acids. Non-natural amino acids, such as those that contain unique side chain functional groups including halogens, unsaturated hydrocarbons, heterocycles, silicon, and organometallic units, can offer advantages in improving the stability of proteins. Many such non-naturally occurring amino acids are known. Such non-naturally occurring amino acids can be used in the K3Cys mutant.

In one embodiment the cysteine 87 residue of the K3Cys mutant is deleted. In another embodiment, the cysteine 87 residue of the K3Cys mutant is substituted with a non-positively charged amino acid (i.e. a non-conservative substitution). In another embodiment the cysteine 87 residue of the K3Cys mutant, is substituted with a negatively charged amino acid (i.e. a non-conservative substitution). In another embodiment, the cysteine 87 residue of the K3Cys mutant is substituted with an alanine residue. In another embodiment, the K3Cys mutant may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, or substitutions for negatively charged amino acids may be present at any one, two, three, four, five, six, seven, eight nine, ten, eleven, twelve, or all thirteen of the above listed amino acid residues. In preferred embodiments, the K3Cys mutant is not mutated (i.e. has the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 15 is substituted with an uncharged amino acid, including, but not limited to, Ser (S). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 46 is substituted with a negatively charged amino acid, including, but not limited to, Glu (E). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 50 is substituted with an uncharged amino acid, including, but not limited to, Thr (T). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 59 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 62 is substituted with an uncharged amino acid, including, but not limited to, Gly (G). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 73 is substituted with a negatively charged amino acid, including, but not limited to, Asp (D). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 74 is substituted with a negatively charged amino acid, including, but not limited to, Asp (D). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 75 is substituted with an aliphatic amino acid, including, but not limited to, Gly (G). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 98 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides a K3Cys mutant in which H is (H) 118 is substituted with a non-polar amino acid, including, but not limited to, Phe (F). In one preferred embodiment the present invention provides a K3Cys mutant in which Arg (R) 130 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides a K3Cys mutant in which Lys (K) 149 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides a K3Cys mutant in which His (H) 165 is substituted with an uncharged amino acid, including, but not limited to, Asn (N).

In one embodiment, the present invention provides a K3Cys mutant protein that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K3Cys protein (SEQ ID NO. 252), or a fragment thereof, wherein one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or all thirteen residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the K3Cys mutant protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than the K3Cys protein and/or WT NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the K3Cys protein and/or WT NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to the K3Cys protein and/or WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the K3Cys protein and/or WT NGAL, and wherein the K3Cys mutant protein also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In preferred embodiments, such K3Cys mutant proteins are not mutated (i.e. have the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In some embodiments, the K3Cys mutant has the amino acids specified in SEQ ID NO:252 (Table 2) at residues 15, 46, 59, 62, 73, 74, 75, 98, 118, 130, 149, and 165, but other amino acid residues can differ from the specified sequences provided that the K3Cys mutant protein is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K3Cys protein (SEQ ID NO: 252), or a fragment thereof, and provided that the K3Cys mutant protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than K3Cys protein and/or WT NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the K3Cys protein and/or WT NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to K3Cys protein and/or WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the K3Cys protein and/or WT NGAL, and also provided that the K3Cys mutant protein (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to the K3Cys protein. In preferred embodiments such K3Cys mutant proteins are not mutated (i.e. have the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In further embodiments, a K3Cys mutant protein described above that has mutations in one or more of the thirteen non-conserved positive/basic surface residues, can also have mutations in one or more of the five conserved positive/based surface residues below, or one or more of the other mutations described in other following sections of this Detailed Description.

Five Conserved Positive/Basic Surface Residues in NGAL

The K3Cys protein contains five basic/positive surface amino acid residues that are conserved among human, rat, mouse, chimpanzee, cow, dog, wild boar and rhesus monkey species, namely residues Arg(R) 43, Arg(R) 72, Arg(R) 140, Lys(K) 142, and Lys(K) 157. In one embodiment, the present invention provides K3Cys mutant proteins having one, two, three, four, or all five of these amino acid positions mutated as compared to the K3Cys protein. In one embodiment the mutated amino acid residue or residues are deleted. In another embodiment the mutated amino acid residue or residues are substituted with a non-positively charged amino acid (i.e. a non-conservative change). In another embodiment the mutated amino acid residue or residues are substituted with a negatively charged amino acid (i.e. a non-conservative change). In another embodiment the K3Cys mutant protein may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, or substitutions for negatively charged amino acids may be provided at one, two, three, four, or five of the above listed amino acid residues.

In one embodiment, the present invention provides a K3Cys mutant protein that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K3Cys protein (SEQ ID NO. 252), or a fragment thereof, wherein one, two, three, four, or all five residues from among (R) 43, Arg(R) 72, Arg(R) 140, Lys(K) 142, and Lys(K) 157 is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the K3Cys mutant protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than the K3Cys protein and/or WT NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the K3Cys protein and/or WT NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to the K3Cys protein and/or WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the K3Cys protein and/or WT NGAL, and wherein the K3Cys mutant protein also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In preferred embodiments such K3Cys mutant proteins are not mutated (i.e. have the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In further embodiments, the K3Cys mutant proteins described in this section that have mutations in one or more of the five conserved positive/basic surface residues, can also have mutations in one or more of the thirteen non-conserved positive/based surface residues described in the previous section of the Detailed Description, or one or more of the other mutations described in the following sections of this Detailed Description.

Additional Surface Residues in NGAL

The following amino acid residues are located on the surface of the K3Cys protein and can play a role in the interaction of the K3Cys protein with the megalin protein and/or in the reabsorption of the K3Cys protein in the kidney: amino acid residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and 170-174.

In one embodiment, the K3Cys mutant proteins of the invention comprise, consist of, or consist essentially of amino acid sequences that are based on the amino acid sequence of human K3Cys protein, or a fragment thereof, but that contain mutations at one or more of the individual amino acid residues located at residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and/or 170-174 of the K3Cys protein. In one embodiment one or more of the mutated amino acid residues can be deleted. In another embodiment one or more of the mutated amino acid residues can be substituted with a non-positively charged amino acid, including, but not limited to a negatively charged amino acid. In another embodiment the K3Cys mutant protein may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, and/or substitutions for negatively charged amino acids at any one or more of the above listed amino acid residues.

In some embodiments, K3Cys mutant proteins are mutated, at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134.

In other embodiments, K3Cys mutant proteins are not mutated (i.e. have the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In one embodiment, the present invention provides a K3Cys mutant protein that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K3Cys protein (SEQ ID NO: 252), or a fragment thereof, wherein one or more of the individual amino acid residues located at residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and/or 170-174 of the K3Cys mutant is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the K3Cys mutant protein: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than the K3Cys protein and/or WT NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to the K3Cys protein and/or WT NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to the K3Cys protein and/or WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to the K3Cys protein and/or WT NGAL, and wherein the K3Cys protein (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In preferred embodiments such K3Cys mutant proteins are not mutated (i.e. have the same amino acid sequence as the K3Cys protein), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

NGAL Mutants

The present invention provides mutant NGAL proteins, including, but not limited to those which have been mutated to remove positively charged residues that may be involved in the megalin interaction. Like WT NGAL, the NGAL mutants of the invention have high affinity for enterochelin-iron complexes but appear to have significantly reduced affinity for megalin (Table 1). Thus, rather than being reabsorbed by a megalin receptor mediated mechanism in the kidney, the NGAL mutants of the invention, and complexes of these mutants with enterochelin and iron, are not efficiently reabsorbed in the kidney and are instead excreted in the urine. The mutant NGAL proteins of the invention can thus be used to efficiently remove excessive iron from the body and traffic it into the urine in a safe redox inactive form. Furthermore, previous reports have shown that NGAL-enterochelin-iron has little or no chemical or cellular toxicity, suggesting that it could be safely used therapeutically, for example in the therapeutic treatment of diseases and disorders associated with iron overload, such as hemochromatosis.

The terms “mutant NGAL protein” and “NGAL mutant” as used herein, refer to a protein or an amino acid sequence that differs by one or more amino acids from the amino acid sequence of WT human NGAL (SEQ ID NO. 1, see sequence of HsNGAL in FIG. 1).

The mutant NGAL proteins of the invention may have one or more “non conservative” changes, wherein a given amino acid is substituted with another amino acid that has different structural or chemical properties. In several embodiments of the invention basic/positively charged lysine, arginine, and/or histidine residues on the surface of the NGAL protein, such as those that interact with megalin, are mutated by substituting these residues with non-basic/non-positively charged residues. These are non-conservative changes. For example, in several embodiments of the invention basic/positively charged lysine (Lys-K), arginine (Arg-R), and/or histidine (His-H), residues, such as those on the surface of the NGAL protein that may be involved in the megalin interaction, are substituted with non-basic/non-positively charged residues such as alanine (Ala-A), asparagine (Asn-N), aspartic acid (Asp-D), cysteine (Cys-C), glutamine (Gln-Q), glutamic acid (glu-E), glycine (Gly-G), isoleucine (Ile-I), leucine (Leu-L), methionine (Met-M), phenylalanine (Phe-F), proline (Pro-P), serine (Ser-S), threonine (thr-T), tryptophan (Trp-W), tyrosine (Tyr-Y), and valine (Val-V). In some embodiments, basic/positively charged lysine, arginine, and/or histidine residues are substituted with negatively charged residues such as aspartic acid (Asp-D) and glutamic acid (Glu-E).

In some embodiments the mutant NGAL proteins of the invention may have one or more “conservative” changes, wherein a given amino acid is substituted for another amino acid that has similar structural or chemical properties. For example, in some embodiments it is desirable to either leave the residues of NGAL that are involved in the siderophore interaction intact or to only make conservative changes at those residues. Various other conservative amino acid substitutions may be made throughout the NGAL protein, such as conservative amino acid substitutions that do not destroy the ability of the NGAL mutants of the invention to transport iron out of the body. One type of conservative amino acid substitution refers to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic hydroxyl side chains is serine and threonine; a group of amino acids having amide containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur containing side chains is cysteine and methionine. Useful conservative amino acids substitution groups are: valine leucine isoleucine, phenylalanine tyrosine, lysine arginine, alanine valine, and asparagine glutamine.

The mutant NGAL proteins of the invention may contain various mutations (including additions, deletions, and substitutions) in addition to the mutations of specific residues set forth herein (below), including, for example, additions to or deletions from the N- and/or C-termini of the NGAL mutants. Any such mutations can be made to the extent that they do not adversely affect the ability of the NGAL mutants to bind to a siderophore, to transport iron, and/or to be excreted in the urine.

In further embodiments, the NGAL mutants of the invention may comprise one or more non-naturally occurring amino acids. Non-natural amino acids, such as those that contain unique side chain functional groups including halogens, unsaturated hydrocarbons, heterocycles, silicon, and organometallic units, can offer advantages in improving the stability of proteins. Many such non-naturally occurring amino acids are known. Such non-naturally occurring amino acids can be used in the NGAL mutants of the invention.

In certain embodiments, the present invention provides NGAL mutants having a certain % identity to WT human NGAL or to some other NGAL mutant. The following terms are used to describe the sequence relationships between two or more polynucleotides or amino acid sequences: “sequence identity,” “percentage sequence identity” and “identity.” These terms are used in accordance with their usual meaning in the art. Percentage sequence identity is measured with reference to a reference sequence. The term “sequence identity” means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide basis). The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences, determining the number of positions at which the identical nucleic acid base or amino acid occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions, and multiplying the result by 100 to yield the percentage of sequence identity.

Thirteen Non-Conserved Positive Surface Residues in NGAL

The NGAL protein contains thirteen basic/positive surface amino acid residues that are not conserved among species, namely residues Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165. Data presented in the present application demonstrate that mutations of various combinations of these thirteen amino acid residues results in the generation of NGAL mutants that, like WT NGAL, have the ability to bind to enterochelin-iron but, unlike WT NGAL, are not effectively reabsorbed in the kidney. Such NGAL mutants, when complexed with a siderophore such as enterochelin, can be used to transport excess iron out of the body by facilitating its excretion in the urine. Such NGAL mutants may also have bacteriostatic activity and can be used to treat bacterial infections of the urinary tract.

In one embodiment, the mutant NGAL proteins of the invention comprise, consist of, or consist essentially of amino acid sequences that are based on the amino acid sequence of WT human NGAL, or a fragment thereof, but that contain one or more mutations. In one embodiment, the present invention provides an NGAL mutant having one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or all thirteen of the following amino acid positions mutated as compared to WT human NGAL: Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL.

In one embodiment the mutated amino acid residues are deleted. In another embodiment the mutated amino acid residues are substituted with a non-positively charged amino acid (i.e. a non-conservative substitution). In another embodiment the mutated amino acid residues are substituted with a negatively charged amino acid (i.e. a non-conservative substitution). In another embodiment the NGAL mutant may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, or substitutions for negatively charged amino acids may be present at any one, two, three, four, five, six, seven, eight nine, ten, eleven, twelve, or all thirteen of the above listed amino acid residues. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 15 is substituted with an uncharged amino acid, including, but not limited to, Ser (S). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 46 is substituted with a negatively charged amino acid, including, but not limited to, Glu (E). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 50 is substituted with an uncharged amino acid, including, but not limited to, Thr (T). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 59 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 62 is substituted with an uncharged amino acid, including, but not limited to, Gly (G). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 73 is substituted with a negatively charged amino acid, including, but not limited to, Asp (D). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 74 is substituted with a negatively charged amino acid, including, but not limited to, Asp (D). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 75 is substituted with an aliphatic amino acid, including, but not limited to, Gly (G). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 98 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides an NGAL mutant in which His (H) 118 is substituted with a non-polar amino acid, including, but not limited to, Phe (F). In one preferred embodiment the present invention provides an NGAL mutant in which Arg (R) 130 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides an NGAL mutant in which Lys (K) 149 is substituted with an uncharged amino acid, including, but not limited to, Gln (O). In one preferred embodiment the present invention provides an NGAL mutant in which His (H) 165 is substituted with an uncharged amino acid, including, but not limited to, Asn (N).

In one embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of WT human NGAL (SEQ ID NO. 1), or a fragment thereof, wherein one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or all thirteen residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

Exemplary NGAL mutants of the invention include those that comprise the sequence of mutants K1, K2, K3, K5, I1, I3, F4, F5, and B2 (see Table 2), or that comprise fragments or variants of such sequences. In some embodiments such variants have the amino acids specified in Table 2 at residues 15, 46, 59, 62, 73, 74, 75, 98, 118, 130, 149, and 165, but other amino acid residues can differ from the specified sequences provided that the NGAL mutant is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of WT human NGAL (SEQ ID NO. 1), or a fragment thereof, and provided that the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and also provided that he NGAL mutant (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In one embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K3 NGAL mutant (SEQ ID NO. 2), wherein residues 15, 46, 73, 74, 75, 98, 118, 130, 149, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K2 NGAL mutant (SEQ ID NO. 3), wherein residues 15, 73, 74, 75, 98, 118, 130, 149, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the 13 NGAL mutant (SEQ ID NO. 4), wherein residues 62, 73, 74, 75, and 98 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the I1 NGAL mutant (SEQ ID NO. 5), wherein residues 15, 73, 74, 75, and 130 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also ((i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K5 NGAL mutant (SEQ ID NO. 6), wherein residues 15, 46, 98, 118, 130, 149, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the F4 NGAL mutant (SEQ ID NO. 8), wherein residues 15 and 46 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the F5 NGAL mutant (SEQ ID NO. 9), wherein residues 15, 46, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the B2 NGAL mutant (SEQ ID NO. 10), wherein residues 15, 46, 118, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In another embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of the K1 NGAL mutant (SEQ ID NO. 7), wherein residues 15, 46, 59, 98, 118, 130, 149, and 165 each differ from the sequence of WT human NGAL and are each non-positively charged amino acids, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In some embodiments five or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments six or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments seven or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments eight or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments nine or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In some embodiments ten or more of the thirteen listed amino acid positions are mutated as compared to WT human NGAL. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In further embodiments the NGAL mutants described above that have mutations in one or more of the thirteen non-conserved positive/basic surface residues, can also have mutations in one or more of the five conserved positive/based surface residues below, or one or more of the other mutations described in other following sections of this Detailed Description.

Five Conserved Positive/Basic Surface Residues in NGAL

The NGAL protein contains five basic/positive surface amino acid residues that are conserved among human, rat, mouse, chimpanzee, cow, dog, wild boar and rhesus monkey species, namely residues Arg(R) 43, Arg(R) 72, Arg(R) 140, Lys(K) 142, and Lys(K) 157. In one embodiment, the present invention provides an NGAL mutant having one, two, three, four, or all five of these amino acid positions mutated as compared to WT human NGAL. In one embodiment the mutated amino acid residue or residues are deleted. In another embodiment the mutated amino acid residue or residues are substituted with a non-positively charged amino acid (i.e. a non-conservative change). In another embodiment the mutated amino acid residue or residues are substituted with a negatively charged amino acid (i.e. a non-conservative change). In another embodiment the NGAL mutant may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, or substitutions for negatively charged amino acids may be provided at one, two, three, four, or five of the above listed amino acid residues.

In one embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of WT human NGAL (SEQ ID NO. 1), or a fragment thereof, wherein one, two, three, four, or all five residues from among (R) 43, Arg(R) 72, Arg(R) 140, Lys(K) 142, and Lys(K) 157 is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant also (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In further embodiments the NGAL mutants described in this section that have mutations in one or more of the five conserved positive/basic surface residues, can also have mutations in one or more of the thirteen non-conserved positive/based surface residues described in the previous section of the Detailed Description, or one or more of the other mutations described in the following sections of this Detailed Description.

Additional Surface Residues in NGAL

The following amino acid residues are located on the surface of the NGAL protein and can play a role in the interaction of the NGAL protein with the megalin protein and/or in the reabsorption of NGAL in the kidney: amino acid residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and 170-174.

In one embodiment, the mutant NGAL proteins of the invention comprise, consist of, or consist essentially of amino acid sequences that are based on the amino acid sequence of human NGAL, or a fragment thereof, but that contain mutations as at one or more of the individual amino acid residues located at residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and/or 170-174 of WT human NGAL. In one embodiment one or more of the mutated amino acid residues can be deleted. In another embodiment one or more of the mutated amino acid residues can be substituted with a non-positively charged amino acid, including, but not limited to a negatively charged amino acid.

In another embodiment the NGAL mutant may comprise any combination of such mutations, i.e. any combination of deletions, substitutions for non-positively charged amino acids, and/or substitutions for negatively charged amino acids at any one or more of the above listed amino acid residues. Table 2 provides details of all possible mutations of the surface residues of NGAL that are contemplated by the present invention. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

In one embodiment, the present invention provides an NGAL mutant that comprises, consists essentially of, or consists of an amino acid sequence that is at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% identical to the sequence of WT human NGAL (SEQ ID NO. 1), or a fragment thereof, wherein one or more of the individual amino acid residues located at residues 1-15, 17-26, 40-50, 57-62, 71-82, 84-89, 96-105, 114-118, 128-131, 134, 140-151, 157-165, and/or 170-174 of WT human NGAL is deleted or substituted with a non-positively charged amino acid, such as a negatively charged amino acid, and wherein the NGAL mutant: (a) is excreted in the urine or exhibits a greater level of excretion in the urine than WT human NGAL, and/or (b) is not reabsorbed in the proximal tubule of the kidney or exhibits a lower level of reabsorption in the proximal tubule of the kidney as compared to WT human NGAL, and/or (c) is not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism, and/or (d) has reduced affinity for the megalin-cubilin-receptor as compared to WT NGAL, and/or (e) has fewer positively charged residues on its solvent accessible surface as compared to WT human NGAL, and wherein the NGAL mutant (i) is able to bind to a siderophore, and/or (ii) is able to bind to a siderophore complexed with iron, and/or (iii) has a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) has bacteriostatic activity. In preferred embodiments such NGAL mutants are not mutated (i.e. have the same amino acid sequence as WT human NGAL), at one or more, or more preferably all, of the following amino acid residues that are involved in the NGAL-enterochelin interaction: Asparagine 39, Alanine 40, Tyrosine 52, Serine 68, Trptophan 79, Arginine 81, Tyrosine 100, Tyrosine 106, Phenylalanine 123, Lysine 125, Tyrosine 132, Phenylalanine 133, and Lysine 134, or if mutated at these residues only conservative substitutions are made.

Functional Properties of NGAL Mutants

In certain embodiments the mutant NGAL proteins of the invention have certain specified functions. For example, in some embodiments the mutant NGAL proteins of the invention have one or more of the following properties: (a) they are excreted in the urine or exhibit a greater level of excretion in the urine than WT human NGAL, and/or (b) they are not reabsorbed in the proximal tubule of the kidney or exhibit a lower level of reabsorption in the proximal tubule of the kidney than WT human NGAL, and/or (c) they are not a substrate for reabsorption in the kidney by a megalin-cubilin-receptor mediated mechanism. Similarly, in some embodiments the mutant NGAL proteins of the invention have one or more of the following properties: (i) they are able to bind to enterochelin-type siderophores, and/or (ii) they are able to bind to enterochelin-type siderophores complexed with iron, and/or (iii) they have a preserved three-dimensional structure of the enterochelin binding pocket and/or (iv) they have bacteriostatic activity.

Each of the above properties of the mutant NGAL proteins of the invention can be tested for and/or quantified, and in some embodiments the mutant NGAL proteins of the invention have functional properties that fall within a certain numeric range.

For example, in some embodiments the mutant NGAL proteins of the invention are excreted in the urine or exhibit a greater level of excretion in the urine than WT human NGAL. Excretion of the mutant NGAL proteins of the invention can be detected and quantified, for example using the methods described in the Examples section of this application. For example the amount of the mutant NGAL protein present in the urine a given time after its is administered to a subject, such as a mouse or a human subject, can be measured and can be expressed as a percentage of the total amount administered (see Examples and Table 1) to give a % accumulation in the urine. The % accumulation in the urine of a given NGAL mutant can be compared to that of other mutants or of WT NGAL. NGAL or an NGAL mutant or siderophore complex thereof can be radiolabeled (e.g. with radioactive iron) or labeled with some other detectable moiety in order to facilitate its detection and quantification. In some embodiments the present invention provides that the mutant NGAL proteins of the invention exhibit a greater level of excretion in the urine than does WT human NGAL. For example, the NGAL mutants can have a 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 100-fold or higher level of excretion in the urine than WT human NGAL. As seen in FIG. 5, WT NGAL can have a accumulation in the urine (measured as a % of the amount administered intraperitoneally) of less than 0.2%. In contrast, as can be seen from FIG. 3, FIG. 5, and Table 1, the NGAL mutants of the invention can have a % accumulation in the urine (measured as a % of the amount administered intraperitoneally 3 hours after administration) of greater than 1%, or greater than 2%, or greater than 3%, or greater than 4%, or greater than 5%, or greater than 6%, or greater than 7%, or greater than 8%, or greater than 9%, or greater than 10%, or greater than 15%, or greater than 20%, or more.

In some embodiments the mutant NGAL proteins of the invention are able to bind to siderophores, such as enterochelin, and/or they are able to bind to siderophores complexed with iron. The ability of the NGAL mutants of the invention to bind to siderophores and siderophore-iron complexes can be tested and/or quantified, for example using the methods described in the Examples section of this application. For example NGAL (including the NGAL mutants of the invention) and siderophore molecules such as enterochelin and iron associate with each other in a 1:1:1 molar ratio and NGAL (including the NGAL mutants of the invention) and siderophore molecules such as catechol and iron associate with each other in a 1:3:1 molar ratio. Accordingly using a radiolabelled form of iron the binding of NGAL to siderophore molecules and iron can be measured or estimated by examining the % of radiolabelled iron that is retained by a given NGAL protein. The % of iron (iron-siderophore) that is retained can be compared between NGAL mutants or between an NGAL mutant and WT NGAL. In some embodiments the present invention provides that the mutant NGAL proteins of the invention exhibit a similar % of iron (iron-siderophore) retention as compared to WT NGAL. In some embodiments the present invention provides that the mutant NGAL proteins of the invention exhibit a higher % of iron (iron-siderophore) retention as compared to WT NGAL, such as a 1.5-fold, 2-fold, 2.5-fold or greater-fold higher % of iron (iron-siderophore) retention. In some embodiments, the mutant NGAL proteins of the invention exhibit a % iron (iron-siderophore) retention of about 20% or more, or about 30% or more, or about 40% or more.

In some embodiments the mutant NGAL proteins of the invention have anti-bacterial activity. Antibacterial activity of the NGAL mutants of the invention can be tested and/or quantified, for example using standard methodologies known in the art, for example by culturing bacteria in the presence of the NGAL mutants and assessing the effect of the NGAL mutants on bacterial growth, survival, numbers, etc. in comparison to control conditions in which no NGAL mutant is present.

In one embodiment, Ngal mutants bypass megalin. In another embodiment, Ngal mutants bind Ent:iron. Thus, the Ngal mutants of the invention comprise a therapeutic that can safely excrete NTBI in the urine.

Non-NGAL Lipocalins

In addition to mutants of NGAL, the present invention also contemplates that mutants of other lipocalins can be made that, like the NGAL mutants described herein, have the ability to bind to siderophore-iron complexes but that are not reabsorbed in the kidney. It is expected that such lipocalin mutants could be used similarly to the NGAL mutants described herein to traffic iron out of the body and could thus be used in the treatment of iron overload disorders. It is also expected that such lipocalin mutants could also be used to treat bacterial infections of the urinary tract.

There are about 20 known proteins in the lipocalin family. Any lipocalin protein, or homolog, variant, derivative, fragment, or mutant thereof, that binds to a siderophore-iron complex can be mutated in order to provide a lipocalin mutant of the invention. Examples of lipocalins that can be used in accordance with the present invention include, but are not limited to, retinol binding protein, lipocalin allergen, aphrodisin, alpha-2-microglobulin, prostaglandin D synthase, beta-lactoglobulin, bilin-binding protein, the nitrophorins, lipocalin 1, lipcalin 12, and lipocalin 13.

Siderophores

Siderophores are high affinity iron (e.g. Fe³⁺) binding compounds. The vast majority of siderophores known are produced by bacteria. Bacteria release siderophores into the surrounding environment for the purpose of scavenging or chelating iron and transporting the iron to the bacteria—a process necessary for survival of bacteria. Siderophores that are known in the art include, but are not limited to heme, enterochelin, TRENCAM, MECAM, TRENCAM-3,2-HOPO, parabactin, carboxymycobactin, fusigen, triacetylfusarinine, feriichrome, coprogen, rhodotorulic acid, ornibactin, exochelin, ferrioxamine, desferrioxamine B, aerobactin, ferrichrome, rhizoferrin, pyochelin, pyoverdin. The structures of these compounds are disclosed in Holmes et al., Structure, 2005, 13:29-41 and Flo et al., Nature, 2004, 432: 917-921, the contents of which are hereby incorporated by reference.

Several of the above siderophores are known to bind to lipocalins, including NGAL, and complexes of these siderophores and lipocalins are known to be able to sequester iron (see for example, Holmes et al., Structure, 2005, 13:29-41 and Flo et al., Nature, 2004, 432: 917-921; Goetz et al, Molecular Cell, 2002, 10: 1033-1043 and Mori, et al., “Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.” J. Clin Invest., 2005, 115, 610-621). The mutant NGAL proteins of the invention can also form complexes with siderophores and can thereby chelate and transport iron.

In some aspects the present invention provides complexes of a mutant NGAL protein of the invention and a siderophore, including, but not limited to, the siderophores listed herein. In preferred aspects the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants or derivatives thereof. Any variant or derivative of such siderophores that retains the ability to bind to iron (ideally in a pH insensitive manner) and that retains the ability to bind to NGAL and/or one or more of the NGAL mutants of the invention may be used.

Manufacture of Mutant NGAL Proteins and Complexes with Siderophores

The mutant NGAL proteins of the invention can be manufactured by any suitable method known in the art for manufacture of protein drugs. For example the mutant NGAL proteins can be made using standard techniques known for the production of recombinant proteins, for example by delivering to a cell, such as a bacterial cell or a mammalian cell, an expression vector containing a nucleotide sequence that encodes an NGAL mutant under the control of a suitable promoter, and culturing the cell under conditions in which the protein will be expressed. Methods for the large scale culture, isolation, and purification of recombinant proteins are well known in the art and can be used in the manufacture of the NGAL mutants of the present invention. Similarly, methods of producing peptides and proteins synthetically are known in the art and can be used in the manufacture of the NGAL mutants of the present invention.

In certain embodiments, the present invention provides fusion proteins comprising the NGAL mutants of the invention and one or more additional “tags”. Such additional tags can be fused to the N- or C-terminus of the NGAL mutants, or can in some instances be added at an internal location to the extent that the inclusion of the tag does not adversely affect the function of the NGAL mutant. Suitable tags include, but are not limited to glutathione-S-transferase (GST), poly-histidine (His), alkaline phosphatase (AP), horseradish peroxidase (HRP), and green fluorescent protein (GFP). Other suitable tags will also be apparent to those skilled in the art. The tags may be useful for several applications, including to assist in the isolation and/or purification of the NGAL mutants and/or to facilitate their detection.

Many chemical modifications of proteins are known in the art to be useful for improving the properties of protein-based drugs and such modifications can be used in accordance with the present invention to improve the stability and reduce the immunogenicity of the mutant NGAL proteins of the invention for therapeutic applications. For example, it is well known in the art that the process of covalent attachment of polyethylene glycol polymer chains to another molecule (i.e. PEGylation) can “mask” a proteinaceous agent from the host's immune system, and also increase the hydrodynamic size (size in solution), prolongs the circulatory half-life, and improve water solubility of protein-based drugs. Various other chemical modifications are also known and used in the art and can be used in conjunction with the mutant NGAL proteins of the invention.

Complexes containing a mutant NGAL protein of the invention and a siderophore, such as enterochelin or a derivative or variant thereof, can readily be prepared used standard methodologies known in the art, such as those provided in the Examples section of this application. For example, an NGAL-siderophore complex can be prepared by mixing NGAL (including mutant NGAL) and a siderophore together in a molar ratio of 1:1 (e.g. Ent) or 1:3 (e.g. catechol). The mixture can be incubated at room temperature for a suitable time, e.g. 30 minutes, to allow for complex formation. Unbound siderophore can then be removed/separated from the bound siderophore-NGAL complexes using standard separation techniques, such as centrifugation based techniques, filter-based techniques, or other size-based separation techniques.

Methods of Treatment—Iron Overload

In one embodiment, the mutant NGAL proteins of the invention, and complexes and compositions comprising such mutant NGAL proteins, can be used to treat conditions, diseases, or disorders associated with excessive iron levels or iron overload. In particular, complexes of the mutant NGAL proteins of the invention with a siderophore, such as enterochelin, and compositions comprising such complexes, can be used to chelate iron in the body and facilitate its excretion in the urine.

Large amounts of free iron in the bloodstream can lead to cell damage, especially in the liver, heart and endocrine glands. The causes of excess iron may be genetic, for example the iron excess may be caused by a genetic condition such as hemochromatosis type 1 (classical hemochromatosis), hemochromatosis type 2A or 2B (juvenile hemochromatosis), hemochromatosis type 3, hemochromatosis type 4 (African iron overload), neonatal hemochromatosis, aceruloplasminemia, or congenital atransferrinemia. Examples of non-genetic causes of iron excess include dietary iron overload, transfusional iron overload (due to a blood transfusion given to patients with thalassaemia or other congenital hematological disorders), hemodialysis, chronic liver disease (such as hepatitis C, cirrhosis, non-alcoholic steatohepatitis), porphyria cutanea tarda, post-portacaval shunting, dysmetabolic overload syndrome, iron tablet overdose (such as that caused by consumption by children of iron tablets intended for adults), or any other cause of acute or chronic iron overload.

The two common iron-chelating agents available for the treatment of iron overload are deferoxamine (DFO) and deferiprone (oral DFO). Due to its high cost and need for parenteral administration, the standard iron chelator deferoxamine is not used in many individuals with acute and/or chronic iron poisoning. Deferoxamine must be administered parenterally, usually as a continuous subcutaneous infusion over a 12-hour period, from three to seven times a week. Treatment is time consuming and can be painful. As a result compliance is often poor. Side-effects include local skin reactions, hearing loss, nephrotoxicity, pulmonary toxicity, growth retardation and infection. Deferiprone is the only orally active iron-chelating drug to be used therapeutically in conditions of transfusional iron overload. It is indicated as a second-line treatment in patients with thalassaemia major, for whom deferoxamine therapy is contraindicated, or in patients with serious toxicity to deferoxamine therapy. Deferiprone is an oral iron-chelating agent which removes iron from the heart, the target organ of iron toxicity and mortality in iron-loaded thalassaemia patients. However, although deferiprone offers the advantage of oral administration, it is associated with significant toxicity and there are questions about its long-terra safety and efficacy, It is recommended to be used in patients who are unable to use desferrioxamine because of adverse effects, allergy, or lack of effectiveness. Deferiprone is associated with serious safety issues include genotoxicity, neutropenia and agranulocytosis. Weekly monitoring of neutrophils is recommended. Gastrointestinal and joint problems can occur and liver toxicity has been reported. Therefore, there is clearly a need for alternative convenient, safe, and effective iron chelation therapies, such as those provided by the present invention.

The mutant NGAL proteins of the invention, and in particular complexes thereof with siderophores, can be used to chelate free iron and clear the excess iron from the body via the kidneys, for example to reduce toxic circulating levels of iron to below toxic levels.

Methods of Treatment—Bacterial Infections of the Urinary Tract

WT NGAL is known to have bacteriostatic activity, in part due to its ability to tightly bind to bacterial siderophores, leading to depletion of bacterial iron and inhibition of bacterial growth (Goetz et al., Mol. Cell. (2002), 10(5) 1033-1043). The mutant NGAL proteins of the invention, like WT NGAL, have the ability to bind to bacterial siderophores, and thus can have anti-bacterial activity. Furthermore, because the mutant NGAL proteins of the invention are not reabsorbed by the kidney and accumulate in the urine, they are particularly well-suited to use in the treatment of bacterial infections of the urinary tract.

Pharmaceutical Compositions & Administration

The present invention also provides pharmaceutical compositions, formulations, kits, and medical devices that comprise the mutant NGAL proteins described herein, and complexes thereof with siderophores, and which may be useful to treat various diseases, disorders, and conditions, including iron overload and bacterial infections. Pharmaceutical formulations include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration. Examples of medical devices provided by the invention include, but are not limited to, beads, filters, shunts, stents, and extracorporeal loops which are coated with or otherwise contain a mutant NGAL or complexes thereof, as described herein, such that the device is implanted in or otherwise administered to a subject in a manner which permits the mutant NGAL or complexes thereof to chelate or absorb excess iron in the subject.

Administration of a therapeutically effective amount of the mutant NGAL proteins, and complexes thereof can be accomplished via any mode of administration suitable for therapeutic agents. One of skill in the art can readily select mode of administration without undue experimentation. Suitable modes may include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, or intramuscular administration modes. In preferred embodiments, oral or intravenous administration is used. In other preferred embodiments, the compositions of the invention are administered directly to the desired site of action, such as for example, the kidney, for example by local injection or local infusion or by use of (e.g. conjugation to) agents useful for targeting proteins or pharmaceuticals to specific tissues, such as antibodies etc.

Depending on the intended mode of administration, the mutant NGAL proteins and complexes of the invention, in a therapeutically effective amount, may be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like. In one embodiment the mutant NGAL proteins and complexes of the invention may be formulated in unit dosage forms, consistent with conventional pharmaceutical practices. Liquid, particularly injectable, compositions can, for example, be prepared by dissolution or dispersion. For example, mutant NGAL proteins and complexes of the invention can be admixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.

Parental injectable administration can be used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection. One embodiment, for parenteral administration, employs the implantation of a slow-release or sustained-released system, according to U.S. Pat. No. 3,710,795, incorporated herein by reference.

The mutant NGAL proteins and complexes of the invention can be sterilized and may contain any suitable adjuvants, preservatives, stabilizers, wetting agents, emulsifying agents, solution promoters, salts (e.g. for regulating the osmotic pressure), pH buffering agents, and/or other pharmaceutically acceptable substances, including, but not limited to, sodium acetate or triethanolamine oleate. In addition, the compositions of the invention may also contain other therapeutically useful substances, such as, for example, other iron chelators or other agents useful in the treatment of iron overload, or other agents useful in the treatment of any of the conditions described herein.

The compositions of the invention can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, preferably from about 1% to about 70% of the compound or composition of the invention by weight or volume.

The dose and dosage regimen to be used can be determined in accordance with a variety of factors including the species, age, weight, sex and medical condition of the subject; the severity of the condition; the route of administration; the renal or hepatic function of the subject; and the particular mutant or complex employed. A person skilled in the art can readily determine and/or prescribe an effective amount of a mutant or complex of the invention useful for treating or preventing a condition, for example, taking into account the factors described above. Dosage strategies are also provided in L. S. Goodman, et al., The Pharmacological Basis of Therapeutics, 201-26 (5th ed. 1975), which is herein incorporated by reference in its entirety. In one embodiment, compositions of the invention are administered such that the NGAL component is administered at a dose range of about 1 to about 100 mg/kg body weight, and typically at a dosage of about 1 to about 10 mg/kg body weight is administered at a dose that results in a concentration in the range of about 0.1 ng/ml to about 100 ng/ml, e.g., in the range of about 1.0 ng/ml to about 20 ng/ml, in the blood. The amount of a siderophore component of a composition of the invention will be chosen accordingly, such that the desired stoichiometry, e.g. 1:1 or 1:3 binding with the mutant NGAL protein, is achieved.

In addition to the above methods of treatment, the mutant NGAL protein-siderophore complexes of the invention may be useful to chelate and/or remove iron from samples, wherein the samples are not in a subject's body. Thus, in one embodiment, the present invention provides a method for removing iron from a fluid, the method comprising admixing the fluid with a mutant NGAL protein-siderophore complex for a period of time sufficient for iron in the sample to bind to the mutant NGAL protein-siderophore complexes, wherein the mutant NGAL protein-siderophore complex can chelate iron from the sample. In one embodiment, the mutant NGAL protein-siderophore complexes having iron bound thereto may then be removed from the sample. In preferred embodiments, the sample is a biological fluid, such as blood, serum, plasma, or urine. In certain embodiments the mutant NGAL protein-siderophore complexes are admixed with the sample outside the body, e.g. in an extracorporeal device, and the sample is then delivered to or returned to the body. For example, such methods can be used to chelate and/or remove excess iron in blood samples for transfusion, or in a dialysis procedure. For example, blood or another bodily fluid from a subject may be removed from the body, treated with a compound or composition of the invention to chelate or remove excess iron, and then returned to the subject.

EXAMPLES Example 1 Mutant NGAL Proteins and their Use as Therapeutic Iron Chelators and as Antimicrobial Agents

Lipocalin 2 (Lcn2), also called Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a protein that binds to iron with high affinity. To bind iron, NGAL binds a cofactor called a siderophore produced by bacteria (Binding constant K_(m)=0.41×10⁻⁹M for the NGAL:enterochelin-iron interaction; K_(m)=10⁻⁴⁹M for the enterochelin (enterobactin):iron interaction) or catechol containing compounds (K_(m)=0.4±10⁻⁹M for catechol-iron; K_(m)=10^(−45.9)M for the catechol:iron interaction) produced by a combination of bacterial and mammalian enzymes. NGAL is also a secretory protein that is markedly upregulated by bacterial infection and acute kidney injury and is secreted into the blood and urine. During bacterial infection, NGAL sequesters iron from bacteria by binding enterochelin-iron, resulting in the inhibition of bacterial growth.

Serum NGAL with bound enterochelin:Fe is filtered by the glomerulus in the kidney, but then the majority of it is retained (reabsorbed) by kidney where it is degraded. Very little NGAL escapes to the urine and is excreted. For example, as demonstrated by recent research, when NGAL is injected intraperitoneally, more than 70% of the WT NGAL accumulates in kidney while less than 0.1% is found in the urine after 3 hours.

The capture and retention of serum NGAL in the kidney is achieved by the absorption of NGAL by megalin, a multi-ligand receptor also called low-density lipoprotein receptor-related protein 2 (LRP2). Megalin is located at the apical plasma membrane of proximal tubular epithelial cells where it contacts the glomerular filtrate. Megalin associates with cubilin. NGAL can transport iron by using cofactors such as enterochelin or catechol and deliver the iron specifically to the kidney.

Amnionless is another protein associated with the megalin-cubulin-receptor complex. In one embodiment, NGAL interacts with megalin, cubilin, amnionless, or a combination thereof. For additional information on the amnionless protein, see Kozyraki R, Gofflot F, (2007) Curr Pharm Des. 13(29):3038-46 and Nielsen R, Christensen E I., (2010) Pediatr Nephrol., 25(5):813-22, both of which are incorporated by reference in their entireties.

Mutant NGAL as a Therapeutic Iron Chelator and Antimicrobial Agent

The molecular cutoff for glomerular filtration is about 70 kD. Recombinant or native NGAL protein with molecular weights of about 20.5 kD and 23-25 kD respectively can be filtered in the glomerulus, but is then efficiently reabsorbed into the proximal epithelia by megalin and/or by a megalin associated complex which includes cubilin. Megalin has a binding affinity for apo- and iron-loaded NGAL of about 60 nM (Hvidberg, et al., FEBS Letters, 2005, 579: 773-777)). Megalin is a multi-ligand, endocytic receptor, responsible for reabsorption of many proteins including NGAL, apoE, lipoprotein lipase, lactoferrin, approtinin, etc., after glomerular filtration (Christensen and Birn, Nature Reviews-Molecular Cell Biology, 2002, 3: 258-2682002). Electrostatic interactions between megalin's acidic regions of “type A repeats” in megalin protein and basic regions of ligands are involved in ligand-receptor recognition i.e. megalin recognizes positively charged surfaces of ligand proteins (Moestrup and Verrost, Annual Reviews of Nutrition, 2001, 21: 407-428. 2001). Some basic amino acid residues on the surface of human NGAL protein can therefore be involved in its high binding affinity to megalin, and mutation of these basic residues can disrupt the electrostatic interactions between NGAL and megalin while preserving the binding affinity for enterochelin-iron in its interior clayx. The disabled interaction between mutant NGAL and megalin can allow mutant NGAL:enterocalin:iron or apo-mutant NGAL to be filtered into the urine without being reabsorbed from the filtrate after glomerular filtration. In the former case, where enterochelin is present in the mutant NGAL complex, it can absorb iron from the blood and traffic it into the urine. This can allow removal of iron from the subject (e.g. animal or human) associated with the siderophore-iron. Alternatively, in the case of the mutant apo-NGAL, it can lead to an accumulation of NGAL in the urine which can inhibit bacterial growth in the urinary tract.

The mutant NGAL proteins of the invention have at least two potential applications in clinical therapeutics.

Firstly, the mutant NGAL proteins can be used as efficient iron chelators to remove excess iron from subjects, such as human subjects, with iron overload disorders. Iron overload patients (e.g. due to hemachromatosis, sickle cell disease, thalassemia, multiple transfusion of red blood cells or other biological products) are administered mutant NGAL bound to iron-free siderophore, such as enterochelin, by intravenous infusion. Enterochelin chelates serum iron to form an NGAL-enterochelin-iron complex. This complex is mostly transported to the kidney and subsequently filtered by glomerulus. It remains in the glomerular filtrate without being reabsorbed due to its inability to bind megalin in the proximal tubular epithelial cells. It then appears in the urine and is ultimately excreted together with the iron that it binds. Mutant NGAL can be an efficient tool to remove excessive iron from iron overloaded human subjects. The molar ratio for NGAL binding to enterochelin and iron is 1:1:1. If 10 g of mutant apo-NGAL, which equals about 500 μmoles, is given to an iron overloaded patient, about 500 μmoles or about 27.9 mg of iron can theoretically bind mutant NGAL and enterochelin and be delivered into the urine for excretion (assuming accumulation of mutant NGAL protein in urine is 100%). This is a very efficient way to remove excessive iron from a human patient with iron overload given that the human only loses 1-2 mg iron per day mainly via the shedding of intestinal cells and dead skin cells, and only gains 1-2 mg per day from food.

Secondly, the mutant NGAL protein can be used as an anti-microbial to treat patients with a urinary tract infection (UTI). Mutant apo-NGAL is given to human subjects with a UTI by infusion. The mutant NGAL is transported to the kidney and filtered into the urine without reabsorption due to its loss of binding affinity for megalin. Once inside the urine, the mutant apo-NGAL protein binds siderophores of UTI bacteria (e.g. enterochelin) and results in the inhibition of their growth.

Experimental Design and Experimental Procedures

Cloning of Human NGAL

Human NGAL cDNA (Ganbank accession number: NM_(—)005564) is obtained from Open Biosystems, and the open reading frame encoding the secreted NGAL protein is PCR-amplified by using a PfuUltra DNA polymerase (Stratagene), and cloned into a pGEX-4T-3 plasmid vector (GE Healthcare) for site-directed mutagenesis.

Structure of Human NGAL Protein

Based on the structure of the human NGAL protein, amino acid residues, especially basic residues (arginine, lysine and histidine), on the surface of the protein can mediate the electrostatic interaction with megalin for high affinity binding (FIG. 1 and FIG. 4A).

Designation of NGAL Mutants

There are five basic amino acid residues on the surface of NGAL protein which are conserved (R43, 72, 140, and K142, 157) among different mammalian species including human, mouse, rat, Chimpanzee, bovine, dog, wild boar, and Rhesus Monkey, while there are 13 non-conserved basic residues (R130; K15, 46, 50, 59, 62, 73, 74, 75, 97, 149; H118, 165). These basic residues can be mutated to other non-basic residues.

Generation of NGAL Mutants

A variety of different amino acid residues on the surface of NGAL protein were mutated by using a Quickchange Site-Directed Lightning Multi Mutagenesis Kit (Stratagene), and this resulted in the generation of many mutants with mutations at different sites of the NGAL protein. 57 NGAL mutants were made as shown in Table 2, SEQ ID NOS: 2-10, 21-68, 247-251.

Production of NGAL Protein

Wild-type and mutant plasmid constructs are electroporated into BL21 E. coli (GE Healthcare), and expression of wild-type and mutant apo-NGAL proteins are induced by the addition of IPTG to a final concentration of 0.2 mM for 5 hours, and subsequently purified by a combination of GST-based pull-down and gel filtration in a FPLC system with a Sepharose column.

Binding Affinity of Mutant NGAL for Enterochelin and Iron

The NGAL mutant proteins are examined for their ability to bind enterochelin and iron by using a radioactive form of iron, ⁵⁵Fe³⁺. The binding affinity of NGAL for enterochelin and ⁵⁵Fe³⁺ was estimated by examining the percentage of ⁵⁵Fe³⁺ which was retained by mutant and wild type NGAL proteins, and the wild-type NGAL protein can be used as a positive control.

Preparation of NGAL-Enterochelin-Iron Complex

The NGAL-enterochelin-iron complex is prepared by mixing NGAL protein, enterochelin and ⁵⁵Fe³⁺ together in a molar ratio of 1:1:1 (4 nmole each). The mixture is incubated at RT for 30 minutes, and washed in a 10 K microcon by centrifugation 4 times at 7000 rpm for 5 minutes to remove the unbound enterochelin and ⁵⁵Fe³⁺, and the NGAL-enterochelin-⁵⁵Fe³⁺ complex is retained in the microcon.

Screening of NGAL Mutants in Mice

There is 76% amino acid identity and 87% amino acid similarity between human mouse megalin proteins, indicating that they likely have very similar binding properties. In the present experiments the binding of human NGAL protein to mouse megalin was tested. Due to the high degree of amino acid identity and similarity between human and mouse megalin protein, the mouse system provides a useful model to screen mutant NGAL proteins for their ability to escape megalin-cubilin-dependent renal reabsorption and ultimately to be delivered into urine.

The radiolabelled NGAL-enterocalin-⁵⁵Fe³⁺ complex is intraperitoneally injected into female C57BL/6 mice (4 weeks), and urine is collected in metabolic cages. After urine collection for 3 hours, the mice are sacrificed and kidneys and liver are collected, weighed and solubilized in a solution of 0.5M NaOH and 1% SDS at 70° C. overnight. The radioactivity in urine, kidney and liver is examined in a scintillation counter, and the accumulation of the NGAL-enterochelin-iron complex will be calculated as the percentage of total injected complex.

Experimental Results

57 NGAL mutants were generated (Table 2; SEQ ID NOS: 2-10, 21-68, 247-251). Twenty nine mutant apo-proteins were produced in BL21 E. coli, and were examined for their binding affinity to enterochelin and trafficking in C57B6L/6 mice after intraperitoneal (i.p.) injection. As shown in FIG. 3A, all mutant human NGAL proteins retained 16.7% to 45.7% of total iron after incubation with enterochelin-iron in a molar ratio of 1:1:1 (4 nmole each) for 30 minutes at room temperature, indicating their preserved binding affinity for enterochelin-iron (high amounts of enterochelin will increase loading of NGAL).

When administered by i.p. injection, six mutant NGAL-enterochelin-⁵⁵Fe³⁺ complexes showed a markedly increased accumulation in urine compared with wild-type NGAL complex (mutants K3, K2, I3, I1, K5, and K1). Decreased accumulation in liver and kidney after 3 hours (FIGS. 3B, C, D; Table 1) was also seen. There were 6%, 6.9%, 1.9%, 9.3%, 19.6% and 2.9% of I1, I3, K1, K2, K3 and K5 mutant NGAL complexes which were delivered to urine after 3 hours, respectively, while there were only 0.18%, 0.13%, 0.26%, 0.1%, 0.11%, 0.17%, 0.27% and 0.05% of A2, B4, C3, D1, F2, G3, H2 and I5 mutant NGAL complexes in urine.

Using the crystal structure of wild-type NGAL (PDB accession number: 1nglA) as substrate, the structure of K3 mutant protein was predicted by using Swissmodel (http://swissmodel.expasy.org). As shown in FIG. 4A, the predicted 3D structure of K3 mutant protein contains a similar pocket as the wild type protein, supporting our finding that affinity for enterochelin-iron is preserved. However, K3 mutant protein exhibited fewer positive amino acids on the solvent accessible surface than wild-type NGAL protein (FIG. 4B), consistent with its decreased ability for electrostatic interaction with megalin, and increased accumulation in urine once introduced into mice.

TABLE 1 Binding of mutant Ngal proteins to enterochelin-⁵⁵Fe³⁺ and accumulation of mutant Ngal-enterochelin-⁵⁵Fe³⁺ in urine, kidney and liver 3 hours after i.p. injection into C57BL/6 mice. Enterocalin- Accumulation 3 hours after i.p. Ngal iron Binding injection (%) Mutants (%) Urine Kidney Liver A1 23.4 0.55 0.32 1.10 A2 22.6 0.18 0.37 1.11 A3 26.6 0.23 0.39 1.52 B1 20.7 0.22 0.26 1.30 B2 25.7 1.22 0.34 1.27 B3 26.9 0.30 0.26 1.01 B4 45.7 0.13 0.32 0.71 C1 26.2 0.72 0.21 1.15 C3 20.6 0.44 0.33 1.22 C5 21.9 0.26 0.44 0.85 D1 29.1 0.10 0.26 0.94 D2 18.1 0.11 0.16 0.60 F1 26.1 0.51 0.69 0.79 F2 21.5 0.11 0.40 0.51 F4 22.8 1.65 0.43 1.68 F5 27.7 1.23 0.29 1.61 G1 33.5 0.28 0.05 0.33 G3 26.9 0.17 0.58 0.30 H1 38.7 0.37 0.15 0.89 H2 36.1 0.27 0.12 1.06 H3 31.1 0.30 0.15 1.25 H5 38.6 0.24 0.09 1.07 I1 32.1 6.00 0.20 1.21 I3 42.8 6.90 0.27 0.55 I5 16.7 0.05 0.10 0.02 K1 21.2 1.90 0.76 0.82 K2 31.4 9.60 0.43 0.68 K3 22.9 19.60 0.27 0.40 K5 28.4 2.90 0.18 1.37

Example 2

The superscripted numbers in this Example refer to the numbered references in the list of references that follows this Example. Ngal mutants “K numbers 1-8” represent actual Mutants K1, K2, D1-4-2-1-1, K5, D1-4-2-1-1-4, K3, WT-3 and WT4. The sequences of the mutants are provided herein in Table 2.

The transport of iron poses a significant problem because free ferric iron is insoluble (<10-18 M) in aerobic solutions at physiologic pH, while upon solubilization by some chelators, a reactive form of iron is created that can produce toxic oxygen species. Specialized mechanisms are consequently required to traffic iron and these specialized mechanisms are found in proteins which utilize conserved motifs to directly bind iron (transferrin and ferritin) or utilize embedded cofactors. While extracellular iron transport is largely mediated by transferrin, mice carrying deletions of these genes displayed surprisingly limited phenotypes (Barasch, Developmental Cell, 2009). It was found that a member of the lipocalin superfamily called Ngal acted as a high affinity iron carrier (Barasch, Molecular Cell, 2002) when binding a family of novel cofactors called the catechols or related bacterial siderophores constructed from catechol. In the presence of iron, formation of the Ngal:siderophore:FeIII complex occurred at subnanomolar affinity (Barasch, Nature Chemical Biology, 2010) forming a bright red protein, which was stable for many days in solution and stable in vivo for transport of its tightly bound iron. Ngal is expressed in vivo, but a number of “damage” stimuli raise its concentration by orders of magnitude. Thereafter, Ngal traffics in the serum and is thought to be captured by the kidney receptor megalin, where Ngal clears the siderophore:Fe complex. While a great deal is known about the metabolism of the urinary form of Ngal (it is expressed from the distal nephron and is excreted in the urine as a full length protein), much less is known about this clearance system and the role of the megalin receptor, which is the only confirmed receptor for Ngal. To study this process in depth a conditional mutant of megalin can be examined. Also, for studies in wild type mice a series of Ngal mutants can be tested. Some such mutants bypass the proximal tubule where megalin is located, resulting in their presence in the urine. These mutants can still bind to siderophore:FeIII at high affinity (and produce red colored proteins), and can definitely excrete iron, likely in a redox inactive manner. Indeed, rather than donate iron to micro-organisms, which is a major concern for small molecule chelators, the Ngal:siderophore:Fe complexes sequester iron from bacteria. The hypothesis that megalin is the key recycling receptor for Ngal can be tested. It is expected that when the megalin-Ngal complex is inhibited, Ngal can carry tightly bound iron in the urine, hence serving as a safe therapeutic for the common syndromes of iron overload diseases.

Iron overload diseases are common occurrences in clinical medicine, and their therapies have proved toxic to many cell lineages as well as inductive of bacterial growth. Iron overload is a common sequela of blood transfusions, but it is well known in hepatitis, chronic kidney disease as well as in common hereditary diseases such as hemachromatosis. The present invention involves the discovery of an iron trafficking pathway based on the protein Ngal, which is massively expressed in the human in different types of tissue damage. Our studies in Ngal metabolism provide proof of concept that Ngal can be used as a safe therapeutic iron chelator.

Iron is specifically bound by transferrin in circulation, which preserves its bioavailability and prevents its redox toxicity. However, non-transferrin-bound iron (NTBI) appears in patients with a variety of diseases¹⁻³ including both genetic causes and the non-genetic causes. NTBI damages liver⁴⁻⁷, heart⁸⁻¹², endocrine glands¹³⁻¹⁸ and kidneyl⁹⁻²¹ and severe overload can be fatal^(22,23) by catalyzing reactive oxygen species (ROS) via the Haber-Weiss and Fenton reactions²⁴⁻²⁵.

To date, two small molecules, deferoxamine (DFO) and deferiprone are available for the chelation of NTBI and the treatment of iron overload²⁶⁻²⁸. However, these molecules demonstrate significant toxicity. DFO causes skin reactions, hearing loss, renal and pulmonary toxicity, and most interestingly fungal infection²⁹⁻³², which results because DFO (which is a derivative of a fungal “siderophore”) can deliver iron to pathogens³². Deferiprone is also associated with genotoxicity, neutropenia and agranulocytosis and kidney disease^(33,34). Hence, new agents are required for non-toxic NTBI excretion, that do not deliver iron to microorganisms.

The present invention utilizes an endogenous mechanism of iron transport (Molecular Cell, 2002; Nature N&V, 2005; Nature Chemical Biology, 2010)³⁵⁻³⁸, which is manipulated to safely export iron from the body. The carrier is called Neutrophil Gelatinase-Associated Lipocalin (Ngal). The present invention involves Ngal mutants which allow Ngal to be safely excreted in urine, still tightly binding its iron.

Ngal is a small iron carrier protein (22 KDa) which is markedly expressed in the serum and in the urine when a human or an animal is exposed to a stimulus which typically causes acute kidney injury (AKI: JASN, 2003; JCI, 2005; Lancet, 2005; Ann Int Med, 2008)³⁹⁻⁴². As a result, the protein is now well known as a “biomarker” of AKI, with well over 100 papers confirming its robust expression, yet only a few labs study its biology. We have found that once Ngal is expressed, it is rapidly secreted into circulation, where it can capture iron by binding cofactors such as endogenous catechols or related catecholate-type siderophores (Enterochelin, Ent)³⁶ which are synthesized by bacteria to capture iron (See FIGS. 6A-6B). Hence, Ngal interrupts the nutrient supply of iron for bacteria, providing bacteriostasis.

Ngal complexes are stable for transport, and they are filtered by the glomerulus and captured by the proximal tubule (FIG. 7), where Ngal is degraded and iron is released for recycling³⁸. Ngal is thought to be endocytosed by megalin in proximal tubule cells and a direct interaction between Ngal-megalin has been characterized using surface plasmon resonance (SPR/Biacore)⁴³. The present invention involves Ngal mutants that may bypass megalin, yet still bind Ent:iron, hence providing a therapeutic that can safely excrete NTBI in the urine.

Evaluation of the Ngal-Megalin Interaction Using Ngal Mutants

Since megalin may be the major receptor mediating the reabsorption of filtered Ngal⁴³, 40 mutant Ngal proteins were produced, some of which are believed to target the Ngal-megalin interaction. The megalin hypothesis can be tested using one of these mutants (K6, i.e, K3) and its optimized derivatives, which partially bypass the proximal tubule and appear in the urine. This mutant can be used to study protein interactions, and cellular, and organ capture in wild type mice and in conditional megalin knockouts, to confirm that the interruption of megalin permits the excretion of iron. Additional mutants can also be tested using this system.

Evaluation of the Ngal:Ent:Fe^(III) Interaction in Ngal Mutants

Ngal contains a central calyx where, when Ent:Fe^(III) is bound, a bright red protein³⁵ is produced (FIG. 8). Ngal mutants, engineered to reduce their interactions with megalin, were also brightly red colored when mixed with Ent:Fe^(III), indicating retention of ligand affinity. The Ngal complexes can be quantitatively analyzed using Flourescence Quenching techniques and X-Ray Crystallography.

Safe Excretion of Iron by the Delivery of Mutant NGAL:Ent:Fe^(III)

K6 (i.e, K3) and optimized mutants can be administered to mice to test NTBI chelation and urinary excretion of Fe^(III) in murine models of hereditary (HFE^(−/−)) ^(44,45) and acquired hemochromatosis⁴⁴. Efficacy can be evaluated by measuring the depletion of NTBI from serum and liver, and toxicity can be ruled out by measuring oxidative stress and the expression of endogenous Ngal, which we previously discovered, indicates the onset of kidney damage.

Significance

Iron overloaded patients demonstrate elevated serum transferrin saturation (>50%) and elevated serum ferritin levels (>1000 μg/L)¹⁻³. They also demonstrate non-transferrin-bound iron in circulation (NTBI, e.g. 0.9-12.8 μmol/L in thalassemic sera; 4-16.3 μM in hereditary hemachromatosis (HH) sera), as well as a labile iron pool (LIP) within cells⁴⁶. These abnormal pools of iron participate in Haber-Weiss and Fenton reactions which oxidize lipids and proteins and mutate nucleotides by forming hydroxyl, ferryl, or perferryl species^(24-25,47). Ultimately, cell death is found in a variety of sensitive organs, including liver (fibrosis/cirrhosis and hepatocellular carcinoma) ⁴⁻⁷, heart (congestive cardiomyopathy)⁸⁻¹², kidney (necrosis and apoptosis of proximal tubular cells) ¹⁹⁻²¹ and endocrine glands (diabetes, hypothyroidism, and hypogonadism)¹³⁻¹⁸.

In general there are two types of iron overload disorders, hereditary hemachromatosis (HH) and acquired hemochromatosis (AH). HH is caused by loss of function of genes associated with the regulation of iron metabolism, such as HFE (type 1 HH), HJV (type 2A HH), HAMP (type 2B HH), TfR2 (type 3 HH), SLC40A1 (type 4 HH), CP (aceruloplasminaemia), TF (hypotransferrinaemia)^(3,48). In the most common entity, Type I HFE C282Y allele, 28% of males were iron overloaded⁴⁹. AH in contrast is caused by blood transfusions, thalassaemia major, sideroblastic and hemolytic anemias, dietary iron overload, chronic kidney and liver diseases due to hepatitis C or alcohol or porphyria^(3,44,48). The 5 million blood transfusions, >15 million units/yr in the US are the most common cause of AH⁵⁰. Blood transfusions cause iron overload because while the human loses 1-2 mg iron per day, each unit of blood contains 250 mg of iron and clear evidence of toxicity appears after 20 transfusions⁵¹⁻⁵³. Chronic kidney diseases can also produce a syndrome of excess iron deposition in the proximal tubule and in the urinary space. Iron is deposited in the kidney cortex in HIV associated nephropathy⁵⁴ as well as in other forms of nephrotic syndrome⁵⁵. Urinary iron is also a common finding in AKI of various etiologies including hemoglobinuria and myoglobinuria⁵⁶, chemotherapy (cis-platin⁵⁷; doxorubicin⁵⁸), ischemia-reperfusion^(59,60) and transplant ischemia⁶¹. It is believed that the release of iron into the urine is a critical step in cell damage⁶²⁻⁶⁹. In sum, both HH and AH patients suffer organ damage without iron chelation therapy^(22,23).

Two iron-chelating chemicals are currently in clinical use²⁶⁻²⁸, but both are limited by toxicity and long-term safety concerns (e.g. “Deferasirox: Uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf. 2007 6:235-9)²⁹⁻³⁴. The present invention provides a novel strategy which takes advantage of the endogenous mechanisms of iron trafficking which is manipulated to develop a highly efficient, non-toxic iron chelator for the treatment of iron overload. Ngal is well suited to this approach because of the following characteristics. Ngal was first identified as an iron carrier and growth factor in kidney cells³⁵. Second, Ngal binds iron (FIG. 6A-6B) by using bacterial siderophores (such as enterochelin [Ent] from Gram-negative bacteria, bacillibactin from Gram-positive bacteria and carboxymycobactins from mycobacteria^(36,70)) or alternatively endogenous catechols found in mammals³⁸. Ent and catechols have extremely high affinity for iron (K_(d)=10⁻⁴⁹M and 10^(−45.9)M, respectively)^(71,72), and Ngal strongly binds Ent:Fe and catechol:Fe (K_(d)=0.4 nM)^(36,38), which allows these complexes to sequester iron. In fact, the chelation of bacterial siderophores by Ngal is a critical aspect of the innate immune response, given that the Ngal^(−/−) mice do not clear bacterial inocula³⁷. These data stand in contrast to the high affinity iron chelator DFO (K_(d)=10⁻³⁰M)⁷³ which can deliver its iron to Rhizopus and induce fatal MucorMycosis³². Third, binding of iron to Ngal limited its reactivity as demonstrated by the suppression of phenanthroline and 3′-(p-hydroxyphenyl) fluorescein (HPF) tests of reactive Fe²⁺; in other words, binding to Ngal blocked the Fenton reaction³⁸. Fourth, Ngal can load with iron in vivo when it was presented with Ent:⁵⁵Fe or Catechol:⁵⁵Fe; the Ngal complex can then be recovered from the serum five minutes later. Fourth, Ngal loaded with iron traveled through the circulation and targeted the mouse kidney, as demonstrated by radioautography^(38,40) (FIG. 9). This process most likely involved glomerular filtration of the Ngal complex, followed by megalin-mediated endocytosis at the apical membrane of the proximal tubule⁴³ since we found Ngal in the urine of megalin knock-out mice⁷⁴ (FIG. 10), and since Surface Plasmon Resonance Analysis (Biacore) showed that Ngal and megalin interacted directly (K_(d)=60 nM⁴³). Fifth, the same process was ongoing in humans, since Ngal was visualized in lysosomes of the proximal tubule of patients with AKI (FIG. 11). Sixth, Ent had a very high affinity for Ngal even in the absence of iron (K_(d)=3.57 nM)⁷⁵, while catechol itself bound to Ngal with poor affinity (K_(d)=200±6 nM)³⁸ meaning that Ent was even a better candidate for iron capture and transport than catechol. Finally, the Ngal:Ent:Fe^(III) complex was pH insensitive, failing to dissociate even at pH 4.0, while Ngal:catechol:Fe^(III) complexes were stable until pH6.5, but acidification progressively reversed catechol-dependent fluorescence quenching and resulted in the dissociation of iron by pH 6.0 (FIG. 12)³⁸. Hence, because of its stability at acidic pH, Ngal:Ent:Fe^(III) is not expected to dissociate in acidified urine.

In summary, Ngal:catechol/Ent can chelate NTBI in the circulation with high affinity and clear iron in the kidney. This pathway is active in humans in vivo and potentially traffics large amounts of Ngal and iron: if the GFR is 140 L/Day and the concentration of serum Ngal is 20 ng/ml, 2.8 mg/day of NGAL (0.14 μmole) and 8 μg iron are recycled in the proximal tubule, but in the setting of ischemia, renal failure, sepsis, the level of Ngal rises 100-1000 fold, meaning a very substantial mechanism of clearance may be ongoing (depending on the residual GFR). Therefore, to understand the capture of iron in the kidney and to create a new therapy, we have decided to disrupt the reabsorption of Ngal.

Innovation:

A. The first area of innovation has to do with the treatment of iron overload diseases which for too long has relied on toxic chelators²⁹⁻³⁴. The present invention provides a strategy to develop high-efficacy, non-toxic NTBI chelators. This strategy has many advantages over current iron chelators in that (1) Ngal provides an endogenous pathway for delivering iron to the kidney^(35,36,38,39); (2) Ngal:Ent has higher affinity for iron than any other known substance^(71,72); (3) Ngal:Ent:Fe^(III) is redox inactive³⁸; (4) Ngal:Ent:Fe^(III) is stable in acidified urine³⁸ and hence (5) may chelate urinary iron, perhaps alleviating damage in certain renal diseases. A second area of innovation is a description of the metabolism of Ngal-iron. A bioluminescent mouse can be used to compare the timing and intensity of Ngal gene expression in the kidney and in the urine, which has provided a clear understanding of the biosynthesis and excretion of this pool (Paragas et al, In Review). Ngal mutants can directly test the role of megalin in wild type mice and provide complimentary data for the analysis of megalin defective mice. This approach can also test the notion that a second NGAL receptor (24p3R)⁷⁶ may be present in the nephron.

Evaluation of the Ngal-Megalin Interaction by the Generation of Ngal Mutants

Megalin is thought to bind its ligands using a series of electrostatic interactions between megalin's negatively-charged ligand-binding domains and the positively-charged surface-domains of the ligand⁷⁷. Consequently, by mutating Ngal's positively charged surface residues the megalin-Ngal interaction can be disrupted. Surface domains of human Ngal were identified based on its crystal structure (R. Strong; PDB no. 1L6M) using the software Pymol⁷⁸. The surface domains contained 18 positively charged amino acids (Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165, R43, 72, 140, and K142, 157), 5 of which were conserved in mammalians³⁶, and these residues were chosen for site-directed mutagenesis. The human Ngal ORF (without signal peptide sequence) was cloned into pGEX-4T-3 bacterial expression plasmid (Amersham) to generate a GST-Ngal fusion to create a template for mutagenesis. The conserved positively charged surface residues were then mutated to alanine. Non-conserved amino acids were mutated to non-positively charged residues which occupied the same position in non-human Ngal proteins. For mutagenesis a single or a combined strategy with the Quick-Change Site-Directed Mutagenesis kit (Stratagene) was used, producing 40 Ngal mutant clones. Wild-type and mutant Ngal proteins were then produced in BL21 E. coli by induction with 0.2 mM IPTG, and purification by GST-based affinity isolation and gel filtration chromatography using our established protocols^(35,38). We then functionally screened these Ngal proteins by introducing them (80 μg/400 μl) into C57BL/6 mice (4 weeks) to identify which mutants could bypass renal absorption and appear in urine within 3 hrs. Ngal mutants K1, K2, K3, K5, K6 (i.e, K3), and K8 were detected in the urine by SDS-PAGE as well as by immunoblot using a human Ngal-specific antibody developed in rat (R&D System) (recombinant Ngal=21 KDa; endogenous Ngal=25 KDa), suggesting that the mutations resulted in loss of affinity for the recycling receptors on the apical plasma membrane of proximal tubular epithelia. In contrast, wild-type, K4 and K7 mutants could not be detected in the urine and consequently were most likely reabsorbed (FIG. 13). These data provide valuable information about the Ngal-megalin interaction because they test whether variations in Ngal reabsorption may be ascribed to variations in the megalin-Ngal interaction, providing insight into the mechanisms of clearance of serum Ngal, and allowing the optimization of mutants to excrete iron.

Structural Basis for NGAL-Megalin Interaction

Interactions with Megalin

The interaction between wild-type human Ngal (ligand-free) and chip-coupled megalin (K_(d)=˜60 nM)⁴³ purified from human kidney cortex was previously analyzed by α₂-macroglobulin-affinity chromatography⁷⁹. Biacore T100 technology can be used to compare wild type and K6 (i.e, K3) (or other mutant) interactions with megalin. Whether ligand-binding influences Ngal-Megalin interaction can also be tested by using bacterial siderophores and catechol ligands. Data can be calculated with BIAevaluation 4.1 software (Biacore), globally fitting data to derive kinetic and equilibrium parameters. A range of coupling and regeneration conditions can also be used, though antibody-capture often provides the cleanest data.

Megalin Mediated Endocytosis

Classical megalin-expressing cell models can be used to investigate megalin-binding and endocytosis. Such cells include HK-2⁹⁰ and Brown Norway rat yolk sac epithelia⁴³. Rat yolk sac cells are important because megalin is the only receptor which mediates endocytosis of human Ngal in these cells, since uptake was completely abolished with anti-megalin antibodies⁴³ (the neutralizing antibodies proved more effective than megalin shRNA). Wild-type and K6 ((i.e, K3) mutant proteins (and other mutants) can be labeled with fluorescent probes (Alexa 488, Molecular Probes) cleaned-up by gel filtration (GE Biotech, PD10) and dialysis (Pierce 10K cassette)^(35,43) in order to study their rate of uptake (50 μg/ml in serum-free DMEM for 0.5-6 hours) in the presence or absence of anti-human or anti-rat megalin antibodies (Santa Cruz; 200 μg/ml)⁴³ which were previously shown to block uptake of wild type human Ngal in BN cells⁴³. Endocytosis of Ngal can be measured both by using a Zeiss LSM510-META inverted confocal laser scanning microscope and immunoblots of cell extracts to detect the presence of human Ngal. These experiments can determine whether the failure to capture K6 (i.e, K3) (or other mutants) can be ascribed to defective Ngal-megalin interactions and if the affinity defect or the endocytosis defect is truly partial. If so, then additional mutations can be provided to disrupt the remaining interactions with megalin. The remaining positively charged surface residues in K6 (i.e, K3) (or other mutants) can be mutated using a single or combinational approach as above, and then reiteratively tested using the Biacore assays and the cellular uptake assays. As a result of these mutations, the role in megalin in Ngal capture and Ngal's megalin binding domain can be defined. Additionally optimized mutants can be generated.

Alternative Receptors

Our data (FIGS. 9 and 13) and a previously published report⁴³ suggests that megalin is an essential receptor for Ngal. However, there may be non-megalin receptor(s) in the proximal tubule. The main candidate is 24p3R (SLC22A17), which is found throughout the kidney and shown to mediate Ngal endocytosis⁷⁶, but its function is not yet confirmed. Stably transfected HEK293 cells over-expressing human 24p3R can be generated, and the uptake of Alexa-488 labeled wild-type and K6 (i.e, K3) mutant Ngal and Ngal:Ent:Fe^(III) can be determined, for example by using confocal microscopy and immunoblots. If 24p3R stimulates the uptake of wild-type Ngal, it can be a receptor for Ngal, and the K6 (i.e, K3) mutant (and other mutants) may show defective interactions with this receptor.

Distribution of Ngal Mutants In Vivo

A further test of the Ngal-megalin interaction can be performed using a megalin conditional knockout murine model⁹¹, in which megalin is deleted in the proximal tubular epithelia using floxed-megalin mice and gGT-Cre which specifically deletes genes in 80% of cells in the S3 segment of the proximal tubule⁹². According to TE Willnow⁹¹, these conditionally deleted mice are viable and fertile. The efficiency of the megalin deletion can be confirmed by immunohistochemical staining with anti-megalin antibodies. If the deletion is complete, megalin^(f/f) mice can be bred with megalin^(f/+) gGT-Cre mice to generate megalin^(f/f):gGT-Cre mice (25%) and littermate controls megalin^(f/f) (25%), megalin^(f/+):gGT-Cre (25%) and megalin^(f/+) (25%). The megalin deleted mice (n=12) can be identified by PCR-genotyping the floxed allele and the gGT-cre recombinase. Alexa-488- or rhodamine labeled wild-type or K6 (i.e, K3) mutants (two different labels to avoid the contribution of negative (Alexa-488) or positive (Rhodamine) charges) can be tested by i.p. injection into 4 week old mice and their trafficking analyzed by using a Zeiss LSM510-META inverted confocal laser scanning microscope and immunoblots with anti-human antibodies. Since megalin expression is limited to proximal kidney epithelia, parathyroid cells, epididymal epithelial cells, type II pneumocytes, mammary epithelial and thyroid follicular cells, the distribution of both wt and mutant Ngal in wt and knockout mice can be investigated to explore the Ngal-megalin interaction in vivo. If the capture of wt Ngal by the proximal tubule is abolished in the conditional megalin-ko kidney, and Ngal is excreted (similar to FIG. 10), megalin is likely the only Ngal receptor in the kidney and the proposed receptor 24p3R is non-essential. If this is the case, then the distribution of wt Ngal should also correlate with the distribution of megalin in different tissues. Moreover, if Ngal mutants such as K6 (i.e, K3) have poor affinity for megalin, their escape in the urine can be directly explained. On the other hand, if wt Ngal is captured in the megalin knockout proximal tubule and by cells of the body where megalin is not expressed, then alternative receptor(s) are expected. In this case, the excretion of mutant Ngal may be the result of loss-of-affinity not only for megalin, but for non-megalin receptors.

Evaluation of the Ngal:Ent:Fe^(III) Interaction in Ngal Mutants

Ngal specifically binds Ent:Fe^(III) and Ent with high affinities (0.4 nM and 3.57 nM, respectively)^(36,75), and it fails to release bound iron even at low pH³⁸. Ngal sequestered iron no longer participates in chemical reactions and the complex is stable for transport in circulation. Whether loss-of-“reabsorption” mutants still have the capacity to bind ferric siderophores at high affinity can be tested. Initial data shows that the mutants retain iron in the presence of Ent (FIG. 14) and demonstrates a distinct red coloration. The K6 (i.e, K3) Ngal:Ent interaction can be quantified and the structural effects of the introduced mutations can be determined.

Quantitative Measurement of Ent:Fe^(III) Binding by Ngal

A fluorescence quenching (FQ) strategy (Nature Chemical Biology, 2010³⁸, FIG. 10) can be utilized to quantify the spectrum of Ngal and Ngal mutant:ferric siderophore interactions⁹³⁻⁹⁸ to derive affinity measurements for Ent binding. Excitation λ_(exc)=281 nm and emission λ_(em)=340 nm data can be collected from 100 nM K6 (i.e, K3) Ngal mutant protein solutions (with 32 μg/mL ubiquitin and 5% DMSO), exposed to Ent:Fe. The pH sensitivity of the complex can be determined by incrementally adjusting the solution's pH until the fluorescence signal stabilizes. The data can be examined using nonlinear regression analysis using a one-site binding model (DYNAFIT)⁹⁹. Control experiments can be performed to ensure protein stability. Alternative techniques include SPR and isothermal titration calorimetry (e.g. from the Strong group⁸⁶).

Structural Basis for the Formation of Mutant Ngal:Ent:Fe^(III)

In order to confirm that mutations introduced to disable megalin binding do not interfere with ferric siderophore ligand recognition, the structure of K6 (i.e, K3)±Ent:Fe^(III) can be determined by X-Ray Crystallography. Over 20 Ngal crystal structures, including human, murine and mutant forms, ±N-linked CHO, both empty and bound to a series of natural siderophores or synthetic analogs have been determined previously^((36,38,93,99,100)). Since the K6 (i.e, K3) mutations affect crystal contacts in all the known Ngal crystal forms, this can be approached as a de novo structure determination. For crystallization, the protein can be highly purified by GST chromatography, followed by gel filtration and ion exchange chromatography, with purity and monodispersivity determined by reduced/non-reduced PAGE and mass-spectroscopy with concurrent static/dynamic light scattering (SLS/DLS). Monodispersed protein preparations can be screened for crystallizability using sub-microliter robotics and commercially-available factorial screens. Preliminary crystals can be optimized in conventional crystallization formats using established methodologies that catalyze crystallization. Alternatively, the protein can be more stringently purified or complexed with Fabs (the structure of a murine Ngal:Fab complex [crystallized from 20% PEG 4000 and 10% isopropanol, pH=7.0; space group: P2₁ 2 ₁ 2 ₁, a=37.9 Å, b=69.4 Å, c=117.6 Å; d_(min)=2.15 Å, R_(merge)=0.04] was determined—a panel of over 16 anti-human Ngal antibody Fabs can be used for co-crystallization). Diffraction data can be collected. Data can be reduced with any of a variety of available software packages and can be phased by direct difference Fourier (for isomorphous crystals), molecular replacement (MR), MAD (generally using selenomethionine) or MIRAS (using any of a variety of derivatization strategies). These data can quantitatively characterize Ngal:Ent interactions, indicating whether K6 (i.e, K3) (or other mutants) have retained affinity for Ent:Fe^(III). These studies can show that the introduced mutations impair ligand binding, and the structures can be used to engineer additional mutations.

Safe Excretion of Iron by the Delivery of Mutant NGAL:Ent:Fe^(III)

To test whether K6 (i.e, K3) Ngal:Ent can efficiently chelate and deliver NTBI to the urine through the kidney, the K6 (i.e, K3):Ent:⁵⁵Fe^(III) complex (80 μg) was introduced into mice (4 weeks), and collected the urine for 3 hrs in metabolic cages. As shown in FIG. 16, 23% of the injected K6 (i.e., K3)-⁵⁵Fe^(III) complex was delivered to the urine, paralleling the percentage of K6 (i.e, K3) protein found in the urine (FIG. 13), while less than 0.1% of the wild type injectate was excreted. Only trace amounts of ⁵⁵Fe^(III) accumulated in the liver (<1%), indicating that once iron was chelated by K6 (i.e, K3):Ent, it was mainly delivered to the kidney and the urine. Based on these results, it can be tested whether K6 (i.e, K3):Ent can capture, chelate, traffic and remove endogenous NTBI.

Chelation and Excretion of NTBI by K6 (i.e, K3):Ent in Murine Models of Hemochromatosis

Establishment and Evaluation of Mouse Models

A mouse model of Type 1 hereditary hemochromatosis lacking the Hfe gene is available from the Jackson Labs (Stock #: 003812). These mice develop organ iron overload 12 weeks after weaning⁴⁵. A mouse model of acquired hemochromatosis can be established as reported previously¹⁰¹. This mouse model of transfusion mediated iron overload was made by transfusing stored (14 days at 4° C.) mouse RBC (200 or 400 μL at 17.0-17.5 g/dL hemoglobin) into a recipient via the retro-orbital plexus of isoflurane-anesthetized mice, which is the equivalent of transfusing a human with 1-2 units of RBC. Briefly, the RBCs are obtained from 30-50 C57BL/6 mice in CPDA-1 solution (Baxter), leukoreduced using a Neonatal High-Efficiency Leukocyte Reduction Filter (Purecell Neo) and then concentrated by centrifugation to a final hemoglobin level of 17 g/dL, as determined by Drabkin assays (Ricca)¹⁰² and the optical density (540 nm) compared with the Count-a-Part Cyanmethemoglob-in Standards (Diagnostic Technology)¹⁰¹. Residual leukocytes are counted by cytometry (LeucoCOUNT; BD)¹⁰¹. NTBI was previously observed in both HFE^(−/−) (3.704)¹⁰³ and RBC transfused (˜2.5 μM) mice¹⁰¹. NTBI can be measured in these models using a standard nitrilotriacetic acid (NTA) ultrafiltration assay¹⁰¹. This can be done by incubating heparinized plasma (90 μL) with NTA (800 mM, pH 7.0) and then preparing a 30K ultrafiltrate (NanoSep, 30-kDa cutoff, polysulfone type) and measuring NTBI with ferrozine¹⁰⁴. Total organ iron can be determined using a procedure which involves desiccation at 65° C., followed by acidification and detection of NTBI with a chromogen (1.6 mM bathophenanthroline)¹⁰⁵. Hemoglobinemia can be detected spectrophotometrically using a PowerWave XS spectrophotometer (BioTek)¹⁰¹. Intracellular iron accumulation in the liver and spleen can be detected in paraffin sections with Perl's reagent which reveals blue granules⁵⁴ and in sections with co-immunostaining to detect macrophages with anti-mouse F4/80 antibody (eBioscience) and ABC and DAB kits (Vector Laboratories)¹⁰¹.

As reported previously, a number of cytokines/chemokines, especially interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory protein-1β (MIP-1β), and keratinocyte-derived chemokine/CXCL1 (KC/CXCL1) are increased in the plasma 2 hrs after transfusion of old stored RBC¹⁰¹. Hence, these cytokines can be measured as markers of iron overload and as a measure of treatment efficacy of Ngal. The cytokines/chemokines can be quantified using the Cytometric Bead Array Mouse Flex Kit (BD Biosciences) and plasma with a FACSCalibur cytometer (BD Biosciences) equipped with FlowJo software¹⁰¹.

Treatment of Iron Overload with K6 (i.e, K3)::Ent and Evaluation of Treatment Efficacy.

The K6 (i.e, K3):Ent complex can be introduced into HFE^(−/−) or RBC transfused mice by intravenous infusion with a micro-osmotic pump (ALZET®). For HFE^(−/−) mice, the dose of K6 (i.e, K3):Ent can be 17.9 mg K6 (i.e, K3):Ent for 12 hours, 3 times a week for 4 weeks. This dose is based on the following calculation: For HFE^(−/−) mice, NTBI is ˜3.7 μM and blood volume is ˜1.6 ml; to maximize iron chelation and removal, equal moles of Ngal:Ent should be continually present in circulation for a 12 hour treatment with the consideration of Ngal's half life of 10 min, or approximately ˜0.85 mmoles (˜17.9 mg) of Ngal:Ent are theoretically required over 12-hours. Similarly, for the transfusion mice the dose is ˜0.58 mmoles (˜12 mg) of Ngal:Ent over 12 hours in a single treatment period. Apo-K6 (i.e, K3) is as a negative control because it does not bind iron and associated endogenous catechols would dissociate. Wt Ngal is also a useful control because it is captured by megalin, and it does not traffic iron into the urine.

The efficacy of treatment can be evaluated by the measurement of serum and urinary iron, iron concentration in the liver, spleen and kidney, intracellular iron accumulation in macrophages and hepatocytes, and cytokines/chemokines in the plasma of K6 (i.e, K3):Ent- vs K6 (i.e, K3)- or Wt-treated mice as described above. K6 (i.e, K3) Ngal can be detected in urine by immunoblot with anti-human antibodies. Preliminary data suggests that K6 (i.e, K3) will appear in the urine, and that K6 (i.e, K3):Ent will markedly diminish serum NTBI, decrease the iron content of HFE^(−/−) mice and transfusion overload, and additionally normalize the levels of cytokines/chemokines in old-RBC transfusions.

Effect of K6 (i.e, K3):Ent Treatment on Iron-Mediated Cell Damage

Measurement of Redox Activity in the Kidney Peroxidized lipids are a marker of iron catalyzed oxidant stress, which are measured by malondialdehyde. The renal cortex of mice subjected to K6 (i.e, K3) treatment is separated from the medulla, homogenized^(106,107) and treated with TCA and thiobarbituric acid and the supernatant read at 535 nm. Malondialdehyde, expressed in nmoles, is calculated using a molar extinction coefficient of 1.56×10⁵ M⁻¹ cm⁻¹ at 535 nm. An additional measurement of kidney damage during the treatment with K6 (i.e, K3) is the detection of endogenous mouse uNgal (25 KDa) with mouse antibody (R&D system). Ngal is expressed within 3 hrs of damage by stimuli that cause AKI including radical attack, and here we will measure uNgal in the different treatment groups.

Measurement of Free Iron and Redox Activity in Mouse Urine

The data presented herein suggests that the iron will be tightly bound to K6 (i.e, K3) Ngal and redox inactive even in the acidic urine. This can be tested using the classic spectrophotometric bleomycin test of Gutteridge⁵⁷ to measure urinary “catalytic” iron in mice treated with K6 (i.e, K3), K6 (i.e, K3):Ent and wild type Ngal. Urine is collected in Chelex-treated, pyrogen-free water and an ultrafiltrate created using a microcon (10K, Millipore) measured with the bleomycin assays. A standard curve is prepared with urine spiked with FeCl₃ and bleomycin-detectable iron recorded per mg creatinine (Abcam). A second strategy to measure redox activity can also be used—the iron mediated generation of hydroxyl radicals can be detected by the conversion of 3′-(p-hydroxyphenyl) fluorescein (HPF; Invitrogen) to fluorescein in the presence of ascorbic acid⁹⁴ (Ex 490 nm, Em 515 nm). As shown in FIGS. 17 and 18, wild type Ngal quenched the activity of catechol:Fe^(III)-urine from mice treated with K6 (i.e, K3), K6 (i.e, K3):Ent and Wt Ngal:Ent is tested. A positive control is Ent/catechol:Fe^(III) followed by K6 (i.e, K3) which inhibits the production of superoxide radicals.

Vertebrate Animals

In Vivo Characterization of Ngal-Mediated Iron Chelation and Trafficking:

Adult female and male mice (C57BL/6) are the principal source of experimental tissues for studying the regulation of iron metabolism. We have used adult tissues from these mice for many years to discover how Ngal mediates iron trafficking (Bao et al Nat Chem Biol, 2010). Both male and female adults are used in vivo to characterize the Ngal-mediated iron transport to different tissues (e.g. liver, heart, lung, kidney, spleen, pancreas, brain) and urine (Bao et al Nat Chem Biol, in press, 2010). Animals of all ages and both sexes will be used.

Mouse is a standard model for studying the regulation of iron delivery and metabolism dating back to the 1950's, and many murine models of iron overload diseases such as HFE−/− mice have been established and utilized to study the pathogenesis of these diseases and potential therapeutic treatments. Further, use of mice carrying gene knockouts is a standard of the field which has yielded most of the insights to date in the functions of genes required for iron delivery and metabolism such as megalin which is required for transferrin- and Ngal-bound iron reabsorption in the kidney. There are no alternatives to the use of these mouse models because no other animal models of other species are available and studies based on cultured cell lines can not reflect the in vivo mechanism of iron delivery and metabolism. Hence, these murine models will be used to investigate the in vivo mechanism of Ngal-mediated iron delivery to various tissues and urine.

Based on data on the difference of the ability of the intraperitoneally injected wild-type and K6 (i.e, K3) mutant Ngal proteins to bypass the kidney and enter the urine, we estimated the number of mice (sample size) which are required for the experiments by using Power Analysis with parameters of p<0.05 and Power=0.8 and a Biomath program (http://www.biomath.info/power/ttest.htm), and 6 mice are suggested in each of the groups to achieve statistic significance (t-test on group means). According to the calculation, for each experimental category (control K6 (i.e, K3), K6 (i.e, K3):Ent, Wt:Ent) we will need 6 wild-type mice, 6 megalinf/f;GgT-cre+ mice, 6 HFE−/− mice (total=54 mice). To generate these mice, 10 mating cage, each containing 1 male and 2 females will be used (2 cages for the generation of megalinf/f, 2 cages for GgT-cre/megalinf/+, 2 cages for megalinf/f GgT-cre+, and 2 cages for homozygous HFE−/−). Similarly, for the RBC transfusions we will need 18 mice to test Ngal proteins and, in order to collect plasma from cardiac puncture, we will need 50 wild type mice to blood bank the RBC for transfusion.

No surgical procedures are planned. Genotyping: In the case of animals carrying gene knockouts (eg. Megalinf/f, GgT-cre+, HFE−/−) genotyping is necessary. The animal is genotyped at 14 days by snipping a 2-3 mm of tail dabbing the wound with lidocaine. Pressure is applied to control blood loss/

Euthanasia is performed through CO2 narcosis and cervical dislocation. Following CO2 narcosis the chest cavity is opened to assure death of the animal, and the feti are removed.

REFERENCE LIST

-   1. Hershko, C., and Peto, T. E. Non-transferrin plasma iron. Br. J.     Haematol. 66: 149-151, 1987. -   2. Breuer, W., Ronson, A., Slotki, I. N., Abramov, A., Hershko, C.,     and Cabantchik, Z. I. The assessment of serum nontransferrin-bound     iron in chelation therapy and iron supplementation. Blood. 95:     2975-2982, 2000. -   3. Andrews, N. C. Iron metabolism: Iron Deficiency and Iron     Overload. Annu Rev. Genomics Hum. Genet. 1:75-98, 2000. -   4. Thakerngpol, K., Fucharoen, S., Boonyaphipat, P., Srisook, K.,     Sahaphong, S., Vathanophas, V., and Stitnimankarn, T. Liver injury     due to iron overload in thalassemia: histopathologic and     ultrastructural studies. Biometals. 9: 177-183, 1996. -   5. Conte, D., Piperno, A., Mandelli, C., et al. Clinical,     biochemical and histological features of primary haemochromatosis: a     report of 67 cases. Liver. 6: 310-315, 1986. -   6. Tsukamoto, H., Horne, W., Kamimura, S., Niemela, O., Parkkila,     S., Yla-Herttuala, S., and Brittenham, G. M. Experimental liver     cirrhosis induced by alcohol and iron. J. Clin. Invest. 96: 620-630,     1995. -   7. Berdoukas, V., Bohane, T., Tobias, V., et al. Liver iron     concentration and fibrosis in a cohort of transfusion-dependent     patients on long-term desferrioxamine therapy. Hematol. J. 5:     572-578, 2004. -   8. Liu, P., and Olivieri, N. Iron overload cardiomyopathies: new     insights into an old disease. Cardiovasc. Drugs. Ther. 8: 101-110,     1994. -   9. Buja, L. M., and Roberts, W. C. Iron in the heart. Etiology and     clinical significance. Am. J. Med. 51: 209-221, 1971. -   10. Schwartz, K. A., Li, Z., Schwartz, D. E., et al. Earliest     cardiac toxicity induced by iron overload selectively inhibits     electrical conduction. J. Appl. Physiol. 93: 746-751, 2002. -   11. Oudit, G. Y., Trivieri, M. G., Khaper, N., Liu, P. P., and     Backx, P. H. Role of L-type Ca2+ channels in iron transport and     iron-overload cardiomyopathy. J. Mol. Med. 84: 349-364, 2006. -   12. Oudit, G. Y., Sun, H., Trivieri, M. G., Koch, S. E., Dawood, F.,     Ackerley, C., Yazdanpanah, M., Wilson, G. J., Schwartz, A., Liu, P.     P., and Backx, P. H. L-type Ca²⁺ channels provide a major pathway     for iron entry into cardiomyocytes in iron-overload cardiomyopathy,     Nat. Med. 9: 1187-1194, 2003. -   13. Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med.     341: 1986-1995, 1999. -   14. Argyropoulou, M. I., and Astrakas, L. MRI evaluation of tissue     iron burden in patients with beta-thalassaemia major. Pediatr.     Radiol. 37: 1191-1200, 2007. -   15. Argyropoulou, M. I., Kiortsis, D. N., Astrakas, L., Metafratzi,     Z., Chalissos, N., Efremidis, S. C. Liver, bone marrow, pancreas and     pituitary gland iron overload in young and adult thalassemic     patients: a T2 relaxometry study. Eur. Radiol. 17: 3025-3030, 2007. -   16. Cunningham, M. J., Macklin, E. A., Neufeld, E. J., and     Cohen, A. R. Complications of beta-thalassemia major in North     America. Blood. 104: 34-39, 2004. -   17. Fung, E., Harmatz, P. R., Lee, P. D., Milet, M., Bellevue, R.,     Jeng, M. R., Kalinyak, K. A., Hudes, M., Bhatia, S., and     Vichinsky, E. P. Increased prevalence of iron-overload associated     endocrinopathy in thalassaemia versus sickle-cell disease. Br. J.     Haematol. 135: 574-582, 2006. -   18. Kattamis, C., and Kattamis, A. C. Management of thalassemias:     growth and development, hormone substitution, vitamin     supplementation, and vaccination. Semin. Hematol. 32: 269-279, 1995. -   19. Eschbach, J. W., and Adamson, J. W. Iron overload in renal     failure patients: Changes since the introduction of erythropoietin     therapy. Kidney Int. 55: S35-S43, 1999. -   20. Lorenz, M., Kletzmayr, J., Huber, A., Hörl, A. H.,     Sunder-Plassmann, G., and Födinger, M. Iron overload in kidney     transplants: Prospective analysis of biochemical and genetic     markers. Kidney Int. 67, 691-697, 2005. -   21. Mandalunis, P. M., and Ubios, A. M. Experimental Renal Failure     and Iron Overload: A Histomorphometric Study in Rat Tibia. Toxicol.     Pathol. 33; 398-403, 2005. -   22. Karnon, J., Zeuner, D., Brown, J., Ades, A. E., Wonke, B., and     Modell, B. Lifetime treatment costs of beta-thalassaemia major.     Clin. Lab. Haematol. 21: 377-385, 1999. -   23. Darbari, D. S., Kple-Faget, P., Kwagyan, J., Rana, S.,     Gordeuk, V. R., and Castro, O. Circumstances of death in adult     sickle cell disease patients. Am. J. Hematol. 81: 858-863, 2006. -   24. McCord, J. M. Oxygen-derived free radicals in postischemic     tissue injury. N. Engl. J. Med. 312: 159-163, 1985. -   25. Meneghini, R. Iron homeostasis, oxidative stress, and DNA     damage. Free Radic. Biol. Med. 23: 783-792, 1997. -   26. Kalinowski, D. S., and Richardson, D. R. The Evolution of Iron     Chelators for the Treatment of Iron Overload Disease and Cancer.     Pharmacol. Rev. 57: 547-583, 2005. -   27. Cohen, A. R. New Advances in Iron Chelation Therapy.     Hematology-American Hematology Society Hematology Education Program.     42-47, 2006. -   28. Hoffbrand, A. V., Cohen, A., and Hershko, C. Role of deferiprone     in chelation therapy for transfusional iron overload. Blood 102:     17-24, 2003. -   29. Bosque, M. A., Domingo, J. L., and Corbella, J. Assessment of     the developmental toxicity of deferoxamine in mice. Arch. Toxicol.     69: 467-471, 1995. -   30. Oliveri, N. F., Buncic, J. R., Chew, E., Galant, T., Harrison R.     V., Keenan, N., Logan, W., Mitchell, D., Rici, G., Skarf, B.,     Taylor, M., and Freedman, M. H. Visual and auditory neurotoxicity in     patients receiving subcutaneous deferoxamine infusions. N. Engl. J.     Med. 314: 869-873, 1986. -   31. Boelaert, J. R., and de Locht, M. Side-effects of     desferrioxamine in dialysis patients. Nephrol Dial Transplant. 8:     S43-S46, 1993. -   32. Windus D W, Stokes T J, Julian B A, Fenves A Z. Fatal Rhizopus     infections in hemodialysis patients receiving deferoxamine. Ann.     Intern. Med. 107: 678-80, 1987. -   33. Kowdley, K. V., and Kapla, M. M. Iron-chelation therapy with     oral deferiprone—Toxicity or Lack of Efficacy? N. Engl. J. Med. 339:     468-469, 1998. -   34. Kontoghiorghes, G. J. “Deferasirox: Uncertain future following     renal failure fatalities, agranulocytosis and other toxicities.     Expert. Opin. Drug. Saf. 6:235-239, 2007. -   35. Yang, J., Goetz, D., Li, J. Y., Wang, W., Mori, K., Setlik, D.,     Du, T., Erdjument-Bromage, H., Tempst, P., Strong R., and     Barasch, J. An iron delivery pathway mediated by a lipocalin. Mol.     cell, 10: 1045-56, 2002. -   36. Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E.,     Raymond, K. N., and Strong, R. K. The neutrophil lipocalin NGAL is a     bacteriostatic agent that interferes with siderophore-mediated iron     acquisition. Mol. cell, 10: 1033-1043, 2002. -   37. Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M.     A., and Strong, R. K., Akira, S., and Aderem, A. Lipocalin 2     mediates an innate immune response to bacterial infection by     sequestrating iron. Nature, 432: 917-921, 2004. -   38. Bao, G., Clifton, M., Hoette, T. M., Mori, K., Deng, S. X., Qiu,     A., Viltard, M., Williams, D., Paragas, N., Leete, T., Kulkarni, R.,     Li, X., Lee, B., Kalandadze, A., Ratner, A. J., Pizarro, J. C.,     Schmidt-Ott, K., Landry, D. W., Raymond, K. N., Strong, R. K., and     Barasch, J. Iron Traffics in Circulation Bound to a Siderocalin     (Ngal)-Catechol Complex. Nat. Chem. Biol. in press, 2010. -   39. Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang,     J., Barasch, J., and Devarajan, P. Identification of neutrophil     gelatinase-associated lipocalin as a novel early urinary biomarker     for ischemic renal injury. J. Am. Soc. Nephrol. 14: 2534-43, 2003. -   40. Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K.,     Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S.,     Mishra, J., Cheema, F. H., Markowitz, G., Suganami, T., Sawai, K.,     Mukoyama, M., Kunis, C., D'Agati, V., Devarajan, P., and Barasch, J.     Endocytic delivery of lipocalin-siderophore-iron complex rescues the     kidney from ischemia-reperfusion injury. J. Clin. Invest. 115:     610-621, 2005. -   41. Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M. M., Ma, Q.,     Kelly, C., Ruff, S. M., Zahedi, K., Shao, M., Bean, J., Mori, K.,     Barasch, J., and Devarajan, P. Neutrophil gelatinase-associated     lipocalin (NGAL) as a biomarker for acute renal injury after cardiac     surgery. Lancet. 365: 1231-1238, 2005. -   42. Nickolas, T. L., O'Rourke, M. J., Yang, J., Sise, M. E.,     Canetta, P. A., Barasch, N., Buchen, C., Khan, F., Mori, K., Giglio,     J., Devarajan, P., and Barasch, J. Sensitivity and specificity of a     single emergency department measurement of urinary neutrophil     gelatinase-associated lipocalin for diagnosing acute kidney injury.     Ann. Intern. Med. 148: 810-9, 2008. -   43. Hvidberg, V., Jacobsen, C., Strong, R. K., Cowland, J. B.,     Moestrup, S. K., and Borregaar, N. The endocytic receptor megalin     binds the iron transporting neutrophil-gelatinase-associated     lipocalin with high affinity and mediates its cellular uptake, FEBS     Letters 579: 773-777, 2005. -   44. Andrews, N. C. Iron homeostasis: insights from genetics and     animal models. Nat. Rev. 1: 208-217, 2000. -   45. Bahram, S., Gilfillan, S., Kuhn, L. C., Moret, R., Schulze, J.     B., Lebeau, A., and Schumann, K. Experimental hemochromatosis due to     MHC class I HFE deficiency: immune status and iron metabolism. Proc.     Natl. Acad. Sci. USA. 96: 13312-13317, 1999. -   46. Borwein, S., Ghent, C. N., and Valberg, L. S. Diagnostic     efficacy of screening tests for hereditary hemochromatosis. Cen.     Med. Assoc. 131: 895-901, 1984. -   47. Halliwell, B., and Gutteridge, J. M. Role of free radicals and     catalytic metal ions in human disease: an overview. Methods Enzymol.     186: 1-85, 1990. -   48. Trinder, D., Fox, C., Vautier, G., and Olynyk, J. K. Molecular     pathogenesis of iron overload, Gut 51: 290-295, 2002. -   49. Allen, K. J., Gurrin, L. C., Constantine, C. C., Osborne, N. J.,     Delatycki, M. B., Nicoll, A. J., McLaren, C. E., Bahlo, M.,     Nisselle, A. E., Vulpe, C. D., Anderson, G. J., Southey, M. C.,     Giles, G. G., English, D. R., Hopper, J. L., Olynyk, J. K.,     Powell, L. W., and Gertig, D. M. Iron-overload-related disease in     HFE hereditary hemochromatosis. N. Engl. J. Med. 358: 221-230, 2008. -   50. Landro, L. New rules may shrink ranks of blood donors. Wall     Street Journal. 2007-01-10. -   51. Bennett, J. M. (ed). The Myelodysplastic Syndromes: Pathobiology     and Clinical Management. New York: Marcel Dekker, Inc. 2002. -   52. Iron Disorders Institute, Inc. Transfusion-dependent iron     overload. idInsight. Greenville, S.C. -   53. Schafer, A., Cheron, R. G., Dluhy, R., Cooper, B., Gleason, R.     E., Soeldner, J. S., and Bunn, H. F. Clinical consequences of     acquired transfusional iron overload in adults. N. Engl. J. Med.     304: 319-324, 1981. -   54. Paragas, N., Nickolas, T. L., Wyatt, C., Forster, C. S., Sise,     M., Morgello, S., Jagla, B., Buchen, C., Stella, P., Sanna-Cherchi,     S., Carnevali, M. L., Mattei, S., Bovino, A., Argentiero, L.,     Magnano, A., Devarajan, P., Schmidt-Ott, K. M., Allegri, L.,     Klotman, P., D'Agati, V., Gharavi, A. G., and Barasch, J. Urinary     NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc.     Nephrol. 20: 1687-1692, 2009. -   55. Alfrey, A. Toxicity of tubule fluid iron in nephrotic syndrome.     Am. J. Physiol. 263: F637-641, 1992. -   56. Baliga, R., Zhang, Z., Baliga, M., and Shah, S. V. Evidence for     cytochrome P-450 as a source of catalytic iron in myoglobinuric     acute renal failure. Kidney Int. 49: 362-369, 1996. -   57. Baliga, R., Zhang, Z., Baliga, M., Ueda, N., and Shah, S. V. In     vitro and in vivo evidence suggesting a role for iron in     cisplatin-induced nephrotoxicity. Kidney Int. 53: 394-401, 1998. -   58. Saad, S. Y., Najjar, T. A., and Al-Rikabi, A. C. The preventive     role of deferoxamine against acute doxorubicin-induced cardiac,     renal and hepatic toxicity in rats. Pharmacol. Res. 43: 211-218,     2001. -   59. Paller, M. S., and Jacob, H. S. Cytochrome P-450 mediates     tissue-damaging hydroxyl radical formation during reoxygenation of     the kidney. Proc. Natl. Acad. Sci. USA. 91: 7002-7006, 1994. -   60. Baliga, R., Ueda, N., and Shah, S. V. Increase in     bleomycin-detectable iron in ischaemia/reperfusion injury to rat     kidneys. Biochem. J. 291: 901-905, 1993. -   61. Baron, P., Gomez-Marin, O., Casas, C., Heil, J., Will, N.,     Condie, R., Burke, B., Najarian, J. S., and Sutherland, D. E. Renal     preservation after warm ischemia using oxygen free radical     scavengers to prevent reperfusion injury. J. Surg. Res. 51: 60-65.     1991. -   62. Wu, Z. L., and Paller, M. S. Iron loading enhances     susceptibility to renal ischemia in rats. Ren. Fail. 16: 471-480,     1994. -   63. Baliga, R., Zhang, Z., Baliga, M., Ueda, N., and Shah, S. V. In     vitro and in vivo evidence suggesting a role for iron in     cisplatin-induced nephrotoxicity. Kidney Int. 53: 394-401, 1998. -   64. Walker, P. D., and Shah, S. V. Evidence suggesting a role for     hydroxyl radical in gentamicin-induced acute renal failure in     rats. J. Clin. Invest. 81: 334-341, 1988. -   65. Paller, M. S., and Hedlund, B. E. Role of iron in postischemic     renal injury in the rat. Kidney Int. 34: 474-480, 1988. -   66. Paller, M. S., and Hedlund, B. E. Extracellular iron chelators     protect kidney cells from hypoxia/reoxygenation. Free Radic. Biol.     Med. 17: 597-603, 1994. -   67. de Vries, B., Walter, S. J., von Bonsdorff, L., Wolfs, T. G.,     van Heurn, L. W., Parkkinen, J., and Buurman, W. A. Reduction of     circulating redox-active iron by apotransferrin protects against     renal ischemia-reperfusion injury. Transplantation, 77: 669-675,     2004. -   68. Zager, R. A., Burkhart, K. M., Conrad, D. S., and Gmur, D. J.     Iron, heme oxygenase, and glutathione:effect on myohemoglobinuric     proximal tubular injury. Kidney Int. 48: 1624-1634, 1995. -   69. Paller, M. S., and Hedlund, B. E. Extracellular iron chelators     protect kidney cells from hypoxia/reoxygenation. Free Radic. Biol.     Med. 17: 597-603, 1994. -   70. Holmes, M. A., Paulsene, W., Jide, X., Ratledge, C., and     Strong, R. K. Siderocalin (Lcn 2) also binds carboxymycobactins,     potentially defending against mycobacterial infections through iron     sequestration. Structure 13: 29-41, 2005. -   71. Loomis, L. D., and Raymond, K. N. Solution Equilibria of     Enterobactin and Metal-Enterobactin Complexes. Inorg. Chem. 30:     906-911, 1991. -   72. Jewett, S. L., Eggling, S., and Geller, L. Novel method to     examine the formation of unstable 2:1 and 3:1 complexes of     catecholamines and iron(III), J. Inorg. Biochem. 66: 165-173, 1997. -   73. Keberle, H. The biochemistry of desferrioxamine and its relation     to iron metabolism. Ann. N.Y. Acad. Sci. 119: 758-768, 1964. -   74. Leheste, J. R. et al. Megalin knockout mice as an animal model     of low molecular weight proteinuria. Am. J. Pathol. 155: 1361-1370,     1999. -   75. Abergel, R. J., Wilson, M. K., Arceneaux, J. E. L, Hoette, T.     M., Strong, R. K., Byers, B. R., and Raymond, K. N. Anthrax pathogen     evades the mammalian immune system through stealth siderophore     production. PNAS 103: 18499-18503, 2006. -   76. Devireddy, L. R., Gazin, C., Zhu, X., and Green, M. R. A     cell-surface receptor for lipocalin 24p3 selectively mediates     apoptosis and iron uptake. Cell. 123: 1293-305, 2005. -   77. Moestrup, S. K., and Verroust, P. J. Megalin- and     cubilin-mediated endocytosis of protein-bound vitamins, lipids, and     hormones in polarized epithelia. Annu Rev. Nutr. 21: 407-428, 2001. -   78. Liang, M. P., Banatao, D. R., Klein, T. E., Brutlag, D. L., and     Altman, R. B. WebFEATURE: An interactive web tool for identifying     and visualizing functional sites on macromolecular structures.     Nucleic Acids Res. 31: 3324-3327, 2003. -   79. Moestrup, S. K. and Gliemann, J. Analysis of ligand recognition     by the purified alpha 2-macroglobulin receptor (low density     lipoprotein receptor-related protein). Evidence that high affinity     of alpha 2-macroglobulin-proteinase complex is achieved by binding     to adjacent receptors. J. Biol. Chem. 266: 14011-14017, 1991. -   80. Kaiser, B. K., Barahmand-Pour, F., Paulsene, W., Medley, S.,     Geraghty, D. E., and Strong, R. K., Interactions between NKG2×     immunoreceptors and HLA-E ligands display overlapping affinities and     thermodynamics. J. Immunol. 174: 2878-2884, 2005. -   81. Li, P., McDermott, G., and Strong, R. K., Crystal structures of     RAE-1beta and its complex with the activating immunoreceptor NKG2D.     Immunity, 16: 77-86, 2002. -   82. Li, P., Morris, D. L., Willcox, B. E., Steinle, A., Spies, T.,     and Strong, R. K., Complex Structure of the Activating     Immunoreceptor NKG2D and its MHC Class I-like Ligand MICA. Nature     Immunol. 2: 443-451, 2001. -   83. McBeth, C., Seamons, A., Pizarro, J. C., Fleishman, S. J.,     Baker, D., Kortemme, T., Goverman, J. M., and Strong, R. K., A new     twist in TCR diversity revealed by a forbidden alphabeta TCR. J.     Mol. Biol. 375: 1306-1319, 2008. -   84. McFarland, B. J., and Strong, R. K. Thermodynamic analysis of     degenerate recognition by the NKG2D immunoreceptor: not induced fit     but rigid adaptation. Immunity 19: 803-812, 2003. -   85. Vigdorovich, V., Strong, R. K., and Miller, A. D., Expression     and characterization of a soluble, active form of the jaagsiekte     sheep retrovirus receptor, Hya12. J. Virol. 79: 79-86, 2005. -   86. Xu, H., Song, L., Kim, M., Holmes, M. A., Kraft, Z., Sellhorn,     G., Reinherz, E. L., Stamatatos, L., and Strong, R. K. Interactions     between lipids and human anti-HIV antibody 4E10 can be reduced     without ablating neutralizing activity. J. Virol. 84: 1076-1088,     2010. -   87. Correia, B. E., Ban, Y. E. A., Holmes, M. A., Xu, H., Ellingson,     K., Kraft, Z., Carrico, C., Boni, E., Sather, N., Zenobia, C.,     Burke, K. Y., Bradley-Hewitt, T., Bruhn-Johannsen, J. F.,     Kalyuzhniy, O., Baker, D., Strong, R. K., Stamatatos, L., and     Schief, W. R. Computational design of epitope-scaffolds allows     induction of antibodies specific for a poorly immunogenic HIV     vaccine epitope. Structure, in press, 2010. -   88. Strong, R. K., Bratt, T., Cowland, J. B., Borregaard, N.,     Wiberg, F. C., and Ewald, A. J., Expression, purification,     crystallization and crystallographic characterization of dimeric and     monomeric human neutrophil gelatinase associated lipocalin (NGAL).     Acta Cryst. D54: 93-95, 1998. -   89. Bauer, S., Willie, S. T., Spies, T., and Strong, R. K.     Expression, purification, crystallization and crystallographic     characterization of the human MHC class I related protein MICA. Acta     Cryst. D54: 451-453, 1998. -   90. Ryan, M. J., et al. HK-2: an immortalized proximal tubule     epithelial cell line from normal adult human kidney. Kidney Int. 45:     48-57, 1994. -   91. Leheste, J. R., Melsen, F., Wellner, M., Jansen, P.,     Schlichting, U., Renner-Muller, I., Andreassen, T. T., Wolf, E.,     Bachmann, S., Nykjaer, A., and Willnow, T. E. Hypocalcemia and     osteopathy in mice with kidney-specific megalin gene defect.     FASEB J. 17: 247-249, 2003. -   92. Dworniczak, B., Skryabin, B., Tchinda, J., Heuck, S.,     Seesing, F. J., Metzger, D., Chambon, P., Horst, J., Pennekamp, P.     Inducible Cre/loxP Recombination in the Mouse Proximal Tubule.     Nephron Experimental Nephrology, 106: ell-e20, 2007. -   93. Abergel, R. J., Clifton, M. C., Pizarro, J. C., Warner, J. A.,     Shuh, D. K., Strong, R. K., and Raymond, K. N., The     siderocalin/enterobactin interaction: a link between mammalian     immunity and bacterial iron transport. J. Am. Chem. Soc. 130:     11524-34, 2008. -   94. Abergel, R. J., Moore, E. G., Strong, R. K., and Raymond, K. N.,     Microbial evasion of the immune system: structural modifications of     enterobactin impair siderocalin recognition. J. Am. Chem. Soc. 128:     10998-9, 2006. -   95. Abergel, R. J., Wilson, M. K., Arceneaux, J. E., Hoette, T. M.,     Strong, R. K., Byers, B. R., and Raymond, K. N. Anthrax pathogen     evades the mammalian immune system through stealth siderophore     production. Proc. Natl. Acad. Sci. USA 103: 18499-503, 2006. -   96. Fischbach, M. A., Lin, H., Zhou, L., Yu, Y., Abergel, R. J.,     Liu, D. R., Raymond, K. N., Wanner, B. L., Strong, R. K., Walsh, C.     T., Aderem, A., and Smith, K. D. The pathogen-associated iroA gene     cluster mediates bacterial evasion of lipocalin 2. Proc. Natl. Acad.     Sci. USA 103: 16502-7, 2006. -   97. Hoette, T. M., Abergel, R. J., Xu, J., Strong, R. K., and     Raymond, K. N. The role of electrostatics in siderophore recognition     by the immunoprotein Siderocalin. J. Am. Chem. Soc. 130: 17584-92,     2008. -   98. Goetz, D. H., Willie, S. T., Armen, R. S., Bratt, T.,     Borregaard, N., and Strong, R. K. Ligand preference inferred from     the structure of neutrophil gelatinase associated lipocalin.     Biochemistry, 39: 1935-41, 2000. -   99. Kerjaschkit, D., Orlando, R. A., Farquhar, M. G., and Kuzmic, P.     Program DYNAFIT for the analysis of enzyme kinetic data: application     to HIV proteinase. Anal. Biochem. 237: 260-273, 1996. -   100. Holmes, M. A., Paulsene, W., Jide, X., Ratledge, C., and     Strong, R. K. Siderocalin (Lcn 2) Also Binds Carboxymycobactins,     Potentially Defending against Mycobacterial Infections through Iron     Sequestration. Structure, 13: 29-41, 2005. -   101. Hod, E. A., Zhang, N., Sokol, S. A., Wojczyk, B. S.,     Francis, R. O., Ansaldi, D., Francis, K. P., Della-Latta, P.,     Whittier, S., Sheth, S., Hendrickson, J. E., Zimring, J. C.,     Brittenham, G. M., and Spitalnik, S. L. Transfusion of red blood     cells after prolonged storage produces harmful effects that are     mediated by iron and inflammation. Blood. 115: 4284-4292, 2010. -   102. Moore, G. L., Ledford, M. E., and Merydith, A. A     micromodification of the Drabkin hemoglobin assay for measuring     plasma hemoglobin in the range of 5 to 2000 mg/dl. Biochem. Med. 26:     167-173, 1981. -   103. Anita, C., Chua, G., Olynyk, J. K., Leedman, P. J., and     Trinder, D. Nontransferrin-bound iron uptake by hepatocytes is     increased in the Hfe knockout mouse model of hereditary     hemochromatosis. Blood. 104: 1519-1525, 2004. -   104. Evans, R. W., Rafique, R., Zarea, A., et al. Nature of     non-transferrin-bound iron: studies on iron citrate complexes and     thalassemic sera. J. Biol. Inorg. Chem. 13: 57-74, 2008. -   105. Overmoyer, B. A., McLaren, C. E., and Brittenham, G. M.     Uniformity of liver density and nonheme (storage) iron distribution.     Arch. Pathol. Lab. Med. 111: 549-554, 1987. -   106. Walker, P. D., and Shah, S. V gentamicin-induced acute renal     failure in rats. J. Clin. Invest. 81: 334-341, 1988. -   107. Paller, M. S., and Hedlund, B. E. Role of iron in postischemic     renal injury in the rat. Kidney Int. 34: 474-480. Evidence     suggesting a role for hydroxyl radical in, 1998.

Table 2 shows a listing of amino acid sequences, and the amino acid sequences of mutant NGAL proteins. Mutant NGAL proteins which were generated are shown as SEQ ID NOS: 2-10; 21-68; 247-251. Table 2 also shows putative mutant NGAL proteins having substitutions to non-positively charged amino acids at all positions on NGAL (SEQ ID NOS: 69-246, including all surface residues on NGAL, which surface residues are inclusive of positions 1-15 (SEQ ID NOS: 69-83), positions 17-26 (SEQ ID NOS: 85-94), positions 40-50 (SEQ ID NOS: 108-118), positions 57-62 (SEQ ID NOS: 125-130), positions 71-82 (SEQ ID NOS: 139-150), positions 84-89 (SEQ ID NOS: 152-157), positions 96-105 (SEQ ID NOS: 164-173), positions 114-118 (SEQ ID NOS: 182-186), positions 128-131 (SEQ ID NOS: 196-199), position 134 (SEQ ID NO: 202), positions 140-151 (SEQ ID NOS: 208-219), positions 157-165 (SEQ ID NOS: 225-233), positions 170-174 (SEQ ID NOS: 238-242). The amino acid sequence of the K3Cys protein is depicted in SEQ ID NO:252.

SEQ ID NO Name Sequence SEQ ID WT NGAL QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 1 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID K-3 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 2 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID K-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 3 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID I-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 4 KMYATIYELKEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID I-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 5 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNQEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID K-5 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 6 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID K-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 7 KMYATIYELQEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID F-4 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 8 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID F-5 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 9 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID B-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 10 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID EcNGAL RDPAPKLIPAPPLDRVPLQPDFKDDQFQGKWYVVGVAGNAFKKEEQGQF NO: 11 TMYTTTYELKEDHSYNVTSILLRDQNCDHWIRTFIPSSQPGQFNLGDIK RYFGVQSYIVRVADTDYNQFAIVFFRKVYKNQEYFKTTLYRRTKELTPE LREKFISFAKSLGLTDDHIIFPVPIDQCIDEE SEQ ID CfNGAL QDSTPSLIPAPPPLKVPLQPDFQHDQFQGKWYVIGIAGNILKKEGHGQL NO: 12 KMYTTTYELKDDQSYNVTSTLLRNERCDYWNRDFVPSFQPGQFSLGDIQ LYPGVQSYLVQVVATNYNQYALVYFRKVYKSQEYFKITLYGRTKELPLE LKKEFIRFAKSIGLTEDHIIFPVPIDQCIDE SEQ ID SsNGAL QGTIPNWIPAPPLSKVPLQPNFQADQFQGKWYVVGLAGNAVKKEEQGRF NO: 13 KMYTTTYELKEDGSYNVISTLLRGQLCDNWIRTFVPSLQPGQFKLGDIK KYSGLQSYVVRVVSTNYSQFAIVFFKKVSNNQEYFKTTLYGRTKVLSPE LKENFVRFAKSLGLSDDNIIFPVAIDQCIDGQ SEQ ID PtNGAL QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 14 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGRQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID MamNGAL QDSSSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLSGNAVGRKDEAPL NO: 15 KMYATIYELKEDKSYNVTSILFRKEKCDYWIRTFVPGSQPGEFTLGNIQ NHPGLTSYVVRVVSTNYKQYAMVFFKKVSQNKEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFSVPIDQCING SEQ ID BtNGAL RSSSSRLLRAPPLSRIPLQPNFQADQFQGKWYTVGVAGNAIKKEEQDPL NO: 16 KMYSSNYELKEDGSYNVTSILLKDDLCDYWIRTFVPSSQPGQFTLGNIK SYRGIRSYTVRVVNTDYNQFAIVYFKKVQRKKTYFKITLYGRTKELTPE VRENFINFAKSLGLTDDHIVFTVPIDRCIDDQ SEQ ID MmNGAL QDSTQNLIPAPSLLTVPLQPDFRSDQFRGRWYVVGLAGNAVQKKTEGSF NO: 17 TMYSTIYELQENNSYNVTSILVRDQDQGCRYWIRTFVPSSRAGQFTLGN MHRYPQVQSYNVQVATTDYNQFAMVFFRKTSENKQYFKITLYGRTKELS PELKERFTRFAKSLGLKDDNIIFSVPTDQCIDN SEQ ID RnNGAL QDSTQNLIPAPPLISVPLQPGFWTERFQGRWFVVGLAGNAVQKERQSRF NO: 18 TMYSTIYELQEDNSYNVTSILVRGQGCRYWIRTFVPSSRPGQFTLGNIH SYPQIQSYDVQVADTDYDQFAMVFFQKTSENKQYFKVTLYGRTKGLSDE LKERFVSFAKSLGLKDNNIVFSVPTDQCIDN SEQ ID HsMegalin MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDG NO: 19 TKDCSDDADEIGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSD ERQDCSQSTCSSHQITCSNGQCIPSEYRCDHVRDCPDGADENDCQYPTC EQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTEICLHNEFSCGNGECI PRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWVCDGED DCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPG REDENNTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDS RTCVEFDDCQIWGICDQKCESRPGRHLCHCEEGYILERGQYCKANDSFG EASIIFSNGRDLLIGDIHGRSFRILVESQNRGVAVGVAFHYHLQRVFWT DTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNKIYLVETKVNR IDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLE RAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDG IQRKTVVHGGSLIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQV YYQASLRPYGVTVYHSLRQPYATNPCKDNNGGCEQVCVLSHRTDNDGLG FRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIRGIPFTLSTQEDVMVP VSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAANRVE NVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVV HPFAGYLFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAAS RLYWVDAYFDKIEHSTFDGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDW RLGAIIRVRKADGGEMTVIRSGIAYILHLKSYDVNIQTGSNACNQPTHP NGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNEPPTEQCGLF SFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGE CIPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWV CDTDNDCGDGSDEKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVD GSDEVGCVLNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPTR PPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVPKTCPSS YFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCLGHN ICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAK CLCPLGFLLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYML ESDGRTCKVTASESLLLLVASQNKIIADSVTSQVHNIYSLVENGSYIVA VDFDSISGRIFWSDATQGKTWSAFQNGTDRRVVFDSSIILTETIAIDWV GRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALDPRMNEHLL FWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDS YLDYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVM RANKWHGGNQSVVMYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLL SSQGPHFYSCVCPSGWSLSPDLLNCLRDDQPFLITVRQHIIFGISLNPE VKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGEIHRVKTDGTNRTV FASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTLIA NDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVK TLFTGNLEHLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQL SHPWGIAVHDSFLYYTDEQYEVIERVDKATGANKIVLRDNVPNLRGLQV YHRRNAAESSNGCSNNMNACQQICLPVPGGLFSCACATGFKLNPDNRSC SPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHVDVDVSSG FIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVA GNLYFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLF WADYGQRPKIERSFLDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDS LDIIARIRINGENSEVIRYGSRYPTPYGITVFENSIIWVDRNLKKIFQA SKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAEVNNNPCLENNGG CSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRSL HLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYAT LSSGIHTPTVIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSN RTVIARVPKPRAIVLDPCQGYLYWADWDTHAKIERATLGGNFRVPIVNS SLVMPSGLTLDYEEDLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFG LTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGINTVVKN QKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVD NGERCGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPT AFTCANGRCVQYSYRCDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRC IPREFICNGVDNCHDNNTSDEKNCPDRTCQSGYTKCHNSNICIPRVYLC DGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQHWYCDQETDCFD ASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCT RRTCSENEFTCGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFT CQNGRCISKTFVCDEDNDCGDGSDELMHLCHTPEPTCPPHEFKCDNGRC IEMMKLCNHLDDCLDNSDEKGCGINECHDPSISGCDHNCTDTLTSFYCS CRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAPGYLRE PDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDF DRVEKRLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRK LYWLDARLDGLFVSDLNGGHRRMLAQHCVDANNTFCFDNPRGLALHPQY GYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYTNDLLYW ADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTIYWTDWNTRTV EKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHL CLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPI WWKCDGQKDCSDGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQN CPDGSDEDRLLCENHHCDSNEWQCANKRCIPESWQCDTFNDCEDNSDED SSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDCGDHSDEPIEECMSSA HLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCHPVGD FRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIP SRWICDHYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSAD CLDASDEADCPTRFPDGAYCQATMFECKNHVCIPPYWKCDGDDDCGDGS DEELHLCLDVPCNSPNRFRCDNNRCIYSHEVCNGVDDCGDGTDETEEHC RKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDELGCNKGKERT CAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCP QHCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKY NLSSERFSEYLQDEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIK RAYIPNFESGRNNLVQEVDLKLKYVMQPDGIAVDWVGRHIYWSDVKNKR IEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMFWTDWGKEPKIESAW MNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYDGTD RRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVN PWLTQVRIFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIE GSTTECDAAIELPINLPPPCRCMHGGNCYFDETDLPKCKCPSGYTGKYC EMAFSKGISPGTTAVAVLLTILLIVVIGALAIAGFFHYRRTGSLLPALP KLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAIDRSMAMSE DFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPIN PSEIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQK ESVAATPPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV SEQ ID MmMegalin MERGAAAAAWMLLLAIAACLAPVSGQECGSGNFRCDNGYCIPASWRCDG NO: 20 TRDCLDDTDEIGCPPRSCGSGFFLCPAEGTCIPSSWVCDQDKDCSDGAD EQQNCPGTTCSSQQLTCSNGQCVPIEYRCDHVSDCPDGSDERNCYYPTC DQLTCANGACYNTSQKCDHKVDCRDSSDEANCTTLCSQKEFQCGSGECI LRAYVCDHDNDCEDNSDEHNCNYDTCGGHQFTCSNGQCINQNWVCDGDD DCQDSGDEDGCESNQRHHTCYPREWACPGSGRCISMDKVCDGVPDCPEG EDENNATSGRYCGTGLCSILNCEYQCHQTPYGGECFCPPGHIINSNDSR TCIDFDDCQIWGICDQKCESRQGRHQCLCEEGYILERGQHCKSNDSFSA ASIIFSNGRDLLVGDLHGRNFRILAESKNRGIVMGVDFHYQKHRVFWTD PMQAKVFSTDINGLNTQEILNVSIDAPENLAVDWINNKLYLVETRVNRI DVVNLEGNQRVTLITENLGHPRGIALDPTVGYLFFSDWGSLSGQPKVER AFMDGSNRKDLVTTKLGWPAGITLDLVSKRVYWVDSRYDYIETVTYDGI QRKTVARGGSLVPHPFGISLFEEHVFFTDWTKMAVMKANKFTDTNPQVY HQSSLTPFGVTVYHALRQPNATNPCGNNNGGCAQICVLSHRTDNGGLGY RCKCEFGFELDADEHHCVAVKNFLLFSSQTAVRGIPFTLSTQEDVMVPV TGSPSFFVGIDFDAQHSTIFYSDLSKNIIYQQKIDGTGKEVITANRLQN VECLSFDWISRNLYWTDGGSKSVTVMKLADKSRRQIISNLNNPRSIVVH PAAGYMFLSDWFRPAKIMRAWSDGSHLMPIVNTSLGWPNGLAIDWSTSR LYWVDAFFDKIEHSNLDGLDRKRLGHVDQMTHPFGLTVFKDNVFLTDWR LGAIIRVRKSDGGDMTVVRRGISSIMHVKAYDADLQTGTNYCSQTTHPN GDCSHFCFPVPNFQRVCGCPYGMKLQRDQMTCEGDPAREPPTQQCGSSS FPCNNGKCVPSIFRCDGVDDCHDNSDEHQCGALNNTCSSSAFTCVHGGQ CIPGQWRCDKQNDCLDGSDEQNCPTRSPSSTCPPTSFTCDNHMCIPKEW VCDTDNDCSDGSDEKNCQASGTCHPTQFRCPDHRCISPLYVCDGDKDCV DGSDEAGCVLNCTSSQFKCADGSSCINSRYRCDGVYDCKDNSDEAGCPT RPPGMCHPDEFQCQGDGTCIPNTWECDGHPDCIQGSDEHNGCVPKTCSP SHFLCDNGNCIYNSWVCDGDNDCRDMSDEKDCPTQPFHCPSSQWQCPGY SICVNLSALCDGVFDCPNGTDESPLCNQDSCLHFNGGCTHRCIQGPFGA TCVCPIGYQLANDTKTCEDVNECDIPGFCSQHCVNMRGSFRCACDPEYT LESDGRTCKVTASENLLLVVASRDKIIMDNITAHTHNIYSLVQDVSFVV ALDFDSVTGRVFWSDLLEGKTWSAFQNGTDKRVVHDSGLSLTEMIAVDW IGRNIYWTDYTLETIEVSKIDGSHRTVLISKNVTKPRGLALDPRMGDNV MFWSDWGHHPRIERASMDGTMRTVIVQEKIYWPCGLSIDYPNRLIYFMD AYLDYIEFCDYDGQNRRQVIASDLVLHHPHALTLFEDSVFWTDRGTHQV MQANKWHGRNQSVVMYSVPQPLGIIAIHPSRQPSSPNPCASATCSHLCL LSAQEPRHYSCACPSGWNLSDDSVNCVRGDQPFLISVRENVIFGISLDP EVKSNDAMVPISGIQHGYDVEFDDSEQFIYWVENPGEIHRVKTDGSNRT AFAPLSLLGSSLGLALDWVSRNIYYTTPASRSIEVLTLRGDTRYGKTLI TNDGTPLGVGFPVGIAVDPARGKLYWSDHGTDSGVPAKIASANMDGTSL KILFTGNMEHLEVVTLDIQEQKLYWAVTSRGVIERGNVDGTERMILVHH LAHPWGLVVHGSFLYYSDEQYEVIERVDKSSGSNKVVFRDNIPYLRGLR VYHHRNAADSSNGCSNNPNACQQICLPVPGGMFSCACASGFKLSPDGRS CSPYNSFIVVSMLPAVRGFSLELSDHSEAMVPVAGQGRNVLHADVDVAN GFIYWCDFSSSVRSSNGIRRIKPNGSNFTNIVTYGIGANGIRGVAVDWV AGNLYFTNAFVYETLIEVIRINTTYRRVLLKVSVDMPRHIVVDPKHRYL FWADYGQKPKIERSFLDCTNRTVLVSEGIVTPRGLAVDHDTGYIYWVDD SLDIIARIHRDGGESQVVRYGSRYPTPYGITVFGESIIWVDRNLRKVFQ ASKQPGNTDPPTVIRDSINLLRDVTIFDEHVQPLSPAELNNNPCLQSNG GCSHFCFALPELPTPKCGCAFGTLEDDGKNCATSREDFLIYSLNNSLRS LHFDPQDHNLPFQAISVEGMAIALDYDRRNNRIFFTQKLNPIRGQISYV NLYSGASSPTILLSNIGVTDGIAFDWINRRIYYSDFSNQTINSMAEDGS NRAVIARVSKPRAIVLDPCRGYMYWTDWGTNAKIERATLGGNFRVPIVN TSLVWPNGLTLDLETDLLYWADASLQKIERSTLTGSNREVVISTAFHSF GLTVYGQYIYWTDFYTKKIYRANKYDGSDLIAMTTRLPTQPSGISTVVK TQQQQCSNPCDQFNGGCSHICAPGPNGAECQCPHEGSWYLANDNKYCVV DTGARCNQFQFTCLNGRCISQDWKCDNDNDCGDGSDELPTVCAFHTCRS TAFTCANGRCVPYHYRCDFYNDCGDNSDEAGCLFRSCNSTTEFTCSNGR CIPLSYVCNGINNCHDNDTSDEKNCPPITCQPDFAKCQTTNICVPRAFL CDGDNDCGDGSDENPIYCASHTCRSNEFQCVSPHRCIPSYWFCDGEADC VDSSDEPDTCGHSLNSCSANQFHCDNGRCISSSWVCDGDNDCGDMSDED QRHHCELQNCSSTEFTCINSRPPNRRCIPQHWVCDGDADCADALDELQN CTMRACSTGEFSCANGRCIRQSFRCDRRNDCGDYSDERGCSYPPCRDDQ FTCQNGQCITKLYVCDEDNDCGDGSDEQEHLCHTPEPTCPPHQFRCDNG HCIEMGTVCNHVDDCSDNSDEKGCGINECQDSSISHCDHNCTDTITSFY CSCLPGYKLMSDKRTCVDIDECKETPQLCSQKCENVIGSYICKCAPGYI REPDGKSCRQNSNIEPYLVFSNRYYIRNLTIDGTSYSLILQGLGNVVAL DFDRVEERLYWIDAEKQIIERMFLNKTNQETIISHRLRRAESLAVDWVS RKLYWLDAILDCLFVSDLEGRQRKMLAQHCVDANNTFCFENPRGIVLHP QRGYVYWADWGDHAYIARIGMDGTNKTVIISTKIEWPNAITIDYTNDLL YWADAHLGYIEFSDLEGHHRHTVYDGTLPHPFALTIFEDTVFWTDWNTR TVEKGNKYDGSGRVVLVNTTHKPFDIHVLHPYRQPIMSNPCATNNGGCS HLCLIKAGGRGFTCECPDDFQTVQLRDRTLCMPMCSSTQFLCGNNEKCI PIWWKCDGQKDCSDGSDESDLCPHRFCRLGQFQCRDGNCTSPQALCNAR QDCADGSDEDRVLCEHHRCEANEWQCANKRCIPEYWQCDSVDDCLDNSD EDPSHCASRTCRPGQFKCNNGRCIPQSWKCDVDNDCGDYSDEPIHECMT AAYNCDNHTEFSCKTNYRCIPQWAVCNGFDDCRDNSDEQGCESVPCHPS GDFRCGNHHCIPLRWKCDGIDDCGDNSDEESCVPRECTESEFRCADQQC IPSRWVCDQENDCGDNSDERDCEMKTCHPEHFQCTSGHCVPKALACDGR ADCLDASDESACPTRFPNGTYCPAAMFECKNHVCIQSFWICDGENDCVD GSDEEIHLCFNVPCESPQRFRCDNSRCIYGHQLCNGVDDCGDGSDEKEE HCRKPTHKPCTDTEYKCSNGNCVSQHYVCDNVDDCGDLSDETGCNLGEN RTCAEKICEQNCTQLSNGGFICSCRPGFKPSTLDKNSCQDINECEEFGI CPQSCRNSKGSYECFCVDGFKSMSTHYGERCAADGSPPLLLLPENVRIR KYNISSEKFSEYLEEEEHIQAIDYDWDPEGIGLSVVYYTVLSQGSQFGA IKRAYLPDFESGSNNPVREVDLGLKYLMQPDGLAVDWVGRHIYWSDAKS QRIEVATLDGRYRKWLITTQLDQPAAIAVNPKLGLMFWTDQGKQPKIES AWMNGEHRSVLASANLGWPNGLSIDYLNGDRIYWSDSKEDVIESIKYDG TDRRLIINDAMKPFSLDIFEDQLYWVAKEKGEVWRQNKFGKGNKEKLLV VNPWLTQVRIFHQLRYNQSVSNPCKQVCSHLCLLRPGGYSCACPQGSDF VTGSTVECDAASELPITMPSPCRCMHGGSCYFDENDLPKCKCSSGYSGE YCEIGLSRGIPPGTTMALLLTFAMVIIVGALVLVGFFHYRKTGSLLPSL PKLPSLSSLAKPSENGNGVTFRSGADVNMDIGVSPFGPETIIDRSMAMN EQFVMEVGKQPVIFENPMYAAKDSTSKVGLAVQGPSVSSQVTVPENVEN QNYGRSIDPSEIVPEPKPASPGADETQGTKWNIFKRKPKQTTNFENPIY AEMDTEQKEAVAVAPPPSPSLPAKASKRSSTPGYTATEDTFKDTANLVK EDSDV SEQ ID A-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 21 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID A-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 22 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGQTQELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID A-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILQEDKDPQ NO: 23 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID B-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 24 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID B-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 25 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID B-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 26 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID B-5 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 27 KMYATIYELKEDGSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID C-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 28 TMYATIYELKEDKSYNVTSVLFQKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID C-3 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 29 TMYATIYELKEDKSYNVTSVLFQKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID C-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 30 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNQEYFKITLYGRTKELTSE LKENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID C-5 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 31 KMYATIYELKEDKSYNVTSVLFQKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID D-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 32 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 33 KMYATIYELKEDGSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID E-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 34 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGQTQELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID F-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 35 KMYATIYELQEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID F-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 36 KMYATIYELQEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID G-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILQEDKDPQ NO: 37 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID G-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILQEDKDPQ NO: 38 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGQTQELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID G-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 39 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID H-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 40 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID H-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 41 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID H-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 42 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID H-5 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 43 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID I-4 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 44 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID I-5 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 45 KMYATIYELKEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNQEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID L-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILQEDKDPQ NO: 46 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGQTQELTSE LKENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID L-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILQEDKDPQ NO: 47 KMYATIYELKEDKSYNVTSVLFQKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGQTQELTSE LKENFIRFSQSLGLPENHIVFPVPIDQCIDG SEQ ID B-5-1 QDSTSDLIPAPPLSKVPLAPDFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 48 KMYATIYELKEDGSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID B-5-2 QDSTSDLIPAPPLSKVPLAPDFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 49 KMYATIYELAEDGSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID B-5-5 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 50 KMYATIYELKEDGSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTDYNQFAMVFFKKVSQNREYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID WT-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 51 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGATAELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID WT-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILAEDKDPQ NO: 52 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGATAELTSE LKENFIRFSASLGLPENHIVFPVPIDQCIDG SEQ ID WT-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 53 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGATAELTSE LKENFIRFSASLGLPENHIVFPVPIDQCIDG SEQ ID WT-4-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 54 KMYATIYELKEDKSYNVTSVLFAKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGATAELTSE LKENFIRFSASLGLPENHIVFPVPIDQCIDG SEQ ID WT-4-1-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILAEDKDPQ NO: 55 KMYATIYELKEDKSYNVTSVLFAKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGATAELTSE LKENFIRFSASLGLPENHIVFPVPIDQCIDG SEQ ID D1-1 QDSTSDLIPAPPLSKVPLAPDFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 56 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 57 KMYATIYELKEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 58 KMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPEDAIVFPVPIDQCIDG SEQ ID D1-4-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 59 KMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 60 KMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-1 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 61 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-3 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 62 KMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTDYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-4 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 63 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTDYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-1-1 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 64 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LAENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-1-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 65 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LAENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-1-4 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 66 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTNYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID K3-4 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 67 TMYATIYELKEDKSYNVTSVLFADDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID K3-5 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 68 KMYATIYELKEDKSYNVTSVLFADDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID NGAL Mutant X₁DSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 69 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QX₂STSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 70 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDX₃TSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 71 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSX₄SDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 72 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTX₅DLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 73 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSX₆LIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 74 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDX₇IPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 75 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLX₈PAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 76 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIX₉APPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 77 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPX₁₀PPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 78 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAX₁₁PLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 79 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPX₁₂LSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 80 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPX₁₃SKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 81 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLX₁₄KVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 82 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSX₁₅VPLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 83 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKX₁₆PLQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 84 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVX₁₇LQQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 85 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPX₁₈QQNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 86 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLX₁₉QNFQDNQFQGKWYVVGLAGNAILREDKDP NO: 87 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQX₂₀NFQDNQFQGKWYVVGLAGNAILREDKDP NO: 88 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQX₂₁FQDNQFQGKWYVVGLAGNAILREDKDP NO: 89 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNX₂₂QDNQFQGKWYVVGLAGNAILREDKDP NO: 90 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFX₂₃DNQFQGKWYVVGLAGNAILREDKDP NO: 91 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQX₂₄NQFQGKWYVVGLAGNAILREDKDP NO: 92 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDX₂₅QFQGKWYVVGLAGNAILREDKDP NO: 93 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNX₂₆FQGKWYVVGLAGNAILREDKDP NO: 94 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQX₂₇QGKWYVVGLAGNAILREDKDP NO: 95 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFX₂₈GKWYVVGLAGNAILREDKDP NO: 96 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQX₂₉KWYVVGLAGNAILREDKDP NO: 97 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₂₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGX₃₀WYVVGLAGNAILREDKDP NO: 98 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKX₃₁YVVGLAGNAILREDKDP NO: 99 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWX₃₂VVGLAGNAILREDKDP NO: 100 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYX₃₃VGLAGNAILREDKDP NO: 101 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVX₃₄GLAGNAILREDKDP NO: 102 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVX₃₅LAGNAILREDKDP NO: 103 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGX₃₆AGNAILREDKDP NO: 104 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLX₃₇GNAILREDKDP NO: 105 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAX₃₈NAILREDKDP NO: 106 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGX₃₉AILREDKDP NO: 107 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₃₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNX₄₀ILREDKDP NO: 108 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAX₄₁LREDKDP NO: 109 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAIX₄₂REDKDP NO: 110 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILX₄₃EDKDP NO: 111 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILRX₄₄DKDP NO: 112 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREX₄₅KDP NO: 113 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDX₄₆DP NO: 114 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKX₄₇P NO: 115 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDX₄₈ NO: 116 QKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPX₄ NO: 117 ₉KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₄₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 118 X₅₀MYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 119 KX₅₁YATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 120 KMX₅₂ATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 121 KMYX₅₃TIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 122 KMYAX₅₄IYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 123 KMYATX₅₅YELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 124 KMYATIX₅₆ELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 125 KMYATIYX₅₇LKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 126 KMYATIYEX₅₈KEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 127 KMYATIYELX₅₉EDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₅₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 128 KMYATIYELKX₆₀DKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 129 KMYATIYELKEX₆₁KSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 130 KMYATIYELKEDX₆₂SYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 131 KMYATIYELKEDKX₆₃YNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 132 KMYATIYELKEDKSX₆₄NVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 133 KMYATIYELKEDKSYX₆₅VTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 134 KMYATIYELKEDKSYNX₆₆TSVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 135 KMYATIYELKEDKSYNVX₆₇SVLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 136 KMYATIYELKEDKSYNVTX₆₈VLFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 137 KMYATIYELKEDKSYNVTSX₆₉LFRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₆₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 138 KMYATIYELKEDKSYNVTSVX₇₀FRKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 139 KMYATIYELKEDKSYNVTSVLX₇₁RKKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 140 KMYATIYELKEDKSYNVTSVLFX₇₂KKKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 141 KMYATIYELKEDKSYNVTSVLFRX₇₃KKCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 142 KMYATIYELKEDKSYNVTSVLFRKX₇₄KCDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 143 KMYATIYELKEDKSYNVTSVLFRKKX₇₅CDYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 144 KMYATIYELKEDKSYNVTSVLFRKKKX₇₆DYWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 145 KMYATIYELKEDKSYNVTSVLFRKKKCX₇₇YWIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 146 KMYATIYELKEDKSYNVTSVLFRKKKCDX₇₈WIRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 147 KMYATIYELKEDKSYNVTSVLFRKKKCDYX₇₉IRTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₇₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 148 KMYATIYELKEDKSYNVTSVLFRKKKCDYWX₈₀RTFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 149 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIX₈₁TFVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 150 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRX₈₂FVPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 151 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTX₈₃VPGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 152 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFX₈₄PGCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 153 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVX₈₅GCQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 154 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPX₈₆CQPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 155 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGX₈₇QPGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 156 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCX₈₈PGEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 157 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQX₈₉GEFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₈₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 158 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPX₉₀EFTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 159 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGX₉₁FTLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 160 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEX₉₂TLGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 161 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFX₉₃LGNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 162 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTX₉₄GNI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 163 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLX₉₅NI KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 164 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGX₉₆I KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 165 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNX₉₇ KSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 166 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIX₉ ₈SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 167 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK X₉₉YPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTS ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₉₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 168 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SX₁₀₀PGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 169 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYX₁₀₁GLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 170 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPX₁₀₂LTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 171 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGX₁₀₃TSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 172 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLX₁₀₄SYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 173 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTX₁₀₅YLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 174 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSX₁₀₆LVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 175 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYX₁₀₇VRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 176 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLX₁₀₈RVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 177 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVX₁₀₉VVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₀₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 178 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRX₁₁₀VSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 179 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVX₁₁₁STNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 180 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVX₁₁₂TNYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 181 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSX₁₁₃NYNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 182 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTX₁₁₄YNQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 183 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNX₁₁₅NQHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 184 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYX₁₁₆QHAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 185 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNX₁₁₇HAMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 186 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQX₁₁₈AMVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, H SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 187 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHX₁₁₉MVFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₁₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 188 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAX₁₂₀VFFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 189 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMX₁₂₁FFKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 190 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVX₁₂₂FKKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 191 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFX₁₂₃KKVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 192 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFX₁₂₄KVSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 193 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKX₁₂₅VSQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 194 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKX₁₂₆SQNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 195 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVX₁₂₇QNREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 196 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSX₁₂₈NREYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 197 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQX₁₂₉REYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₂₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 198 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNX₁₃₀EYFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 199 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNRX₁₃₁YFKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 200 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREX₁₃₂FKITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 201 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYX₁₃₃KITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 202 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFX₁₃₄ITLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 203 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKX₁₃₅TLYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 204 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKIX₁₃₆LYGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 205 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITX₁₃₇YGRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 206 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLX₁₃₈GRTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 207 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYX₁₃₉RTKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₃₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 208 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGX₁₄₀TKELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 209 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRX₁₄₁KELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 210 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTX₁₄₂ELT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 211 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKX₁₄₃LT SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 212 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKEX₁₄₄T SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 213 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELX₁₄₅ SELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 214 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTX₁₄ ₆ELKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 215 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSX₁ ₄₇LKENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 216 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE X₁₄₈KENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 217 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LX₁₄₉ENFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₄₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 218 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKX₁₅₀NFIRFSKSLGLPENHIVFPVPIDQCIDG X₁₅₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 219 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKEX₁₅₁FIRFSKSLGLPENHIVFPVPIDQCIDG X₁₅₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 220 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENX₁₅₂IRFSKSLGLPENHIVFPVPIDQCIDG X₁₅₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 221 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFX₁₅₃RFSKSLGLPENHIVFPVPIDQCIDG X₁₅₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 222 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIX₁₅₄FSKSLGLPENHIVFPVPIDQCIDG X₁₅₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, R SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 223 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRX₁₅₅SKSLGLPENHIVFPVPIDQCIDG X₁₅₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 224 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFX₁₅₆KSLGLPENHIVFPVPIDQCIDG X₁₅₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 225 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSX₁₅₇SLGLPENHIVFPVPIDQCIDG X₁₅₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, K SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 226 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKX₁₅₈LGLPENHIVFPVPIDQCIDG X₁₅₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 227 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSX₁₅₉GLPENHIVFPVPIDQCIDG X₁₅₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 228 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLX₁₆₀LPENHIVFPVPIDQCIDG X₁₆₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 229 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGX₁₆₁PENHIVFPVPIDQCIDG X₁₆₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 230 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLX₁₆₂ENHIVFPVPIDQCIDG X₁₆₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 231 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPX₁₆₃NHIVFPVPIDQCIDG X₁₆₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 232 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPEX₁₆₄HIVFPVPIDQCIDG X₁₆₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 233 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENX₁₆₅IVFPVPIDQCIDG X₁₆₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V, H SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 234 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHX₁₆₆VFPVPIDQCIDG X₁₆₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 235 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIX₁₆₇FPVPIDQCIDG X₁₆₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 236 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVX₁₆₈PVPIDQCIDG X₁₆₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 237 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFX₁₆₉VPIDQCIDG X₁₆₉ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 238 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPX₁₇₀PIDQCIDG X₁₇₀ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 239 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVX₁₇₁IDQCIDG X₁₇₁ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 240 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPX₁₇₂DQCIDG X₁₇₂ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 241 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIX₁₇₃QCIDG X₁₇₃ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 242 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDX₁₇₄CIDG X₁₇₄ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 243 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQX₁₇₅IDG X₁₇₅ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 244 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCX₁₇₆DG X₁₇₆ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 245 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIX₁₇₇G X₁₇₇ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID NGAL Mutant QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQ NO: 246 KMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDX₁₇₈ X₁₇₈ = Q, A, N, D, C, E, G, I, L, M, F, P, S, T, W, Y, V SEQ ID D1-4-2-1-4-2 QDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 247 TMYATIYELAEDGSYNVTSVLFADDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTDYNQHAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID D1-4-2-1-4-3 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 248 TMYATIYELAEDGSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIA SYPGLTSYLVRVVSTDYDEFAMVFFKKVSESAEYFKITLYGRTKELTSE LKENFIRFSKSLGLPENHIVFPVPIDQCIDG SEQ ID K3-4-2 QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 249 TMYATIYELKEDGSYNVTSVLFADDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG SEQ ID K3-3Con QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILAEDEDPQ NO: 250 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGATAELTSE LQENFIRFSASLGLPENNIVFPVPIDQCIDG SEQ ID K3-4Con QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILAEDEDPQ NO: 251 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSASLGLPENNIVFPVPIDQCIDG SEQ ID K3Cys QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQ NO: 252 KMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGSQPGEFTLGNIQ SYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSE LQENFIRFSKSLGLPENNIVFPVPIDQCIDG

Example 3

The superscripted numbers in this Example refer to the numbered references in the list of references that follows this Example. Ngal mutant Mut1 or mutant 1 refers to the K3 NGAL protein of SEQ ID NO:2. Ngal mutant Mut2 or mutant 2 refers to the K3Cys protein protein of SEQ ID NO:252.

Iron is specifically bound by transferrin in circulation, which preserves its bioavailability and prevents its redox toxicity. However, non-transferrin-bound iron (NTBI) appears in patients with a variety of diseases¹⁻³. NTBI damages liver⁴⁻⁷, heart⁸⁻¹², endocrine glands¹³⁻¹⁸ and kidneyl⁹⁻²¹ and severe overload can be fatal^(22,23). To date, two small molecules, deferoxamine (DFO) and deferiprone are available for the chelation of NTBI and the treatment of iron overload. However, these molecules demonstrate significant toxicity. We have discovered an endogenous mechanism of iron transport (Barasch: Molecular Cell, 2002; Nature N&V, 2005; Nature Chemical Biology, 2010), which we realized could be manipulated to safely export iron from the body.

The Ngal protein is expressed by damaged epithelia (AKI: JASN, 2003; JCI, 2005; Lancet, 2005; Ann Int Med, 2008) and then it is rapidly secreted. Ngal captures catecholate-type bacterial siderophores (Enterochelin, Ent)³ and endogenous catechols⁶ (FIGS. 6A-6B). Ngal:catechol:Fe complexes are stable for transport. They are filtered from the blood by the glomerulus and captured by proximal tubule megalin where Ngal is degraded and its iron recycled³⁸. Here we evaluated Ngal mutants that we believe bypass megalin, yet still bind Ent:iron, hence providing an unexpected, novel, therapeutic that can safely excrete NTBI in the urine.

Evaluation of the Ngal-Megalin Interaction by the Generation of Ngal Mutants:

We produced a series of defined mutations in the positive surface residues of Ngal and identified clones that traffic into the urine (i.e. bypassing megalin). The appearance in the urine was detected by immunoblot. In order to increase the export of the mutant Ngal, we introduced a new mutation in the so called unpaired cysteine to block the homodimerization of Ngal. This resulted in nearly complete loss of Ngal from the mouse by filtration and urinary excretion—most likely a result of the lower molecular weight of the monomeric—non dimerizable species. This new species of Ngal (called mut2) appeared earlier in the urine than mutants (e.g. mut1) that were still capable of dimerization (FIGS. 22A-22B). We next examined a wide range of organs and found that while wt Ngal was most prominently captured by proximal tubule (and also in Kupfer cells), our mutants were not recognized by the proximal tubule and in fact mutant 2 was depleted from all sites of cellular capture (because it was rapidly excreted, FIG. 25). Further examination revealed that the mutants did in fact have one site of capture in the kidney and that was in cells of the collecting duct. This could be seen when the microscopic image was amplified by increasing exposure time. By staining with antibodies for the two cell types found in the collecting ducts (FIG. 26), both principal and intercalated cells take up the mutant Ngal (in marked contrast to proximal tubules). Numerical counts of the cells that captured Ngal showed that 64.7% were AQ2+ principal cells (n=769/1188) and 27.3% were ATPase+(n=158/579) and 23.5% (n=190/807) were AE1+ indicating that approximately ⅓ of the cells that captured NGAL expressed marker genes typical of alpha intercalated cells. In order to model these findings and to determine whether the uptake represented a cell autonomous process, we utilized a variety of cell lines. While all cell lines took up fluorescent dextran, LLCPK took up wild type Ngal, not the mutant species, intercalated cells took up both wild type and mutant Ngal and UB cells took up neither wild type nor mutant Ngal (FIG. 27). Taken together, the data indicate that megalin (expressed in the proximal tubule and in the LLCPK cell line) captures Ngal, but the mutant form of Ngal can bypass these cells. Additionally, collecting duct cells may express non-megalin Ngal receptors. This extensive characterization indicated that by manipulating the surface residues and the dimerization site for Ngal, we have created a protein which can traffic from the periphery into the urine.

Ngal:Ent:Fe^(III) Interaction in Ngal Mutants

In order to utilize Ngal as a therapeutic agent to remove iron from overloaded mice, we examined the Ngal:iron complex. We decided to use the siderophore Ent as the iron binding co-factor, not only because it has a high affinity for the Ngal calyx (0.4 nM and 3.57 nM, respectively) but also because it fails to release bound iron even at low pH. First, x-ray crystallographic studies of mutant1 were performed. Since our mutants affect crystal contacts in all the known Ngal crystal forms, he approached this as a de novo structural determination. He found that the mutant could be superimposed on wild type Ngal, implying that our extensive mutagenesis did not dramatically alter the overall structure of the protein (FIG. 28). Second, we examined whether ligation by iron siderophores created a stabilized structure that quenched the endogenous chemical reactivity of iron. Using both fluorescein activation assays and ferric reduction assays, we found that the mutants of NGAL bound siderophores and iron without triggering redox activity (FIGS. 29A-29C).

Safe Excretion of Iron by the Delivery of Mutant NGAL:Ent:Fe^(III)

To test whether mutant Ngal can efficiently chelate and deliver NTBI to the urine through the kidney, we introduced the bacterially expressed Ngal ligated to Ent:⁵⁹Fe^(III) into mice, and collected the urine for 3 hrs. We found that mutant 1 delivered 23% of the injected mutant 1 Ngal-⁵⁹Fe^(III) complex to the urine, paralleling the percentage of the protein found in the urine, while less than 0.1% of the wild type injectate was excreted. When we injected mutant2 (cysteine mutation), nearly 100% of the iron was found in the urine. In FIG. 23, we can see that only trace amounts of wild type ⁵⁹Fe^(III) (in the Ngal:Ent complex) was found in the urine—almost all of it accumulated in the kidney, but mutant 2 was not retained in the kidney, but rather it was all found in the urine.

Based on these results, we are planning to test whether mutant 2 can capture, chelate, traffic and remove endogenous NTBI. To do this however requires mammalian expressed Ngal rather than the bacterial species to avoid the effects on iron metabolism of endotoxins. We are now quite advanced in purification of Ngal from 293 cells grown in spinner suspension. The purification utilizes Blue and Heparin Sepharose, gel filtration and anion exchange. The last step of the process is seen in FIG. 30. Note that the small peak contains the majority of Ngal protein. We think this protocol will produce enough Ngal for depletion experiments.

REFERENCES

-   1. Hershko, C., and Peto, T. E. Non-transferrin plasma iron. Br. J.     Haematol. 66: 149-151, 1987. -   2. Breuer, W., Ronson, A., Slotki, I. N., Abramov, A., Hershko, C.,     and Cabantchik, Z. I. The assessment of serum nontransferrin-bound     iron in chelation therapy and iron supplementation. Blood. 95:     2975-2982, 2000. -   3. Andrews, N. C. Iron metabolism: Iron Deficiency and Iron     Overload. Annu Rev. Genomics Hum. Genet. 1:75-98, 2000. -   4. Thakerngpol, K., Fucharoen, S., Boonyaphipat, P., Srisook, K.,     Sahaphong, S., Vathanophas, V., and Stitnimankarn, T. Liver injury     due to iron overload in thalassemia: histopathologic and     ultrastructural studies. Biometals. 9: 177-183, 1996. -   5. Conte, D., Piperno, A., Mandelli, C., et al. Clinical,     biochemical and histological features of primary haemochromatosis: a     report of 67 cases. Liver. 6: 310-315, 1986. -   6. Tsukamoto, H., Horne, W., Kamimura, S., Niemela, O., Parkkila,     S., Yla-Herttuala, S., and Brittenham, G. M. Experimental liver     cirrhosis induced by alcohol and iron. J. Clin. Invest. 96: 620-630,     1995. -   7. Berdoukas, V., Bohane, T., Tobias, V., et al. Liver iron     concentration and fibrosis in a cohort of transfusion-dependent     patients on long-term desferrioxamine therapy. Hematol. J. 5:     572-578, 2004. -   8. Liu, P., and Olivieri, N. Iron overload cardiomyopathies: new     insights into an old disease. Cardiovasc. Drugs. Ther. 8:101-110,     1994. -   9. Buja, L. M., and Roberts, W. C. Iron in the heart. Etiology and     clinical significance. Am. J. Med. 51: 209-221, 1971. -   10. Schwartz, K. A., Li, Z., Schwartz, D. E., et al. Earliest     cardiac toxicity induced by iron overload selectively inhibits     electrical conduction. J. Appl. Physiol. 93: 746-751, 2002. -   11. Oudit, G. Y., Trivieri, M. G., Khaper, N., Liu, P. P., and     Backx, P. H. Role of L-type Ca2+ channels in iron transport and     iron-overload cardiomyopathy. J. Mol. Med. 84: 349-364, 2006. -   12. Oudit, G. Y., Sun, H., Trivieri, M. G., Koch, S. E., Dawood, F.,     Ackerley, C., Yazdanpanah, M., Wilson, G. J., Schwartz, A., Liu, P.     P., and Backx, P. H. L-type Ca²⁺ channels provide a major pathway     for iron entry into cardiomyocytes in iron-overload cardiomyopathy,     Nat. Med. 9: 1187-1194, 2003. -   13. Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med.     341: 1986-1995, 1999. -   14. Argyropoulou, M. I., and Astrakas, L. MRI evaluation of tissue     iron burden in patients with beta-thalassaemia major. Pediatr.     Radiol. 37: 1191-1200, 2007. -   15. Argyropoulou, M. I., Kiortsis, D. N., Astrakas, L., Metafratzi,     Z., Chalissos, N., Efremidis, S. C. Liver, bone marrow, pancreas and     pituitary gland iron overload in young and adult thalassemic     patients: a T2 relaxometry study. Eur. Radiol. 17: 3025-3030, 2007. -   16. Cunningham, M. J., Macklin, E. A., Neufeld, E. J., and     Cohen, A. R. Complications of beta-thalassemia major in North     America. Blood. 104: 34-39, 2004. -   17. Fung, E., Harmatz, P. R., Lee, P. D., Milet, M., Bellevue, R.,     Jeng, M. R., Kalinyak, K. A., Hudes, M., Bhatia, S., and     Vichinsky, E. P. Increased prevalence of iron-overload associated     endocrinopathy in thalassaemia versus sickle-cell disease. Br. J.     Haematol. 135: 574-582, 2006. -   18. Kattamis, C., and Kattamis, A. C. Management of thalassemias:     growth and development, hormone substitution, vitamin     supplementation, and vaccination. Semin. Hematol. 32: 269-279, 1995. -   19. Eschbach, J. W., and Adamson, J. W. Iron overload in renal     failure patients: Changes since the introduction of erythropoietin     therapy. Kidney Int. 55: S35-S43, 1999. -   20. Lorenz, M., Kletzmayr, J., Huber, A., Hörl, A. H.,     Sunder-Plassmann, G., and Födinger, M. Iron overload in kidney     transplants: Prospective analysis of biochemical and genetic     markers. Kidney Int. 67, 691-697, 2005. -   21. Mandalunis, P. M., and Ubios, A. M. Experimental Renal Failure     and Iron Overload: A Histomorphometric Study in Rat Tibia. Toxicol.     Pathol. 33; 398-403, 2005. -   22. Karnon, J., Zeuner, D., Brown, J., Ades, A. E., Wonke, B., and     Modell, B. Lifetime treatment costs of beta-thalassaemia major.     Clin. Lab. Haematol. 21: 377-385, 1999. -   23. Darbari, D. S., Kple-Faget, P., Kwagyan, J., Rana, S.,     Gordeuk, V. R., and Castro, O. Circumstances of death in adult     sickle cell disease patients. Am. J. Hematol. 81: 858-863, 2006.

Although the invention has been described and illustrated in the foregoing illustrative embodiments, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the details of implementation of the invention can be made without departing from the spirit and scope of the invention, which is limited only by the claims that follow. Features of the disclosed embodiments can be combined and rearranged in various ways within the scope and spirit of the invention. 

What is claimed is:
 1. A mutant NGAL protein comprising an amino acid sequence that is at least 70% identical to the sequence of wild-type human NGAL (SEQ ID NO. 1), or a fragment thereof, wherein: (a) five or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 is mutated by deletion or by substitution with a non-positively charged amino acid residue, and (b) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the mutant NGAL protein (c) is able to bind to a siderophore, and (d) is excreted in the urine.
 2. The mutant NGAL protein of claim 1, wherein six or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 3. The mutant NGAL protein of claim 1, wherein seven or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 4. The mutant NGAL protein of claim 1, wherein eight or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 5. The mutant NGAL protein of claim 1, wherein nine or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 6. The mutant NGAL protein of claim 1, wherein ten or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 7. The mutant NGAL protein of claim 1, wherein the mutant NGAL protein has bacteriostatic activity.
 8. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine at a certain time following systemic administration of the mutant NGAL protein to a subject is greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 9. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine at a certain time following systemic administration of the mutant NGAL protein to a subject is 10-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 10. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine at a certain time following systemic administration of the mutant NGAL protein to a subject is 100-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 11. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine at a certain time following systemic administration of the mutant NGAL protein to a subject is 100-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 12. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine three hours after systemic administration of the mutant NGAL protein to a subject is 1% or more.
 13. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine three hours after systemic administration of the mutant NGAL protein to a subject is 2% or more.
 14. The mutant NGAL protein of claim 1, wherein the % of the mutant NGAL protein that accumulates in the urine three hours after systemic administration of the mutant NGAL protein to a subject is 5% or more.
 15. A nucleic acid sequence that encodes a mutant NGAL protein according to claim
 1. 16. An expression vector comprising a nucleic acid sequence according to claim 15 operatively linked to a promoter.
 17. A bacterial cell that stably expresses a nucleic acid according to claim
 15. 18. A mammalian cell that stably expresses a nucleic acid according to claim
 15. 19. A pharmaceutical composition comprising a mutant NGAL protein according to claim
 1. 20. A pharmaceutical composition comprising a complex of a mutant NGAL protein according to claim 1 and a siderophore.
 21. The pharmaceutical composition of claim 20, wherein the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants thereof.
 22. The pharmaceutical composition of claim 20, wherein the siderophore is pH insensitive.
 23. The pharmaceutical composition of claim 20, wherein the siderophore binds to the mutant NGAL protein and iron at urinary pH.
 24. The pharmaceutical composition of claim 20, wherein the siderophore binds to the mutant NGAL protein and iron in the urine.
 25. The pharmaceutical composition of claim 20, wherein the siderophore binds to the mutant NGAL protein and iron at blood pH.
 26. The pharmaceutical composition of claim 20, wherein the siderophore binds to the mutant NGAL protein and iron in the blood.
 27. The pharmaceutical composition of claim 20, wherein the mutant NGAL protein and the siderophore are present in a 1:1 molar ratio.
 28. A method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effect amount of the pharmaceutical composition of claim
 20. 29. A method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim
 19. 30. A polypeptide that encodes a K3 NGAL protein and comprises an amino acid sequence that is identical to SEQ ID NO.
 2. 31. A polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 2, at least 95% identical to SEQ ID No. 2, at least 90% identical to SEQ ID No. 2, at least 80% identical to SEQ ID No. 2, or at least 70% identical to SEQ ID No.
 2. 32. A nucleic acid encoding a polypeptide of claim 30 or
 31. 33. A pharmaceutical composition comprising the polypeptide of claim 30 or
 31. 34. A K3 NGAL protein comprising an amino acid sequence that is identical to SEQ ID NO:2, or a fragment thereof, wherein the K3 NGAL protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.
 35. A polypeptide that encodes a K3Cys protein and comprises an amino acid sequence that is identical to SEQ ID NO.
 252. 36. A polypeptide that comprises an amino acid sequence that is at least 99% identical to SEQ ID No. 252, at least 95% identical to SEQ ID No. 252, at least 90% identical to SEQ ID No. 252, at least 80% identical to SEQ ID No. 252, or at least 70% identical to SEQ ID No.
 252. 37. A nucleic acid encoding a polypeptide of claim 35 or
 36. 38. A pharmaceutical composition comprising the polypeptide of claim 35 or
 36. 39. A K3Cys protein comprising an amino acid sequence that is identical to SEQ ID NO:252, or a fragment thereof, wherein the K3Cys protein (a) is able to bind to a siderophore, and (b) is excreted in the urine.
 40. The K3Cys protein of claim 39, wherein the K3Cys protein has bacteriostatic activity.
 41. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of the WT NGAL protein to a subject over the same time period.
 42. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is 10-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 43. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the urine at a certain time following systemic administration of the K3Cys protein to a subject is 100-fold or more greater than the % of WT NGAL protein that accumulates in the urine following systemic administration of WT NGAL protein to a subject over the same time period.
 44. The K3Cys protein of claim 39, wherein the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3 Cys protein to a subject is about 50% or more.
 45. The K3Cys protein of claim 39, wherein the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3 Cys protein to a subject is about 70% or more.
 46. The K3Cys protein of claim 39, wherein the % of K3Cys protein that accumulates in the urine three hours after systemic administration of the K3 Cys protein to a subject is about 85% or more.
 47. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of the WT NGAL protein to a subject over the same time period.
 48. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is 10-fold or more lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of WT NGAL protein to a subject over the same time period.
 49. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys protein to a subject is 100-fold or more lower than the % of WT NGAL protein that accumulates in the kidney following systemic administration of WT NGAL protein to a subject over the same time period.
 50. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is 1% or less.
 51. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is 2% or less.
 52. The K3Cys protein of claim 39, wherein the % of the K3Cys protein that accumulates in the kidney three hours after systemic administration of the K3Cys protein to a subject is 5% or less.
 53. A pharmaceutical composition comprising a K3Cys protein according to claim
 39. 54. A pharmaceutical composition comprising a complex of a K3Cys protein according to claim 39 and a siderophore.
 55. The pharmaceutical composition of claim 54, wherein the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants thereof.
 56. The pharmaceutical composition of claim 54, wherein the siderophore is pH insensitive.
 57. The pharmaceutical composition of claim 54, wherein the siderophore binds to the K3Cys protein and iron at urinary pH.
 58. The pharmaceutical composition of claim 54, wherein the siderophore binds to the K3Cys protein and iron in the urine.
 59. The pharmaceutical composition of claim 54, wherein the siderophore binds to the K3Cys protein and iron at blood pH.
 60. The pharmaceutical composition of claim 54, wherein the siderophore binds to the K3Cys protein and iron in the blood.
 61. The pharmaceutical composition of claim 54, wherein the K3Cys protein and the siderophore are present in a 1:1 molar ratio.
 62. A method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39, 53 or
 54. 63. A method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39, 53 or
 54. 64. A K3Cys mutant protein comprising an amino acid sequence that is at least 70% identical to the sequence of the K3Cys protein of SEQ ID NO:252, or a fragment thereof, wherein: (a) residues Asn 39, Ala 40, Tyr 52, Ser 68, Trp 79, Arg 81, Tyr 100, Tyr 106, Phe 123, Lys 125, Tyr 132, Phe 133, and Lysine 134 are either not mutated or are conservatively substituted, and wherein the K3Cys mutant protein (b) is able to bind to a siderophore, and (c) is excreted in the urine.
 65. The K3Cys mutant protein of claim 64, wherein six or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 66. The K3Cys mutant protein of claim 64, wherein seven or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 67. The K3Cys mutant protein of claim 64, wherein eight or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 68. The K3Cys mutant protein of claim 64, wherein nine or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 69. The K3Cys mutant protein of claim 64, wherein ten or more residues from among Lys 15, Lys 46, Lys 50, Lys 59, Lys 62, Lys 73, Lys 74, Lys 75, Lys 98, His 118, Arg 130, Lys 149, and His 165 are substituted with a non-positively charged amino acid.
 70. The K3Cys mutant protein of claim 64, wherein the K3Cys mutant protein has bacteriostatic activity.
 71. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is greater than the % of K3Cys protein that accumulates in the urine following systemic administration of the K3Cys protein to a subject over the same time period.
 72. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is 10-fold or more greater than the % of the K3Cys protein that accumulates in the urine following systemic administration of K3Cys protein to a subject over the same time period.
 73. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the urine at a certain time following systemic administration of the K3Cys mutant protein to a subject is 100-fold or more greater than the % of K3Cys protein that accumulates in the urine following systemic administration of K3Cys protein to a subject over the same time period.
 74. The K3Cys mutant protein of claim 64, wherein the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 50% or more.
 75. The K3Cys mutant protein of claim 64, wherein the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 70% or more.
 76. The K3Cys mutant protein of claim 64, wherein the % of K3Cys mutant protein that accumulates in the urine three hours after systemic administration of the K3Cys mutant protein to a subject is about 85% or more.
 77. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of the K3Cys protein to a subject over the same time period.
 78. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is 10-fold or more lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of K3Cys protein to a subject over the same time period.
 79. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney at a certain time following systemic administration of the K3Cys mutant protein to a subject is 100-fold or more lower than the % of K3Cys protein that accumulates in the kidney following systemic administration of K3Cys protein to a subject over the same time period.
 80. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is 1% or less.
 81. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is 2% or less.
 82. The K3Cys mutant protein of claim 64, wherein the % of the K3Cys mutant protein that accumulates in the kidney three hours after systemic administration of the K3Cys mutant protein to a subject is 5% or less.
 83. A nucleic acid sequence that encodes a K3Cys mutant protein according to claim
 64. 84. An expression vector comprising a nucleic acid sequence according to claim 83 operatively linked to a promoter.
 85. A bacterial cell that stably expresses a nucleic acid according to claim
 83. 86. A mammalian cell that stably expresses a nucleic acid according to claim
 83. 87. A pharmaceutical composition comprising a K3Cys mutant protein according to claim
 64. 88. A pharmaceutical composition comprising a complex of a K3Cys mutant protein according to claim 64 and a siderophore.
 89. The pharmaceutical composition of claim 88, wherein the siderophore is selected from the group consisting of enterochelin, pyrogallol, carboxymycobactin, catechol, and variants thereof.
 90. The pharmaceutical composition of claim 88, wherein the siderophore is pH insensitive.
 91. The pharmaceutical composition of claim 88, wherein the siderophore binds to the K3Cys mutant protein and iron at urinary pH.
 92. The pharmaceutical composition of claim 88, wherein the siderophore binds to the K3Cys mutant protein and iron in the urine.
 93. The pharmaceutical composition of claim 88, wherein the siderophore binds to the K3Cys mutant protein and iron at blood pH.
 94. The pharmaceutical composition of claim 88, wherein the siderophore binds to the K3Cys mutant protein and iron in the blood.
 95. The pharmaceutical composition of claim 88, wherein the K3Cys mutant protein and the siderophore are present in a 1:1 molar ratio.
 96. A method for treating iron overload in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim
 88. 97. A method of treating a urinary tract infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim
 88. 